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1 General introduction
The past three decades have witnessed considerable progress in the pharma­
cological treatment of mood1 and anxiety disorders. Tricyclic antidepressants 
(TCA) were initially available for the treatment of major depression, but 
pharmacological treatment options have been extended with the introduction 
of selective serotonin reuptake inhibitors (SSRI). The efficacy of antidepres­
sants has also not been restricted to mood disorders. Patients with anxiety 
disorders also appear to benefit from treatment with antidepressants, and in­
troduction of new antidepressants has enhanced the treatment possibilities. 
Even though there is growing knowledge of the efficacy of different anti­
depressants and their range of utility, it is still not possible to predict antide­
pressant treatment response in mood and anxiety disorders or to meaning­
fully differentiate between TCAs and SSRIs. The prescription of antidepres­
sants in primary care facilities and in psychiatric services is therefore not 
based on consensus. To illustrate, the Dutch depression guideline for general 
practitioners (Van Marwijk et al., 1994) and the American guidelines for the 
treatment of depression are not the same because they are based on different 
empirical evidence (Persons, Thase, & Crits-Christoph, 1996). Further study 
to detect any differences in the efficacy of different treatments with antide­
pressants is thus needed. As soon as more is known about the differential 
efficacy of various antidepressants, treatment indication can be enhanced, 
and thereby more efficient treatment fostered as well. Further study may also 
help us understand the underlying mechanisms better as well. Mood and 
anxiety disorders are the most prevalent psychiatric disorders (Lepine, Witt- 
chen, & Essau, 1993; Bijl, Van Zessen, & Ravelli, 1997) with a high risk of 
recurrence for mood disorders (Angst, 1996), which makes the ongoing 
search for the most effective treatments particularly important.
Many questions remain unanswered. When should we prescribe antide­
pressant treatment? What antidepressant should we prescribe to a patient 
with major depression or a panic disorder or to a patient with a major de­
pression and co-occurring panic attacks? Why do antidepressants work for a 
wide range of mood and anxiety disorders? Do antidepressants work diffe­
rently for mood and anxiety disorders as separate disorders or are disturbed 
mood and anxiety different aspects of the same underlying disorder?
In the present study, an attempt will be made to answer a number of 
these questions.
1 For purposes of the present study, mood disorders are restricted to major depressive dis­
orders and dysthymic disorders. Bipolar disorders are beyond the scope of the present stu­
dy.
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1.1 Comorbidity of mood and anxiety disorders
With the development of standardised classification systems such as the 
Diagnostic and Statistical Manual of Mental disorders (DSM) (APA, 1980, 
1987, 1994), consensus on psychiatric diagnoses has improved. The current 
version of the DSM, the DSM-IV, is widely accepted and enables clinicians 
as well as researchers to use the same categorical language. The DSM is 
highly descriptive and categorises mood and anxiety disorders as separate 
disorders. While the DSM criteria sets for the disorders differ, the diagnostic 
overlap between mood and anxiety disorders is quite high and comorbidity 
often appears to be the case. In the present thesis comorbidity means that 
more than one psychiatric disorder can be diagnosed in the same person 
(Maser & Cloninger, 1990) (also see Chapter 2).
The existence of comorbidity between mood and anxiety disorders is an im­
portant, although often ignored, issue in interpreting treatment outcome. The 
efficacy of antidepressants is usually studied in patient populations selected 
on the basis of the DSM criteria. Comorbidity is also frequently used as an 
exclusion criterion even though comorbid symptoms of mood and anxiety 
disorders are the rule rather than the exception in clinical practice (Wittchen, 
Essau, & Krieg, 1991). This situation greatly limits the generalisation of re­
search findings to clinical practice. More important is the assumption that 
the selection of ‘homogeneous’ or ‘pure’ patient groups can help us find 
specific treatment indications. To illustrate, with the exclusion of major 
depression, researchers assume that they are studying a diagnostically ‘pure’ 
group of anxiety disorder patients. In fact, however, only those patients with 
a clear clinical picture, such as severe depression, are recognised and exclu­
ded. Patients with other types of depression are most likely included, which 
means that comorbidity is present. The use of DSM criteria to select patient 
groups thus suggests that a different population is included in a study on ma­
jor depression than in a study on anxiety disorders. DSM categorisations im­
ply the existence of different syndromes. In practice, however, partly the 
same patients may be treated for major depression in one study and anxiety 
disorder in the other. To illustrate this point, in a meta-analysis of clinical 
trials concerned with generalized anxiety disorder or major depression, one- 
third of the generalized anxiety disorder patients were found to have depres­
sive symptoms severe enough to be entered into the major depression trials. 
Two-thirds of the major depression patients were found to have anxiety 
symptoms severe enough to enter the trials on generalized anxiety disorder 
(Copp, Schwiderski, & Robinson, 1990).
In conclusion, appropriate classification of mood and anxiety disorders 
remains difficult due to widespread comorbidity. The DSM criteria do not 
adequately distinguish these patient groups. In fact, the existing overlap in 
mood and anxiety symptoms raises the question of whether mood and
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anxiety disorders are actually different disorders or part of the same syn­
drome. Furthermore, when different antidepressants (e.g., TCA versus SSRI) 
are studied with these presumably ‘pure’ groups, the question remains as to 
whether the treatments really have the same effect when they do not produce 
significantly different results. It is unknown if the patient recovered from 
mood symptoms, a co-existing anxiety disorder or vice versa. In other words 
possible differences between antidepressants can remain undetected when 
patient selection is based on the DSM criteria.
1.2 Antidepressant treatment response in mood and anxiety disorders
There is a general consensus that a positive response to treatment with anti­
depressants is not limited to mood disorders. Initially, tricyclic antidepres­
sants (e.g., imipramine, clomipramine) were indicated for depressed patients 
(Morris & Beck, 1974). Treatment response was best predicted in patients 
with melancholic symptoms (Bielski & Friedel, 1976). Tricyclic antidepres­
sants also turned out to be effective for the treatment of anxiety disorders as 
well and particularly for patients with panic disorder or obsessive compul­
sive disorder (McTavish & Benfield, 1990; Van Balkom, 1994). Interesting­
ly, the efficacy of the treatment could not be explained in terms of antide­
pressant response because patients without comorbid depressive symptoms 
responded as well. The antidepressant treatment options expanded with the 
development of selective serotonin reuptake inhibitors (SSRI), which are re­
gistered as antidepressants. As with the TCAs, the SSRIs also proved effec­
tive for the treatment of anxiety disorders, initially studied primarily in pa­
tients with panic disorder and obsessive compulsive disorder (Boyer, 1995; 
Den Boer & Westenberg, 1988; Jefferson, 1997; Piccinelli, Pini, Bellantuo- 
no, & Wilkinson, 1995; Stein, Spadacinni, & Hollander, 1995; Van Balkom, 
1994). In placebo controlled studies, SSRIs have also been found to be ef­
fective for the treatment of social phobia (Allgulander, 1999; Baldwin, Bo- 
bes, Stein, Scharwächter, & Faure, 1999; Stein, Fyer, Davidson, Pollack, & 
Wiita, 1999; Stein et al., 1998). Venlafaxine, another modern antidepressant, 
has been registered recently for the treatment of generalized anxiety dis­
order. Overall, no significant differences have been found between response 
to SSRIs and TCAs for the treatment of anxiety disorders.
In clinical practice, antidepressant treatment has become a valuable op­
tion for a large group of patients. Nevertheless, the current empirical evi­
dence regarding the differential effects of TCAs and SSRIs is limited. The 
only difference that can be stated is that TCAs are probably more effective 
for the treatment of severe major depression than SSRIs (Kraghsorensen, 
1990; Elkin et al., 1995; Anderson & Tomenson, 1994; Anderson, 1998). At 
least, the opposite has never been found. A possible explanation for the
9
better response of patients with severe major depression to TCAs is that se­
vere cases are generally easy to classify. The symptoms are sufficiently se­
vere to be recognised as part of a depressive disorder and, as a consequence, 
a relatively ‘pure’ patient group is studied. This is also, then, in line with the 
classical findings of Bielski and Friedel (1976) who found melancholic 
symptoms to best predict TCA response. The symptoms were loss of appe­
tite, loss of weight, early morning awakening and retardation versus agita­
tion. A subgroup of patients can thus be identified as responding favourably 
to TCAs on the basis of the severity and specificity of their symptoms. Dia­
gnostic expressions such as ‘depressive neurosis’ or ‘endogenous’ ‘vital’ or 
‘melancholic’ depression have been used to identify such subgroups, al­
though their etiological background remains unknown. Interestingly, two 
psychobiological indicators, clinical severity and an abnormal EEG sleep 
profile, have been associated with poorer response to cognitive behaviour 
therapy (Thase, Simons, & Renold, 1996). These findings again suggest the 
existence of a subgroup of severely depressed patients with a differential 
treatment response. Although a pharmacotreatment group was not included 
in the latter study, it may be hypothesised that these patients would respond 
favourably to TCAs. This is also consistent with earlier research in which 
patients with a major depression and a shortened rapid eye movement 
latency were found to respond favourably to TCAs (Rush et al., 1985).
A caveat in the empirical evidence showing more severely depressed 
patients to respond better to TCAs than SSRIs is a possible selection bias. 
More specifically, part of the severe patient population may have been non­
responders to initial treatment with an SSRI because that is the treatment of 
first choice. In current guidelines for the treatment of depression, it is recom­
mended that one starts with an SSRI, due to better tolerability and fewer side 
effects (Schulberg, Katon, Simon, & Rush, 1998). In other words, the treat­
ment history of severely depressed patients may bias outcome results (Bou- 
vy, 1997). Such a selection bias may be particularly the case in more recent 
studies as a result of the growing acceptance of SSRIs over the past decen­
nium. Furthermore, few inpatient studies have compared TCAs to SSRIs 
(Boyer, 1995).
Apart from the evidence that TCAs are probably more effective for the 
treatment of severely depressed patients, no differences in the efficacy of 
TCAs versus SSRIs have been found (Anderson & Tomenson, 1994). Pa­
tients with milder symptoms of depression or patients with an anxiety disor­
der showed no differences in response. One explanation is that differential 
diagnosis is more difficult in less severe cases as already mentioned. Patients 
with mood or anxiety disorders show a large degree of overlap in their symp­
toms. Correlations between severity measures for anxiety and depression are 
also found to be consistently high, about .70 (Bouman, 1987). As pointed out 
earlier, the DSM criteria have proved inadequate to distinguish these patient
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groups although the criteria are generally used for patient selection. Incon­
sistent categorisations may occur and possible differences between TCA and 
SSRI response go undetected due to the overlap in the symptoms of the dif­
ferent groups. In anxiety disorders, no differential response is detected (Van 
Balkom, 1994) but this does not mean that TCAs and SSRIs are equally ef­
fective in practice. The effect sizes varied per treatment condition for obses­
sive compulsive disorder patients2. For the treatment of an obsessive com­
pulsive disorder the efficacy of clomipramine (a partial selective serotonin 
re-uptake inhibitor) is generally accepted in clinical practice although diffe­
rential effects of SSRIs and TCAs have not been consistently found. Due to 
the very few placebo-controlled studies with a large number of subjects and 
the lack of studies with TCAs, meta-analyses are also not able to demon­
strate a differential response (Stein et al., 1995; Van Balkom, 1994). TCAs 
are studied more frequently in connection with panic disorder. Nevertheless, 
in only one meta-analysis (Boyer, 1995) SSRIs were found to be signifi­
cantly superior to imipramine. It should be noted, however, that with a suffi­
ciently high dosage of imipramine, the SSRIs were no longer superior. Over­
all, no differential response for TCAs versus SSRIs is found.
In conclusion, although the DSM is widely accepted, classification ac­
cording to the DSM has not resulted in the identification of the proper pa­
tient groups for treatment with specific antidepressants. The question which 
remains is whether the DSM has been consistently followed in clinical prac­
tice. Structured interviews are mainly used for research purposes, but most 
studies do not report use of a systematic procedure to acquire the DSM dia­
gnosis. The role of selection bias is also often ignored in treatment outcome 
studies although it has important consequences for the interpretation of the 
research results.
How to detect differences in antidepressant treatment response?
The high comorbidity between mood and anxiety disorders, diagnosed with 
the DSM, raises problems in interpretation of current clinical research. As 
part of this, research has not been able to find differences in antidepressant 
treatment response. Alternative models may help to identify patient groups 
that are supposed to be of relevance to detect antidepressant treatment diffe­
rences.
2 Meta-analysis of the efficacy of antidepressants in obsessive compulsive disorder: 
n=number of studies: clomipramine n=21, Cohen=s d=1.71, SD=1.01; fluvoxamine n=7, 
Cohen=s d=1.38, SD=0.72; imipramine n=2, Cohen=s d=1.55, SD=0.32 (Van Balkom, 
1994)
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One approach to the phenomenon of comorbidity has been the use of the pri­
mary-secondary diagnosis distinction. Initially the distinction of primary and 
secondary diagnosis was restricted to chronology. The disorder that came 
first chronologically is viewed as the primary diagnosis. Once again, the pri­
mary-secondary distinction is used to generate homogeneous groups and 
thereby contribute to our knowledge of aetiology (Klerman, 1990). Although 
the term primary diagnosis is often used in other senses (e.g., to indicate the 
predominance of a particular clinical feature), the chronology perspective 
may be most suited to the detection of the types of depression related to 
treatment differences. In the present thesis, the term primary diagnosis refers 
to the diagnosis that comes first chronologically or, in other words, the dia­
gnosis at first episode.
Cloninger and colleagues (1990) adopted this chronology perspective to 
distinguish depressed patients according to their comorbid diagnosis and 
stated the importance of determining the first disorder of a person for etiolo­
gical reasons and treatment choices. Primary depression has been distin­
guished from secondary depression or ‘demoralisation depression’. The hy­
pothesis is that secondary depression is usually a nonspecific demoralisation 
reaction. The risk of a depressive disorder in chronic anxiety patients is also 
higher than the risk of an anxiety disorder in patients with depressive disor­
ders. Finally, it is very rare for an anxiety disorder to be a chronic residual 
state following remission of a primary depressive disorder (Cloninger, Mar­
tin, Guze, & Clayton, 1990).
Winokur (1997) has also emphasised the importance of the chronology 
of disorders to detect different types of depression despite no differences in 
current symptomatology. In doing this, he distinguished ‘familial pure de­
pressive disease (FPDD)’ from ‘depression spectrum disease (DSD)’ as DSD 
is seen in emotionally unstable individuals, characterised by pre-existing 
psychiatric or personality disorders and/or associated with a family history 
of alcoholism. Secondary depression is considered equal to DSD. Research 
findings show that FPDD patients respond better to pharmacotreatment and 
electroconvulsive treatment than DSD patients. Winokur has also therefore 
argued for the importance of distinguishing subtypes of depression based on 
other levels of pathology than current symptomatology. That is, other clas­
sification dimensions, such as chronology of the disorders, may be relevant 
for the detection of etiological subtypes although the current clinical picture 
may not differ. Finally, Winokur has emphasised the need for etiological ho­
mogeneous patient groups to predict pharmacotreatment response more ade­
quately.
1.3 The role of primary diagnosis
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1.4 The role of temperament
The psychobiological personality model of Cloninger (Cloninger, 1987; Clo­
ninger, Svrakic, & Przybeck, 1993) is yet another model with implications 
for treatment response. The model has been reputed to differentiate between 
responders and nonresponders to antidepressant treatment (Cloninger, Przy­
beck, Svrakic, & Wetzel, 1994). The model consists of four basic dimen­
sions of temperament: Harm Avoidance, Novelty Seeking, Reward Depen­
dence and Persistence. The different dimensions refer to automatic emotio­
nal responses which are moderately heritable and stable throughout life. 
Large-scale twin studies have confirmed that the temperament dimensions 
are genetically homogeneous and independent of one another (Heath, Clo­
ninger, & Martin, 1994; Stallings, Hewitt, Cloninger, Heath, & Eaves, 
1994). According to the theoretical model, the temperament dimensions may 
also be related to an increased susceptibility to different neurotic syndromes 
(Cloninger et al., 1993). Harm Avoidance is postulated to relate to the func­
tions of the serotonergic brain system or, in other words, the behavioural in­
hibition system. Harm avoidance is thought to reflect a heritable tendency to 
intensely respond to aversive stimuli and thereby a tendency to inhibit beha­
viour to avoid novelty, the frustration of nonreward and punishment. A pas­
sive avoidance pattern thus appears. In line with this, Harm Avoidance 
scores have been found to be elevated in anxiety disorder patients and mood 
disorder patients. Harm Avoidance is assumed to be directly related to a 
susceptibility to anxiety disorders. In contrast, different subtypes of depres­
sion have been related to interactions between temperaments. For example, 
high Harm Avoidance in combination with high Novelty Seeking is assumed 
to lead to dysthymia due to continuing approach-avoidance conflicts within 
the individual. Furthermore, high Reward Dependence is assumed to be rela­
ted to a heightened sensitivity to loss, which then in turn produces the reac­
tive dysphoria characteristic of atypical depression. Cloninger concluded on 
the basis of the existing empirical evidence that depressives are clinically 
and etiologically heterogeneous and that temperament is a more powerful 
means of characterising this heterogeneity than depressive symptomatology 
or comorbid psychopathology (Cloninger et al., 1994). The study of persona­
lity temperaments also presents a useful perspective for the present study. 
Rather than focus on single DSM categorisations based on current sympto­
matology, the personality model enables an alternative typology of patients 
based on temperament. Classification of patients according to temperament 
may then provide insight into different responses to antidepressant treatment 
in patients with mood and/or anxiety disorders. The present study is thus an 
initial exploration of a possible relation between temperament scores and 
treatment outcome within a broad range of patients with the attempt to iden­
tify relevant subtypes.
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1.5 Main research questions addressed in this thesis
The aim of the present study was to examine the differential responses to 
treatment with TCAs versus SSRIs for a broad range of mood and anxiety 
disorders. Alternative models for the identification of subgroups differen­
tially responding to antidepressant treatment were explored. The use of sys­
tematic diagnostic procedures for the selection of the patient sample was also 
of particular interest. The present study thus has two main areas of interest: 
1) diagnostic accuracy for mood and anxiety disorders and 2) antidepressant 
treatment response.
1. How accurately do we diagnose mood and anxiety disorders? More spe­
cifically, what is the agreement between clinical diagnosis and diagnosis 
based on a structured diagnostic instrument? (Chapter 5)
2. Are we able to differentiate TCA and SSRI response in patients with 
mood and anxiety disorders using alternative classification models?
More specifically,
a) is it possible to differentiate antidepressant treatment response in pa­
tients with mood and anxiety disorders based on their primary diagno­
sis (e.g., diagnosis at first episode)? (Chapter 6)
b) does temperament, according to the personality model o f Cloninger, 
appear to be related to a differential antidepressant treatment respon­
se in patients with mood and anxiety disorders? (Chapter 7)
1.6 Outline of the contents
In the second chapter issues regarding the comorbidity of mood and anxiety 
disorders will be considered in greater detail along with the implications for 
research. In the third chapter, the psychobiological personality model of 
Cloninger and the corresponding inventory, the Tridimensional Personality 
Questionnaire (TPQ), will be presented. In the next chapters, the results of 
the empirical research will be presented. First of all, in the fourth chapter, an 
outline of the research project will be given. Special attention is paid to the 
patient selection procedures and the sample sizes analysed to answer the dif­
ferent research questions. In the fifth chapter, the degree of agreement on the 
diagnoses of mood and anxiety disorders will be examined. Clinical diagno­
sis and diagnosis based on a structured diagnostic interview will be com­
pared in particular. In the sixth chapter, the role of primary diagnosis or the 
diagnosis at first episode in a patient’s lifetime will be explored in an attempt 
to detect differences in the responses of patients to antidepressants. Two an­
tidepressants, imipramine (a TCA) and fluvoxamine (an SSRI), will be
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examined in a 6-week study of patients with mood or anxiety disorders. In 
the seventh chapter, the results regarding the relation between temperament 
and response to antidepressant treatment will be presented. Finally, in the 
eighth chapter, the general results and implications of these will be outlined. 
In addition, some limitations on the present study and suggestions for further 
research will be provided.
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2 Comorbidity of mood and anxiety disorders
Together with the growing acceptance and use of such diagnostic classifi­
cation systems for psychopathology, as the DSM3 and ICD4, the comorbidity 
of different disorders has become increasingly apparent. The comorbidity of 
mood and anxiety disorders has been shown to be particularly common. In 
line with the Kraepelinian disease model, the DSM makes a clear distinction 
between mood and anxiety disorders using specific criteria sets and exclu­
sion/inclusion rules. This suggests discrete and independent disease entities 
and as a consequence, both clinicians and researchers often assume clear dia­
gnostic categories. Nevertheless, the existence of comorbidity tells us that 
mood and anxiety disorders are not always easy to distinguish. Patients with 
milder depressions and/or more pervasive anxiety are particularly difficult to 
distinguish and classify. Comorbidity also raises problems with regard to the 
inclusion of specific patient groups for research purposes (e.g., patients with 
a panic disorder). Nevertheless, most outcome research is concentrated on a 
single diagnostic category with the intention to study a ‘pure’ patient group. 
Selection bias may appear in the form that only the most extreme or clear-cut 
cases will be recognised and excluded in line with the exclusion rules, which 
can clearly influence research findings and treatment choices. Furthermore, 
the prevalence of comorbidity raises questions regarding the disease entity 
underlying mood and anxiety. Are mood and anxiety disorders actually dif­
ferent diseases or is there one underlying disease? This is of obvious interest 
for research on the efficacy of antidepressant treatment. In the search to de­
tect and understand any differences in antidepressant treatment response, an 
alternative approach is to include patients within a broad spectrum of mood 
and anxiety disorders in order to cope with comorbidity and decrease selec­
tion bias.
In the present chapter issues of comorbidity will be discussed in greater de­
tail. A definition and different types of comorbidity will be presented, dra­
wing on the somatic view of comorbidity (2.1). Thereafter, a number of mo­
dels of comorbidity will be presented (2.2). Furthermore, an overview of the 
empirical evidence on the comorbidity of mood and anxiety disorders will be
3 The Diagnostic and Statistical Manual of Mental Disorders has been revised from DSM- 
III (American Psychiatric Association, 1980) to DSM-III-R (APA, 1987) to DSM-IV 
(APA, 1994), which is currently in use.
4 The International Classification of Diseases, published by the World Health Organiza­
tion, has been revised from the ICD-9th edition revised (WHO, 1977) to the ICD-10 
(WHO, 1990).
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presented, with a focus on the critical issues in comorbidity research (2.3), 
prevalence (2.4), the overlap of symptoms (2.5), sequential relationship (2.6) 
and clinical implications (2.7).
2.1 Somatic view of comorbidity
2.1.1 Definition o f comorbidity
Although frequently used in research and practice, the term comorbidity re­
mains poorly defined and lacks clear conceptualisation (Maser & Cloninger, 
1990). The term comorbidity, introduced by Feinstein (1970), refers to “any 
additional clinical entity that has existed or that may occur during the clini­
cal course of a patient who has the index disease under study” (pp. 456-457). 
Feinstein based his description of comorbidity on somatic medicine and 
restricted the term to diseases or disorders and not symptoms. This concept 
of comorbidity is also used in the field of psychopathology to indicate that 
more than one psychiatric disorder can be diagnosed in one and the same 
person (Maser & Cloninger, 1990).
Feinstein’s view of comorbidity pertains to treatment outcome for spe­
cific disease entities and follow-up study, and thus implies a longitudinal 
perspective on comorbidity. However, in many clinical studies, the term co­
morbidity is also used to describe symptomatic overlap irrespective of 
whether the phenomena meet the criteria for a mental disorder, although 
strictly speaking, comorbidity refers to diseases or disorders (Latin: morbus 
= illness) (Wittchen, 1996).
Compared to Feinstein’s somatic view of comorbidity, the more recent 
definitions of comorbidity in the field of psychopathology have not impro­
ved much. To illustrate, Boyd et al. (1984) defined comorbidity primarily for 
epidemiological studies as ‘the relative risk for a person with one disorder to 
acquire another disorder’. Burke, Wittchen, Regier and Sartorius (1990) de­
fined comorbidity as ‘the presence of more than one specific disorder in a 
person in a defined period of time’. Beyond the inclusion of a time frame, 
there are no essential changes in the definition compared to the earlier defi­
nition of Feinstein. Not one of the definitions, moreover, is uniformly accep­
ted. In the present dissertation, comorbidity is viewed in line with Maser and 
Cloninger (1990), namely that more than one psychiatric disorder can be 
diagnosed in the same person. Psychiatric disorders must be viewed as ‘cli­
nical entities’ as opposed to diseases as long as the pathogenic mechanisms 
underlying psychiatric conditions remain unknown. The operationalisation 
of psychiatric conditions is largely a matter of consensus based on current 
knowledge as represented in the DSM and the ICD, and the study of psy­
chiatric comorbidity thus relies heavily on the acceptance of current diagnos­
tic classification systems.
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2.1.2 Types o f comorbidity
Thirty years ago, Feinstein (1970) described the importance of studying co­
morbidity and this description is largely in line with the basic assumptions of 
this thesis. Feinstein stated that the neglect of comorbidity has many detri­
mental effects on general disease statistics and that the worst clinical conse­
quences occur during efforts to evaluate treatment. To evaluate different 
modes of therapy, clinicians usually assemble two or more groups of patients 
and compare their treatment responses. For scientifically valid comparison, 
the groups must be initially comparable. In addition, only randomised trials 
are considered acceptable for drawing conclusions. Without this prethera- 
peutic similarity and randomised treatment, the different therapies cannot be 
properly evaluated.
The usual method of identifying the comparability of patient groups is 
to note similar diagnoses, demography and anatomy. In other words, all the 
patients usually have the same disease; they may also be similar in age, race 
and sex; and cancer patients, for example, may all have the same anatomic 
stage of dissemination. Although patients are similar with regard to the afore 
mentioned categories, they may nevertheless show major differences with 
regard to clinical features. Among the clinical features listed by Feinstein are 
the mode of detection of the disease, the cluster of symptoms and signs, and 
the sequence and timing of the symptoms. Even when these clinical features 
are added to the classification, groups of ‘similar’ patients may still largely 
differ with regard to comorbid diseases which can affect the outcome of 
therapy. If comorbidity is ignored, observed differences in treatment out­
come for a particular disease may be attributed to the treatment and not to 
undetected associated diseases in the patient. The opposite is also possible; 
that is, no differences in the treatments for a particular disease do not auto­
matically imply equally effective treatments because comorbidity may mask 
possible differences.
Although Feinstein illustrated the importance of classifying comorbidity 
for the evaluation of cancer treatments, recognition of comorbidity is also 
important in research comparing treatment outcome for mood and anxiety 
disorders. Different responses to different antidepressant treatments for 
mood and anxiety disorders may go undetected as a result of comorbidity. 
The comorbid disorder (mood or anxiety) may simulate the index disease 
(anxiety or mood), with no identification of the initial disorder as a result. 
Furthermore, patients diagnosed with an anxiety disorder in one study may 
be diagnosed with a mood disorder in another study. It is here, thus, that the 
problems associated with the evaluation of antidepressant treatment outcome 
for mood and anxiety disorders arise as a result of comorbidity is omitted.
Based on previous work, Kaplan and Feinstein (1974) introduced three 
types of comorbidity which arise in medicine and may be of interest in psy­
chiatry as well. The focus of their research was on the importance of classi­
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fying initial comorbidity for evaluating the outcome of treatment for diabetes 
mellitus. In order to do this, they distinguished pathogenic, diagnostic and 
prognostic comorbidity.
Pathogenic comorbidity arises when a particular disease leads to cer­
tain other complications or diseases, which are therefore considered etiologi­
cally related. Kaplan and Feinstein give the example of various cardiovas­
cular-renal system diseases (e.g., hypertension, cardiac disorders excluding 
cor pulmonale, peripheral vascular disease, retinopathy and cerebrovascular 
disease), which are commonly regarded as pathogenically related to diabetes. 
In psychiatry, an example is the development of agoraphobia secondary to 
recurrent panic attacks, or major depression secondary to a psychiatric dis­
order of a chronic nature such as schizophrenia. In the present dissertation, 
primary and secondary depression are distinguished based on chronology. 
This is in line with the pathogenic comorbidity concept. Secondary depres­
sion following a chronic anxiety disorder thus constitutes pathogenic comor­
bidity.
Diagnostically comorbid diseases share common symptoms. Diagnostic 
comorbidity is likely whenever the diagnostic criteria are based on patterns 
of symptoms which are not individually specific. Kaplan and Einstein give 
polyuria as an example of a symptom found in a patient who has both 
diabetes mellitus and a coexisting renal ailment which can produce polyuria. 
The coexisting renal ailment is diagnostically comorbid. In the field of psy­
chiatry, diagnostic comorbidity is common in the sense that the current DSM 
classification of psychopathology includes nonspecific criteria which may 
also stem from other disorders. Examples are diminished ability to concen­
trate because of both a mood and a generalized anxiety disorder or loss of 
weight due to both a mood and an eating disorder. Excessive worry may be a 
symptom of generalized anxiety disorder, a mood disorder or an obsessive 
compulsive disorder and social phobia may be an associated feature of a ma­
jor depressive disorder (APA, 1994).
Another illustration of diagnostic comorbidity arises in the classifica­
tion of personality disorders. The differential diagnosis of axis I and axis II 
personality disorders is complicated by shared features. The diagnosis of 
borderline personality disorder lacks specificity and shows diagnostic co­
morbidity with mood disorders. Furthermore, comorbidity of axis II disor­
ders is common. In fact, more patients are diagnosed with two or more per­
sonality disorders than with one. The ten personality disorders can be 
grouped into three clusters based on descriptive similarities: Cluster A (odd 
cluster) includes paranoid, schizoid and schizotypal personality disorders; 
Cluster B (dramatic cluster) includes the antisocial, borderline, histrionic and 
narcissistic personality disorders; Cluster C (anxious cluster) includes the 
avoidant, dependent and obsessive compulsive personality disorders. Comor­
bidity occurs not only within clusters (e.g., coexistence of borderline and
20
histrionic personality disorders both included in the odd cluster) but also be­
tween clusters (e.g., coexistence of the borderline and dependent personality 
disorders from the odd cluster and the anxious cluster, respectively).
Prognostic comorbidity is spoken of when disorders predispose a per­
son to develop other disorders. Kaplan and Feinstein give the example of a 
patient with diabetes and hypertension being more likely to develop retino­
pathy than a patient with diabetes alone. A comparable example from the 
field of psychiatry is the increased risk of alcoholism in a patient with both a 
panic and a mood disorder. That is, the combination of the two disorders is 
more likely to precipitate alcoholism than either one alone (Maser & Clo- 
ninger, 1990). Yet another example from current research is the increased 
risk of children with attention-deficit/hyperactivity disorder to develop an 
antisocial personality disorder later in life (Barkley, 1998).
Although Kaplan and Feinstein based their types of comorbidity on so­
matic medicine, the types are useful for understanding comorbidity in psy­
chopathology as well. The present thesis is based on the assumption that the 
comorbidity between mood and anxiety disorders is often neglected in out­
come research, and that such neglect may clearly influence treatment results. 
More specifically, possible differences between antidepressant treatments 
may go undetected due to a neglect of comorbidity. The groups of patients 
being compared may not be as similar as proposed. Diagnostic comorbidity 
of mood and anxiety disorders appears to be the case for DSM classification, 
even though the DSM requires separate diagnoses. Of particular interest in 
the present thesis, however, is the search for pathogenic and prognostic co­
morbidity, because this can help unravel the pathogenesis of mood and 
anxiety disorders. The objective of the present study is thus to include all pa­
tients with a mood and/or an anxiety disorder and differentiate them accor­
ding to primary diagnosis or the diagnosis which occurs first in life. In doing 
this, the selection bias which usually occurs in studying single diagnostic 
categories will be reduced. In addition to patients with a clear clinical picture 
of major depression or an anxiety disorder, comorbid cases which are usual­
ly difficult to classify will also enter the study. No artificial choices are made 
during the classification procedure and the primary diagnosis will play a cri­
tical role in the measurement of treatment outcome which is in line with the 
concept of pathogenic comorbidity. For this reason, the current DSM catego­
ries are also not studied in the present study. Diagnostic comorbidity pro­
blems would arise and possible differences in the efficacy of antidepressants 
for subgroups of patients would go undetected. The search for pathogenic 
comorbidity in terms of primary versus secondary depression and primary 
anxiety is thus assumed to be a more valuable focus for the evaluation of an­
tidepressant treatment response.
21
2.2 Models of comorbidity
Another way of approaching comorbidity is to examine different models of 
comorbidity. Three conceptual models of the relationship between mood and 
anxiety have been distinguished by Stavrakaki and Vargo (1986); the unitary 
model, the pluralistic model and the mixed anxiety-depression model. Al­
though the concept of pathogenic comorbidity appears to be best suited to 
the purposes of the present research, the different models distinguished will 
also be considered below.
The unitary model presents mood and anxiety symptoms as variants of 
the same affective disorder. Mood and anxiety disorders are represented a­
long a continuum and thus differ only quantitatively. The overlap in the cli­
nical symptomatology associated with mood and anxiety disorders has been 
cited as the greatest source of support for this model. Further support for the 
unitary model comes from treatment studies in which anxiety disorder pa­
tients have been found to respond favourably to antidepressants. The tenden­
cy for patients with long standing anxiety disorders to develop mood symp­
toms is also cited as support for the unitary model (Stavrakaki & Vargo, 
1986).
The pluralistic model presents mood and anxiety as separate and quali­
tative distinct entities. Although the overlap in symptomatology is recogni­
sed, it is argued that the use of appropriate measures and statistics will show 
the two disorders to clearly differ along certain dimensions. The relevant re­
search data concerns differences in clinical characteristics, rating scales, 
prognosis, personality, treatment response, course and outcome, physiologi­
cal response to stress and family history data (Stavrakaki & Vargo, 1986). 
Despite these efforts, however, it has not been possible to detect important 
differences between patients with mood versus anxiety disorders.
The mixed anxiety-depression model consists of three groups. In addi­
tion to patients with discrete mood disorders and patients with discrete an­
xiety disorders, a mixed group of patients is distinguished. Research indica­
tes that when the two disorders coexist, there is increased chronicity, reduced 
treatment response and a poorer prognosis. Mood and anxiety in combina­
tion are thus argued to represent a quantitative and qualitative distinct disor­
der when compared to either mood disorder or anxiety disorder alone.
Each of the above models has its own heuristic value for the description 
of the possible relationships between mood and anxiety. It has been pro­
posed that mood and anxiety disorders are no more than two surface mani­
festations of a ‘general distress factor’. Efforts to define separate mood and 
anxiety disorders are therefore limited by the features common to the diffe­
rent disorders and an artificial splitting of a complex syndrome into separate 
parts is suggested by the unitary view of comorbidity (Frances et al., 1992).
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The unitary model in its purest form combines all mood and anxiety disor­
ders into a single complex syndrome with the same underlying pathogenesis.
Despite a great deal of overlap, relatively ‘pure’ or distinct disorders 
have also been observed which raises the need for both a unitary model and 
a pluralistic model or what, in fact, is a mixed anxiety-depression model. 
The tripartite model of anxiety and depression (Clark & Watson, 1991) is 
such a mixed anxiety-depression model. Based on factor-analytic studies, 
Clark and Watson suggested that anxiety and mood disorders be reorganised 
into three groups: 1) generalised mood disorder (characterised by general 
distress, anxiety and low mood); 2) major depressive disorder (characterised 
by pervasive anhedonia and lack of positive affect) and 3) major anxiety dis­
order (characterised by somatic symptoms of hyperarousal which best discri­
minates anxiety from mood disorder). In line with this, generalized anxiety 
disorder and major depression have been found to be genetically related, and 
a shared genetic factor has also been found for phobia and panic disorder 
(Kendler et al., 1995).
2.3 Critical issues in comorbidity research
The co-occurrence of mood and anxiety disorders has been studied extensi­
vely over the past 30 years. One of the main findings is that the observed co­
morbidity rates differ enormously across studies (15% to 91%). Comorbidity 
rates may differ depending on the population being studied. Epidemiological 
studies show least one third of all current cases in the general population to 
meet the criteria for more than one disorder. Comorbidity rates in primary 
health-care settings indicate an even higher co-occurrence rate with clinical 
psychiatric inpatient and outpatient studies demonstrating the highest comor­
bidity rates (Wittchen, 1996). Nevertheless, there is still considerable varia­
tion in the comorbidity rates due to different uses of the term across studies. 
Based on Wittchen (1996), consideration of several critical issues can help 
us understand the variability in findings regarding psychopathological co­
morbidity.
Conceptual differences
The term comorbidity is used to indicate an overlap in symptoms as well as 
descriptive classes of disorders and stresshold conditions. The observed 
overlap between mood and anxiety can depend on the level of psychopatho­
logy that is defined namely, the level of symptoms, syndromes or disorders. 
The highest comorbidity rates are observed at the symptom level. Overlap of 
symptoms is almost twice as high as for diagnoses (Hiller, Zaudig, & Van 
Bose, 1989). Clayton (1990) examined comorbidity studies from the pre­
vious 16 years and found the highest rate of 91% to occur in patients with
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anxiety symptoms. Conceptual differences are most striking when syn­
dromes are the focus of the study. Due to the use of different definitions, the 
comparability of such studies is limited and the comorbidity rates differ de­
pending on the dimensional level of the syndrome (see Hiller et al., 1989).
Confusion also occurs because the diagnostic criteria and use of exclu­
sion rules are not fully described in many studies. Some studies report rates 
of major depression but not the exclusion rules for such a diagnosis, which 
could be the presence of manic episodes, psychotic disorders, grief reactions 
and/or organic conditions (Wittchen, 1996). Even with the use of the DSM 
and ICD-10, it is often not specified whether none, some or all of the dia­
gnostic exclusions have been considered.
Sample selection
Comorbidity rates can vary depending on the number and type of diagnostic 
categories considered in the study. For example, the group of anxiety disor­
der patients under study often includes different subtypes. As a consequence, 
there is little comparability between studies (see also 2.4.2). Apart from this 
difference in diagnostic coverage, a small sample size may create some se­
lection bias. Comorbidity rates are found to be highest for small samples 
(Clayton, 1990). A selection bias also occurs when patients are recruited via 
advertisements or a number of selection procedures are combined (see Ball, 
Buchwald, Waddell, & Shekhar, 1995). Although the patients in the afore 
mentioned study met the DSM-III-R criteria for panic disorder with or with­
out agoraphobia, it is questionable if the patients are representative of the po­
pulation of panic disorder patients in clinical practice. Nevertheless, clinical 
samples are also vulnerable to selection bias. According to Bouvy (1997) in­
patient samples typically include patients who have been resistant to former 
treatment and this treatment history, although often ignored during the eva­
luation of treatment outcome, clearly influences treatment response.
Time span
Comorbidity rates may also depend on the time frame of assessment: cross­
sectional (two weeks, one month, six months, etc.), longitudinal (one year, 
three years, etc.) or lifetime (across the entire lifespan). Lifetime comorbidi­
ty rates tend to be higher than current comorbidity rates, as consistently indi­
cated in epidemiological studies. This is partly due to the higher lifetime pre­
valence of disorders, when compared to the current prevalence of disorders 
(Kessler et al., 1996). An overview of the lifetime and current comorbidity 
rates for mood and anxiety disorders are presented in Table 2.1 and Table 
2 .2 .
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Table 2.1 Epidemiological studies o f  comorbidity o f  mood and anxiety disorders
Major depression Anxiety disorder
study assessment comorbid anxiety disorder (%) comorbid major depression (%)
instrument lifetime 12-months lifetime 12-months
ECA DIS (DSM-III)
NCS CIDI (DSM-III-R)
NEMESIS CIDI (DSM-III-R)
WHO CIDI (ICD-10)
any anxiety disorder 47.2
Simple phobia 25.6
Agoraphobia 20.4
Social phobia 13.6
Panic disorder 13.0
OCD 14.4
any anxiety disorder 58.0
GAD 17.2
Agoraphobia 16.3
Simple phobia 24.3
Social phobia 27.1
Panic disorder 9.9
PTSD 19.5
Panic disorder
Agoraphobia
Simple phobia
Social phobia
GAD
OCD
34.5a 26.1
21.7 23.7
51.2
15.4 62.4c 38.6b
12.6 45.9d
23.7 42.3d 
20.0 37.2d
8.6
15.2 47.9 (men)/
48.5 (women)e
45.5 17.1
25.5 6.7
21.8 26.2
29.3 23.8
50.3 21.9
65.6 5.0 
40 45
Note abbreviations. CIDI, Composite International Diagnostic Interview; DIS, Diagnostic Interview Schedule; ECA, Epidemiological Catchment Area Survey (Regier 
et al., 1998); NCS, National Comorbidity Survey (Kessler et al., 1996;eKessler et al., 1995;dMagee et al., 1996;cWittchen et al., 1994); NEMESIS, Netherlands Mental 
Health Survey and Incidence study (Ravelli et al., 1998); WHO, The WHO study on Psychological Problems in General Health Care (Lecrubier & Üstün, 1998); GAD, 
Generalized anxiety disorder, OCD, Obsessive compulsive disorder; PTSD, Posttraumatic stress disorder. a any mood disorder, b 30-days prevalence.
Table 2.2 Prevalence rates o f  comorbidity o f  mood and anxiety disorders
Authors population n diagnosis assessment comorbid features comorbidity rate
Ball et al., 
1995
advertisement trial 
(N=53), referrals 
from mental health 
professionals and 
physicians (N=11)
64 panic disorder with/ 
without agoraphobia 
DSM-III-R
SCID (53) 
ADIS (11)
major depression 36%
Coryell et al., 
1992
NIMH cohort 
(in/outpatients)
359 major depression 
RDC
SADS phobia, panic attacks 
obsessions-compulsions
45.4%
Dilsaver et al., 
1992
outpatients 42 major depression
recurrent
DSM-III-R
SCID social phobia 45.2%
Fava et al., 
1997
outpatients 294 major depression 
DSM-III-R
SCID-P anxiety disorders 
social phobia 
social phobia 
simple phobia 
GAD
panic disorder
agoraphobia without panic 
OCD
44.9%
58%
58%
32%
16%
14%
12%
8%
Hiller et al., outpatients 150 major depression MDCL
1989 dysthymia lifetime
Table 2.2 (continued)
symptoms 52%
syndromes (cut-off scores) 29-51%
Authors population n diagnosis assessment comorbid features comorbidity rate
panic disorder with/ diagnoses 28.7%
without agoraphobia
agoraphobia
social phobia
simple phobia
GAD
DSM-III-R
Sanderson et al., 
1990
outpatients 260 major depression
(N=197)
dysthymia
(N=63)
DSM-III-R
SCID anxiety disorders 41.6%
47.6%
Stein et al., 
1990
outpatients 63
54
social phobia
panic disorder 
DSM-III-R
ADIS +
SADS-L
SADS-LA
major depression 35% (lifetime) 
63% (lifetime)
Van Ameringen outpatients 
et al., 1991
57 social phobia 
DSM-III-R
SCID-P major depression 
dysthymia
70.2%
31.6%
Note abbreviations. ADIS, Anxiety Disorders Interview Schedule, Revised Version; MDCL, Munich Diagnostic Checklist; SADS, Schedule for Affective Disorders 
and Schizophrenia; SADS-L, Schedule for Affective Disorders and Schizophrenia-Lifetime Version; SADS-LA, Schedule for Affective Disorders and Schizophrenia­
Lifetime Version for Anxiety Disorders; RDC, Research Diagnostic Criteria SCID, Structured Clinical Interview for DSM-III-R; SCID-P, Structured Clinical Interview 
for DSM-III-R diagnosis-Patient Edition.
The assessment instrument
The particular assessment strategy that is used is generally very critical in 
clinical research. More specifically, the procedure to operationalise psy­
chiatric disorders can differ across studies from clinical diagnosis to the use 
of fully standardised diagnostic instruments. Standardised instruments such 
as the CIDI5 produce more than twice as many diagnoses as the clinician 
would assign during routine diagnostic assessment (Wittchen, 1996). For this 
reason, comparison of studies with different assessment procedures is of li­
mited value. Particularly when different diagnostic criteria are used and con­
ceptual differences occur. In a review by Clayton (1990) comparing different 
diagnoses of panic disorder, this problem was made very clear: ’anxious 
neurotic’ outpatients, patients with anxiety states, patients with panic and 
agoraphobia, patients with generalized anxiety disorder and patients with pa­
nic were all considered but in different studies.
2.4 Prevalence of comorbidity
Epidemiological studies have consistently found high comorbidity rates for 
psychiatric disorders and for mood and anxiety disorders in particular. About 
half of those people meeting the lifetime criteria for major depression also 
show a comorbid anxiety disorder. The one-year prevalence rates are some­
what lower than the lifetime rates (Kessler et al., 1996; Lecrubier & Üstün, 
1998; Ravelli, Bijl, & Van Zessen, 1998; Regier, Rae, Narrow, Kaelber, & 
Schatzberg, 1998; Sartorius, Üstün, Lecrubier, & Wittchen, 1996).
Although the various anxiety disorders are highly comorbid with each 
other, they are equally often comorbid with mood disorders (Kessler, Zhao, 
Blazer, & Swartz, 1997; Lecrubier & Üstün, 1998). The National Comorbi­
dity Survey (Kessler et al., 1996) showed different comorbidity rates per 
anxiety disorder, as presented in Table 2.1. Simple and social phobia co­
exist most in patients with major depression (lifetime and current). Comor- 
bid mood disorders in patients with anxiety disorders (lifetime) were even 
more common, particularly for generalized anxiety disorder (Wittchen, 
Zhao, Kessler, & Eaton, 1994), agoraphobia with or without panic, simple 
phobia and social phobia (Magee, Eaton, Wittchen, McGonagle, & Kessler,
1996). The current comorbidity rate was only reported for generalized an­
xiety disorder, which limits the comparability of this data with clinical data 
based on current diagnoses.
In clinical studies, the co-occurrence of panic disorder and major de­
pression is studied most often, with comorbidity rates ranging from 10% to 
70%. Restricted to current episodes, about one third of panic disorder pa­
tients show a comorbid major depression (Baldwin, 1998; Ball et al., 1995;
5 Composite International Diagnostic Interview (WHO, 1990).
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Clayton, 1990; Zajecka & Ross, 1995). In patients with social phobia, com­
parable rates have been observed with the social phobia mostly preceding the 
depression (Stein, Tancer, Gelernter, Vittone, & Uhde, 1990; Van Amerin­
gen, Mancini, Styan, & Donison, 1991). Nevertheless, almost half of the pa­
tients with recurrent major depression show social phobia only when de­
pressed (Dilsaver, Qamar, & DelMedico, 1992). A few clinical studies have 
included more than one anxiety disorder in order to compare rates across se­
parate disorders (see Fava et al., 1997; Sanderson, Beck, & Beck, 1990). So­
cial phobia, generalized anxiety disorder and panic disorder consistently 
show high comorbidity with major depression. An overview of the character­
istics of the clinical studies and the observed comorbidity rates can be found 
in Table 2.2.
To conclude, no consistent differences have been found regarding the 
comorbidity of separate anxiety disorders with mood disorders. The fact that 
anxiety disorders show also high comorbidity with each other, further raises 
doubt on the relevance to study comorbidity rates of separate anxiety disor­
ders with mood disorders. The high comorbidity rates furthermore support 
the relevance to study a broad range of patients with different anxiety disor­
ders and/or mood disorders as one group.
2.5 Overlap of symptoms
Although mood and anxiety disorders appear to be different disorders in the 
diagnostic classification systems, overlap in their symptoms is common. In 
other words ‘specific’ anxiety symptoms and ‘specific’ mood symptoms 
often appear together in one and the same patient. Although there is no con­
sensus on the ‘specific’ symptoms, the following distinction can be made, 
drawing partly on Clayton (1990) and Clark and Watson (1991): Specific 
anxiety symptoms include somatic anxiety, psychic anxiety and panic at­
tacks. Specific mood symptoms include depressed mood, anhedonia and sui­
cidal thoughts. Common symptoms include sleep and appetite disturbances, 
irritability, difficulty concentrating, fatigue, agitation (restlessness) and wor­
ry (ruminations). The overlap in symptoms is nevertheless not limited to the 
common symptoms. To illustrate, worry, psychic anxiety, somatic anxiety 
and the occurrence of panic attacks are also common in mood disorder pa­
tients (Fawcett, 1997).
The problem of symptom overlap in mood and anxiety disorders is best 
illustrated by the use of rating scales. For example, the Hamilton Rating 
Scale for Depression (HRSD; HAM-D) (Hamilton, 1960) is used to measure 
severity of depression, but also includes a number of anxiety items (e.g., 
psychic anxiety, somatic anxiety, agitation). These anxiety symptoms strong­
ly correlate with the severity of the depression as measured by the total 
HAM-D score, moreover (Gibbons, Clark, & Kupfer, 1993). In other words,
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patients with high scores on anxiety items have relatively high scores on 
mood items as well. In using the HAM-D, thus, severity of depression judge­
ments is actually based on a mixture of mood and anxiety symptoms and 
comorbidity problems can thus arise. Due to the lack of specificity, charac­
teristic of the rating scale, both mood and anxiety disorder patients may also 
obtain comparable scores on the HAM-D.
The correlations between measures of severity for anxiety and depres­
sion have also been found to be consistently high (Barbee, 1998; Bramley, 
Easton, Morley, & Snaith, 1988; Bouman, 1987; Frances et al., 1992). As a 
consequence, the ability of such measures to differentiate between mood and 
anxiety disorder patients is poor. The results of a meta-analysis once showed 
the average correlation between anxiety and depression scales to be 0.61 
(Dobson, 1985). The correlations are highest for self-rating instruments and 
in studies with non-patient samples. Clinicians may strive (whether right or 
wrong) for greater discrimination in their ratings than the patients them­
selves. Discrimination is probably better in clinical samples, probably be­
cause of an increased frequency of severe cases (Frances et al., 1992). Fran­
ces has suggested that a strong nonspecific ‘distress factor’ may account for 
much of the overlap in mood and anxiety disorder patients.
Clark and Watson (1991) concluded, based on factor analyses, that 
mood disorders can best be discriminated by the presence of pervasive anhe- 
donia while anxiety disorders can best be discriminated by the presence of 
somatic symptoms of hyperarousal. It is noteworthy that these physiological 
anxiety symptoms are most typical of panic, and not other anxiety disorders 
such as generalized anxiety disorder. This pattern suggests that there are 
very few symptoms unique to anxiety disorders when compared to mood dis­
orders, which may also explain the lower convergent validity of anxiety 
scales compared to depression scales (Barbee, 1998). Beyond the specific 
factors of hyperarousal for anxiety and anhedonia for depression, mood and 
anxiety disorders share a substantial component of general affective di­
stress. This nonspecific distress factor is called negative affect (Clark & 
Watson, 1991) and represents the extent to which a person is feeling upset or 
unpleasantly engaged as opposed to peaceful and pleasantly engaged, and it 
encompasses various aversive states including being upset, angry, guilty, 
afraid, sad or worried.
The observed covariation between mood and anxiety may thus be attri­
butable to a shared genetic factor reflecting individual vulnerability to sub­
jective distress and negative affect (Mineka, Watson, & Clark, 1998). Within 
this view, the appearance of an anxiety disorder or a mood disorder is no 
more than a response to a burden prompting a particular stress reaction due 
to a shared underlying genetic entity. The shared general distress factor can 
manifest itself both as a state and a more stable trait of a rather chronic 
nature. The general distress symptoms are met in several different diagnostic 
categories currently being used in clinical practice, such as in neurasthenia
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(in ICD-10), adaptation disorder (in DSM) and burnout. Patients whose pre­
dominant symptoms are nonspecific (i.e., distress, demoralization, irritabili­
ty, mild disturbances of sleep and appetite, distractibility and vague somatic 
complaints) without marked symptoms of hyperarousal or anhedonia thus 
may receive one of the afore mentioned ‘general affective distress’ diagno­
ses.
2.6 Sequential relationship of mood and anxiety disorders
Within a single episode, anxiety symptoms are more likely to precede de­
pressive symptoms than the reverse (Alloy, Kelly, Mineka, & Clements, 
1990). A comparable pattern is observed for lifetime comorbidity, in that an­
xiety disorders are signifycantly more likely to precede a mood disorder than 
the reverse (Alloy et al., 1990; Lepine, Wittchen, & Essau, 1993). Anxiety 
disorders are associated with an elevated risk of a mood disorder later in life 
(Kessler et al., 1997). In other words, anxiety disorders are more likely to be 
temporally primary to mood disorders. To illustrate, most lifetime anxiety 
disorders were primary disorders6 while almost two thirds of lifetime major 
depressive disorders were secondary to other DSM-III-R disorders, with an­
xiety disorders being the most common primary condition (68%). Only a­
bout one quarter (26%) of the population reports major depressive disorder 
as their only lifetime disorder (pure major depression) (Kessler et al., 1996).
Coryell, Endicott, and Winokur (1992) explicitly explored the possibili­
ty of anxiety syndromes appearing within depressive episodes involving a 
separate disease process. The results showed the development of autono­
mous anxiety disorders to be rare. Patients with an initial major depression 
were most likely to develop a new episode of major depression. Depressive 
symptoms were more persistent and recurrent among patients with coexis­
ting anxiety syndromes. Depressed patients with associated obsessions or 
compulsions, panic attacks or phobias were not likely to develop these 
symptoms as autonomous disorders during follow-up; they were much more 
likely to develop recurrent major depressive episodes instead.
To conclude, the diagnostic stability of primary depression has been 
shown to be high. Anxiety symptoms occurring within depressive episodes 
do not indicate a separate disorder but nevertheless have clear prognostic im­
portance as depressed patients with any of the anxiety syndromes show 
poorer outcomes than those without. Once again, however, this poor out­
come can not be attributed to the development of additional autonomous an­
xiety disorders. As Coryell et al. (1992) have therefore suggested, anxiety 
symptoms accompanying depression may actually be an epiphenomenon re­
flecting a more severe and persistent underlying illness.
6 The primary diagnosis is defined as the diagnosis that comes first in a patient’s lifetime.
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2.7 Implications of comorbidity
When mood and anxiety disorders occur together, they tend to be associated 
with more severe symptoms, increased impairment, a more chronic illness 
course, poorer treatment outcome and a higher incidence of suicide (Bakish, 
1999). There is consistent evidence showing mixed symptoms of mood and 
anxiety to reflect more severe illness (Ballenger, 1998; Barbee, 1998; Clay­
ton, 1990; Clayton et al., 1991; Coryell et al., 1988; Coryell et al., 1992; 
Fawcett, 1997; Lecrubier & Üstün, 1998; Sherbourne & Wells, 1997). The 
probability of a new depressive episode is also increased in mood disorder 
patients with comorbid anxiety disorders. Comorbid panic and phobia de­
crease the likelihood of remission from depression (Sherbourne & Wells,
1997) and produce longer episode durations. Finally, patients with comorbid 
mood and anxiety disorders tend to be younger at intake and at first episode 
of major depression than patients with major depression alone (Coryell et al., 
1992).
Comorbidity of mood and anxiety disorders consistently shows a nega­
tive correlation with treatment outcome. To illustrate, patients with major 
depression and panic attacks treated with antidepressants were less likely to 
recover during a two year follow-up than patients without panic attacks 
(Coryell et al., 1988). Among a group of patients with major depression, 
those with higher anxiety ratings took twice as long to recover from drug 
treatments or psychotherapy than those with lower anxiety ratings (Clayton 
et al., 1991). More recent studies have specifically considered the role of co­
morbidity of mood and anxiety disorders in treatment outcome. Fava et al. 
(1997) investigated the role of depressive subtypes in response to fluoxetine 
in outpatients with major depression and found nonanxious depressives (pa­
tients without any comorbid anxiety disorder) to improve more during treat­
ment than anxious depressives, while other subtypes did not show differen­
ces in treatment outcome. The presence or absence of comorbid anxiety in 
inpatients with severe major depression made no difference to treatment out­
come (Rodney et al., 1997). As noted before, however, selection bias ob­
viously occurs in inpatient samples (Bouvy, 1997) which is reflected in the 
results.
Finally, severe anxiety symptoms and particularly when associated with 
major depression appear to constitute an acute risk factor for suicide (Angst, 
Angst, & Stassen, 1999; Fawcett, 1997; Lecrubier & Üstün, 1998). Suicidal 
ideation, a history of past suicide attempts and the severity of hopelessness 
have not found to correlate significantly with suicide over the subsequent 
year but the severity of psychic anxiety and the presence of panic attacks do 
correlate significantly. Rapid and aggressive treatment of symptoms of an­
xiety/agitation symptoms with suitable antidepressants or benzodiazepines 
should thus be considered to reduce the acute risk of suicide (Fawcett, 1997).
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3 The personality model of Cloninger
The personality model of Cloninger (Cloninger, 1987) has been reputed to 
differentiate between responders and nonresponders to antidepressant treat­
ment. In the present study, the model is therefore included to explore the dif­
ferential responses of patients with mood and/or anxiety disorders to antide­
pressant treatment (e.g., TCA versus SSRI). In the present chapter, the theo­
retical model and corresponding inventory, the Tridimensional Personality 
Questionnaire (TPQ), will be considered in greater detail. Thereafter, the re­
levance of the personality model will be considered from two perspectives: 
the underlying theoretical assumptions regarding temperament and the psy­
chopathology of mood and anxiety disorders (3.2) and the empirical support 
for the role of temperament in antidepressant treatment response (3.3).
3.1 The personality model of Cloninger
Cloninger has developed a general model of personality that applied to both 
normal and abnormal personality (Cloninger, 1987; Cloninger, Svrakic & 
Przybeck, 1993). The existing personality models were focused on either 
normal personality in terms of trait dimensions or abnormal personality in 
terms of the classification of personality disorders. Although in both areas of 
research, three dimensions or clusters of characteristics have been found to 
arise, no systematic relationship has been described between both areas. Clo- 
ninger described not only the observed structure of personality (phenotype), 
as in the model of Eysenck (Neuroticism-Extraversion-Psychoticism), but al­
so included the underlying biogenetic structure (genotype). Eysenck assu­
med that phenotypic structure and genotypic structure were the same al­
though this is questionable, according to Cloninger. To illustrate, extraver­
sion has been found to be genetically heterogeneous; that is, extraversion ap­
pears to be composed of the two genetically independent factors of impulsi- 
vity and sociability which constitute a single behavioural dimension due to 
shared environmental influences. In addition, anti-anxiety drugs have been 
found to reduce not only scores on neuroticism but also on introversion, 
which suggests that these dimensions of personality share biological deter­
minants even though they are typically assumed to represent independent 
processes (Cloninger, 1987). Yet another illustration of the limited value of 
traits for the assessment of personality disorder is the content of the factor 
called neuroticism which is a clinically heterogeneous composite of anxiety, 
hostility, depression, self-consciousness, impulsiveness and general emotio­
nal vulnerability. High neuroticism scores are frequent for individuals with a 
personality disorder but also for many psychiatric patients without a perso­
33
nality disorder; even some people with no psychiatric disorder have high 
neuroticism scores (Cloninger et al., 1993).
On the basis of foregoing types of evidence, Cloninger concluded that 
personality factors are clinically and genetically heterogeneous and therefore 
inadequate for understanding the underlying determinants of psychopatho­
logy. In order to test a number of hypotheses about the causal structure of 
personality, Cloninger developed a general psychobiological model of perso­
nality in which the psychosocial and neurobiological approaches to patient 
assessment and treatment are integrated (Cloninger, 1987). The original mo­
del included three dimensions of temperament postulated to be genetically 
homogeneous and independent of each other: Novelty Seeking, Harm Avoid­
ance and Reward Dependence. More recently, the model has been extended 
to include seven factors pertaining to temperament and character7. Tempera­
ment involves individual differences in automatic emotional reactions and 
habits, character involves differences in self-concepts about goals and atti­
tudes. Cloninger defined personality as “differences between individuals in 
the adaptive systems involved in the reception, processing, and storing o f in­
formation about experience” (Cloninger et al., 1993). Although the model 
was extended to be more comprehensive and improve the diagnosis of perso­
nality disorders, temperament continues to be of primary interest in the 
search for the biological determinants of mood and anxiety disorders. Di­
mensions of temperament appear to be more directly tied to the neurobiolo- 
gical and genetic determinants of behaviour than dimensions of character, so 
the model of temperament will therefore be the focus of the present study 
and described in greater detail below.
3.1.1 The model o f temperament
The temperament dimensions are defined in terms of individual differences 
in associative learning in response to novelty, danger or punishment and re­
ward (see Figure 3.1). Each dimension of temperament has been hypothe­
sised to reflect the underlying biogenetic structure of an individual in terms 
of variations of the dopaminergic, serotonergic and noradrenergic brain sys­
tems.
Novelty Seeking is viewed as a heritable bias towards the activation or 
initiation of behaviour, which may include frequent exploratory activity in 
response to novelty, impulsive decision making, quick loss of temper and ac­
tive avoidance of monotony and frustration. Dopaminergic projections from 
the ventral tegmental area in the brainstem to the striatum (caudate and puta- 
men) and other limbic and cortical sites are predicted to play a crucial role in
7 Persistence was originally a subscale of reward dependence and is now recognised as an 
independent dimension. Three additional character dimensions are: self-directedness, co­
operativeness and self-transcendence.
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the neuromodulation of behavioural activation in response to novelty and to 
signals of reward.
Harm Avoidance is a heritable tendency to respond intensely to signals 
of aversive stimuli, which may include the inhibition of behaviour to avoid 
punishment, the avoidance of novelty and the avoidance of frustrative nonre­
ward. Examples of such a behavioural inhibition pattern are: pessimistic 
worry in anticipation of future problems, such passive avoidant behaviours 
as a fear of uncertainty and a shyness of strangers, and rapid fatigability. Se­
rotonergic, noradrenergic and cholinergic projections to the amygdala and 
septohippocampal regions underlying the temperal cortex are predicted to 
play a crucial role in the neuromodulation of behavioural inhibition in res­
ponse to signals of punishment or non-reward.
Reward Dependence is viewed as a heritable bias towards the mainte­
nance or continuation of ongoing behaviours which can manifest itself as 
sentimentality, social attachment and dependence on the approval of others. 
Individual differences in postsynaptic sensitivity of neurons in the frontal 
cortex to noradrenergic projections from the locus ceruleus in the brainstem 
are predicted to play a role in reward dependence.
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Source: Cloninger unpublished (1996) 
Figure 3.1 Model o f  temperament
Persistence, was originally taken to be a component of Reward Depen­
dence but emerged as a separate fourth dimension measured in terms of per­
severance despite frustration and fatigue. Persistence is predicted to reflect 
individual differences in the brain’s systems for the modulation of intermit­
tent reinforcement. Signals of intermittent punishment are converted into 
signals of eventual reward by short-circuiting activation of the behavioural 
inhibition system and thereby stimulating the behavioural activation system 
which depends on crucial projections from the hippocampal subiculum (part 
of the inhibition system) and the nucleus accumbens (part of the activation 
system).
These four dimensions of temperament are assumed to be heritable, manifest 
themselves early in life and involve unconscious biases in learning. Large- 
scale twin studies have shown the heritability of the dimensions between 
50% and 65% and confirmed that the dimensions were genetically homoge-
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neous and independent (Heath, Cloninger, & Martin, 1994; Stallings, Hewitt, 
Cloninger, Heath, & Eaves, 1996). In both normal and abnormal samples, 
the dimensions of temperament have been found to be highly reliable and 
stable despite mood state. Only Harm Avoidance has been found to increase 
when patients are agitated or distressed (Cloninger, Przybeck, Svrakic, & 
Wetzel, 1994). Unfortunately, the relation of temperament to regional brain 
activity is difficult to assess because the networks of brain connections are 
very complicated. Cloninger found support for a number of his neurobiolo- 
gical predictions using brain imaging, neurocognitive, neurochemical and 
neuroendocrine measures (Cloninger et al., 1994). Nevertheless, the empiri­
cal evidence regarding the relations of temperament to variations in the do­
paminergic, serotonergic and noradrenergic brain systems is still quite limi­
ted. Empirical evaluation of the specific relations between the neurotrans­
mission brain systems and temperament is beyond the scope of the present 
thesis, moreover.
3.1.2 The Tridimensional Personality Questionnaire (TPQ)
The Tridimensional Personality Questionnaire was developed to operatio­
nalise the theoretical construct of temperament (Cloninger, 1987; Cloninger, 
Przybeck, & Svrakic, 1991). This selfreport inventory consists of 100 true- 
false items and originally measured three dimensions of temperament: No­
velty Seeking (NS), Harm Avoidance (HA) and Reward Dependence (RD) 
with each scale consisting of four subscales (see Table 3.1). As already no­
ted, however, normative studies using the TPQ showed Persistence to be un­
correlated with other aspects of Reward Dependence and to therefore con­
stitute an independent dimension of temperament: Persistence (P) (Cloninger 
et al., 1993). The TPQ is the precursor to the Temperament and Character 
Inventory (TCI)8 (Cloninger et al., 1994) and the psychometric properties of 
the TCI have been best described. The correlations between the TPQ and 
TCI temperament scale scores have been found to be high (.971 for NS, .997 
for HA, .932 for RD and .883 for P) and the TCI scales have been found to 
be moderately to highly reliable. The internal consistency of the scales, as 
measured by Cronbach’s alpha has been found to range from .65 for P to .87 
for HA. The test-retest reliability of the scales has been found to range from 
.54 for HA to .72 for P in an inpatient population and range from .71 for RD 
to .79 for NS in an outpatient population. The reliability of the TPQ has not 
been considered separately.
8 The TCI assesses seven dimensions of personality and consists of 240 items, including 
90 original TPQ items.
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Empirical validation of the TPQ rests, rather, on the strong association of 
eight temperament types (combinations of NS, HA and RD) with the DSM- 
III-R clusters of personality disorders in adults (Svrakic, Whitehead, Przy­
beck, & Cloninger, 1993; Goldman, Skodal, Mc Grath, & Oldham, 1994). In 
addition, longitudinal studies have shown a childhood configuration of high 
NS, low HA, low RD and low P to predict adolescent antisocial behaviour, 
alcohol and drug abuse and adult criminality (Cloninger et al., 1994). When 
Stallings et al. (1994) carried out a structural analysis of the underlying ge­
netic and environmental antecedents of the TPQ in a large population of 
twins, moreover, the results also showed the different dimensions of tempe­
rament to be genetically homogeneous and genetically independent of each 
other.
The TPQ has been translated and studied in several countries and is also 
avialable in Dutch. Psychometric data based on a normal Dutch population is 
available for only the TCI, however (Duijsens, Goekoop, J.G., Spinhoven, 
P., & Eurelings-Bontekoe, 1997). The mean scores for HA and RD were 
found to be significantly higher than the scores from an American sample: 
15.15 versus 12.6 and 16.14 versus 15.4, respectively. The mean score for P 
was significantly lower with 4.19 versus 5.6. The internal consistency of the 
scales was comparable to that for the American sample (Cloninger et al., 
1994).
3.2 The relation of temperament to mood and anxiety disorders
The different dimensions of temperament appear to be closely related to a 
differential susceptibility to neurotic syndromes (Cloninger et al., 1993). 
Different levels of Harm Avoidance are hypothesised to reflect variations in 
the brain’s behavioural inhibition system. An intense response to signals of 
aversive stimuli and an associated tendency to inhibit behaviour in order to 
avoid punishment, novelty or the frustration of nonreward will lead to a pas­
sive avoidance pattern of behaviour. In addition to this, high Harm Avoid­
ance is hypothesised to increase susceptibility to mood and anxiety disorders 
and empirical findings have indeed shown consistently elevated Harm A-
9 The subtypes of personality disorders can be largely understood in terms of the interac­
tion of the different dimensions of temperament (called temperament types).Temperament 
scores are grouped into low, average or high categories (of equal size in terms of percen­
tile scores) to create eight extreme temperament types which also correspond to the tradi­
tional personality categories found in the DSM. Everyone can be assigned to one tempera­
ment type. In contrast, the DSM system often shows overlap in diagnoses due to a lack of 
specificity of the diagnostic criteria. The test-retest reliability of the temperament types 
has been found to be moderately high (.75) (Cloninger et al., 1994) and the stability was 
best for the severe cases.
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voidance scores in patients with mood and anxiety disorders when compared 
to the normal population (Brown, Svrakic, Przybeck, & Cloninger, 1992; 
Cloninger et al., 1994; Cowley, Roy-Byrne, Greenblatt, & Hommer, 1993; 
Joffe, Bagby, Levitt, Regan, & Parker, 1993). Individuals with various an­
xiety disorders are also expected to score high on Harm Avoidance and have 
consistently been found to do so. However, individuals with high Harm A­
voidance do not necessarily show an anxiety disorder, that is, they may be 
healthy or demonstrate some other form of psychopathology (e.g., major de­
pression). In addition, high Novelty Seeking was found to be related to a lo­
wer sedation stresshold or, in other words, greater sensitivity to sedation. 
Compliance with drug taking was also found to be lower for anxiety disorder 
patients with high Novelty Seeking (Cloninger et al., 1994).
According to Cloninger’s theory, Harm Avoidance is assumed to be di­
rectly related to a susceptibility to anxiety disorders, while the different sub­
types of depression are assumed to be related to different interactions be­
tween temperaments. Empirical studies have indeed shown Harm Avoid­
ance scores to be consistently elevated in patients with mood disorders when 
compared to the general population (Cloninger et al., 1994). Furthermore, 
the assumption that high Novelty Seeking in combination with high Harm A­
voidance will lead to dysthymia due to a continuous approach-avoidance 
conflict within the individual (i.e., an imbalance between behavioural acti­
vation and inhibition) has been supported. Conversely, impulsive-aggression 
is expected when high Novelty Seeking is combined with low Harm Avoid­
ance. In addition, people with high Reward Dependence scores are predicted 
to be sensitive to social loss, which can lead to the reactive dysphoria cha­
racteristic of atypical depression (Cloninger et al., 1994).
A crucial question is whether elevated temperament scores reflect life­
long personality traits or state mood. Harm Avoidance has been found to be 
related to current mood state, while the other dimensions of temperament 
show much less sensitivity to changes in mood state. Harm Avoidance 
scores are less stable in depressed patients than in the general population 
(test-retest correlations of .79 versus .51) and Harm Avoidance scores have 
been shown to covary with changes in mood measured before and after treat­
ment (Brown et al., 1992). In panic disorder patients, however, Harm Avoid­
ance scores have been found to remain stable, despite reductions in panic 
attacks, which suggests that Harm Avoidance may increase during acute de­
pressed states but constitutes a stable feature of many anxiety disorders (Clo­
ninger et al., 1994).The finding that both mood and anxiety disorder patients 
score high on Harm Avoidance raises the question of how to discriminate 
susceptibility to these disorders. At this point, more research is needed. The 
discriminant validity of the TCI with regard to anxiety and depression shows 
anxiety to be solely related to high Harm Avoidance while depression is re­
lated to a combination of high Harm Avoidance and high Novelty Seeking 
(Cloninger et al., 1994). These findings are in line with the assumption that
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anxiety is directly related to Harm Avoidance, while depression is influenced 
by the interaction of the different dimensions of temperament.
3.3 Temperament and antidepressant treatment response
Several studies have explored the role of temperament as a possible predictor 
of antidepressant treatment response. Joffe et al. (1993) showed outpatients 
who were nonresponders to standard antidepressant treatment10 for major de­
pression to score higher on Harm Avoidance than responders at both base­
line and after three months of treatment. In another study, specific combina­
tions of temperaments (temperament types) have been related to response to 
antidepressants (Joyce, Mulder, & Cloninger; 1994). In fact, temperament 
type turned out to be the only predictor of outcome when compared to perso­
nality disorder, severity of depression, age and sex, and it accounted for 25% 
of the variance. Patients with low scores on all three dimensions of tempera­
ment and patients with high Harm Avoidance combined with high Reward 
Dependence showed a high response rate to antidepressants (desipramine 
and clomipramine). Patients with high scores on Novelty Seeking but low 
scores on the other dimensions of temperament and patients with high scores 
on Harm Avoidance and low scores on Reward Dependence or visa versa 
showed low treatment response. Cloninger concludes that depressives are 
clinically and etiological heterogeneous and that temperament is a more po­
werful way of characterising this heterogeneity than variation in depressive 
symptoms or comorbid psychopathology (Cloninger et al., 1994). More re­
cently, Nelson and Cloninger (1997) showed that patients with major de­
pression and high scores on Reward Dependence showed lowest response to 
antidepressants (nefazodone). In line with previous findings, Harm Avoid­
ance, Reward Dependence and their interaction predicted treatment respon­
se. It should be noted that the model showed a significant predictive value 
due to the large number of patients but only accounted for 1 .1% of the va­
riance in the results. Nelson and Cloninger therefore conclude that although 
the clinical utility of these findings is uncertain, such a line of investigation 
nevertheless constitutes a potentially useful strategy for linking temperament 
to pharmacological response.
As shown, the role of temperament in antidepressant treatment response 
has been studied primarily in patients with a mood disorder. In a study of the 
treatment of patients with a panic disorder or generalized anxiety disorder 
(Wingerson et al., 1993), it was found that dropouts scored significantly
10 Standard treatment involved initial trial on imipramine or desipramine for five weeks. 
Initial failures then received augmentation with lithium, triiodothyronine or both, an 
SSRI, and then after washout a monoamine oxidase inhibitor (Joffe et al., 1993).
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higher than completers on Novelty Seeking; other demographic and clinical 
variables, moreover, did not differentiate dropouts from completers.
To summarise: there is considerable empirical evidence that high Harm 
Avoidance is consistently related to a nonresponse to antidepressant treat­
ment. Temperament type has also been found to be related to treatment res­
ponse although the predisposing role of certain temperament types (e.g., high 
Harm Avoidance/high Novelty Seeking or high Harm Avoidance/high Re­
ward Dependence) has yet to be demonstrated. More replication studies are 
certainly needed. The personality model of Cloninger provides a new per­
spective on the identification of patients within the broad spectrum of mood 
and anxiety disorders. Rather than a focus on the DSM categories based on 
current symptomatology, the psychobiological model of Cloninger provides 
an alternative typology of patients based on temperament dimensions. Such a 
personality approach, linked to underlying neurobiological structures, may 
be particularly useful for the detection of differences in antidepressant treat­
ment response.
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4 Outline of the empirical research
The aim of the present study was to explore possible, previously undetected, 
differences between antidepressants. The comorbidity between mood and an­
xiety disorders raises problems for accurate diagnosis and thereby problems 
for the selection of patients in outcome research. In recognition of such co­
morbidity problems and to reduce selection bias, we therefore chose a design 
different from that used in previous clinical trials: All patients who might be­
nefit from antidepressant treatment were included - both patients with mood 
as well as anxiety disorders. The study design and selection procedures will 
be considered in greater detail below.
4.1 Overall study outline
At three study sites, all new outpatients were screened for inclusion in the 
study. Patients were screened by the treating psychiatrist at intake for the 
presence of a mood or anxiety disorder, for the absence of exclusion condi­
tions and for the severity of the pathology. Subsequent assessment of those 
patients considered eligible was then done by an independent rater both at 
baseline and during treatment.
4.2 Participating centres
The participating centres were a community mental health centre (RIAGG 
Dordrecht: centre 1), an outpatient clinic affiliated with a psychiatric hospital 
(Delta Hospital, Multifunctional Centre Rotterdam-South: centre 2) and an 
outpatient clinic affiliated with a general hospital (Hospital Velp: centre 3). 
The centres were all situated in the Netherlands. Data collection took place 
between May 1994 and October 1996 and was initiated at the RIAGG Dord­
recht, followed by centre 2 in January 1995 and centre 3 in May 1995.
4.3 Study design
The study was an open, randomised, 6-week treatment study to compare imi­
pramine and fluvoxamine. One of the aims of the study was to include a 
sample as representative of normal clinical practice as possible. A double 
blind design was considered unsuitable as we anticipated serious bias due to 
the refusal of certain patients to participate. Knowing what medication they 
are taking appears to be important to patients, and the conditions for provi­
ding one’s informed consent appear to be easier to accept under such cir­
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cumstances. Non-blindness is nevertheless a disadvantage for researchers 
due to possible judgement biases during the evaluation of treatment out­
come. In order to reduce the bias possibly introduced by non-blind experi­
mental treatment, the outcome ratings were performed by a person blind to 
treatment condition.
4.4 Inclusion criteria
All new attending patients were screened using the following inclusion crite­
ria.
1. Age between 18 and 65 years.
2. Current diagnosis with a mood or anxiety disorder according to the 
DSM-III-R criteria as assessed using the Munich Diagnostic Checklist 
(MDCL: Hiller, Zaudig & Mombour, 1990).
3. At least a moderate illness severity on the Clinical Global Impression 
(CGI: Guy, 1976).
4. Provision of informed consent.
To facilitate selection of a broad diagnostic group of patients and encourage 
application of a systematic diagnostic procedure, we semi-structured the 
MDCL by selecting the relevant checklists to be completed at screening. A 
subset of 14 checklists was used: adjustment disorder, agoraphobia, alcohol 
dependence and abuse, bulimia nervosa, cyclothymia, dysthymia, generali­
zed anxiety disorder, major depressive disorder, obsessive compulsive disor­
der, panic disorder with and without agoraphobia, schizoaffective disorder, 
simple phobia and somatization disorder (see also Chapter 5, pp. 59; Chapter 
6, pp. 70).
4.5 Exclusion criteria
1. Unsuccessful treatment with an accurate dose and accurate duration of 
fluvoxamine or imipramine during this episode.
2. Pregnancy, lactation or females with childbearing potential not using ade­
quate contraception.
1 . History of epilepsy or seizures.
4. Clinically important or unstable disease, or some other disease which 
could interfere with the diagnosis or treatment of depression.
5. Liver or kidney disease.
6 . Patients with clinically relevant abnormal laboratory test results.
7. Cardiovascular insufficiency, AV-block grade I-III, arrhythmia, recent 
myocardial infarction, prolonged cardiac conduction times.
8. Adrenal tumours (pheochromocytoma, neuroblastoma).
9. Miction disturbances, prostate hypertrophy, glaucoma.
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10. Multiple drug allergies.
11. Treatment with an experimental drug, a MAOI, lithium, antipsychotic or 
electroconvulsive shock therapy (ECT) within two weeks of entering the 
study.
12. Treatment with an antidepressant within one week of randomisation and 
fluoxetine within five weeks of entering the study.
13. Concurrent use of central nervous system (CNS) medication, other than 
for nighttime sedation and to control anxiety.
14. Patients with language or understanding difficulties which make assess­
ment impossible or difficult.
15. Patients previously enrolled in this study.
16. Use of cocaine, amphetamine or opiates, or daily use of alcohol (more 
than 3 drinks a day).
4.6 Size of the patient samples
A total of 114 patients were included and randomised to one of the treatment 
conditions. After randomisation and before initiation of treatment, five pa­
tients refused to participate further and one patient turned out to meet one of 
the exclusion criteria. A total of 108 patients thus participated in the treat­
ment study. Most of the patients were admitted to the RIAGG Dordrecht: a 
total of 92 patients (85%). Six patients were included from the Delta Hospi­
tal Rotterdam, and a total of ten patients from the Hospital Velp were inclu­
ded (see Table 4.1).
Given that most of the multi-centre patient sample came from the RIAGG 
Dordrecht population, we decided to use only this patient sample to study the 
efficacy of treatment. The principal argument for not including the patients 
from the other centres in this analysis was that our goal of obtaining a multi­
centre sample including a variety of patients in different treatment settings 
was not met. The efficacy results would therefore be determined primarily 
by the RIAGG Dordrecht sample.
The question of diagnostic accuracy, in contrast, can be studied using 
the multi-centre sample. The selection procedure in the present study is not 
assumed to interfere with the comparison of diagnostic procedures (clinical 
diagnosis versus structured diagnostic interview).
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Table 4.1 Demographic and clinical characteristics per centre
Centre 1 
RIAGG 
Dordrecht
Centre 2 
Delta Hospital 
Rotterdam
Centre 3 
Hospital Velp
M SD M SD M SD
Agea 34.50 9.94 52.19 11.79 33.01 9.48
n % n % n %
Patient sample 96 6 10
Sexb
male 33 35.9 2 33.3 5 50.0
female 59 64.1 4 66.7 5 50.0
Marital statusc
married 40 43.5 6 60.0
never married 38 41.3 2 33.3 4 40.0
divorced 13 14.1 3 50.0
widowed 1 1.1 1 16.7
Educationd
elementary school 36 39.1 4 66.7 7 70.0
high school 42 45.7 1 16.7 1 10.0
higher 14 15.2 1 16.7 2 20.0
Treatment medicatione
fluvoxamine 48 52.2 2 33.3 5 50.0
imipramine 44 47.8 4 66.7 5 50.0
MDCL diagnosisf
Mood disorder (M) 20 21.7 3 50.0 3 30.0
Anxiety disorder (A) 46 50.0 3 50.0 6 60.0
Comorbid M-A 26 28.3 1 10.0
CIDI diagnosisg
Mood disorder (M) 18 22.2 1 16.7 2 22.2
Anxiety disorder (A) 19 23.5 2 33.3 4 44.4
Comorbid M-A 41 50.6 3 50.0 3 33.3
No diagnosis 3 3.7
Note. a F(2,108) = 9.12, p  < .05; b x2(2,108) = .81, p  > .05; c x2(6,108) = 17.49, p  < .05; d x2(4,108) = 
6.61, p  > .05; e x 2(2,108) = .80, p  > .05; f x2(4,108) = 4.99, p  > .05. g x2(6,96) = 2.63, p  > .05
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The analyses for the different research questions are thus based on dif­
ferent patient samples and sample sizes. An overview of the different sam­
ples is presented in Figure 4.1, and the selection procedures for the separate 
research studies will be described in greater detail below.
regression analysis
Figure 4.1 Selection o f the patient samples
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For the study o f diagnostic accuracy (see Chapter 5), the multi-centre sample 
was analysed. A total of 108 patients started treatment (centre 1: 92 patients; 
centre 2: 6 patients; centre 3: 10 patients). For 96 of these patients, CIDI data 
was available. Because the CIDI was assessed during week 4 of treatment, 
patients who dropped out before week 4 would not be assessed. In order to 
obtain the CIDI data for the entire sample, the patients dropping out before 
week 4 were nevertheless asked to complete the CIDI. The procedure was 
that the treating psychiatrist contact the researcher as soon as possible when 
a patient did not complete the treatment study. The researcher then phoned 
the patient to request further co-operation on the remaining assessments. The 
reasons for noncompletion of the treatment were as follows: non-compliance 
with treatment (4 patients), non-compliance with the study (4 patients) and 
serious side effects (4 patients). For a few patients, the psychiatrist recom­
mended not contacting them for further co-operation because the patient 
stated that they did not want to participate any longer. The other patients 
were telephoned, and one patient was sent a letter because telephone contact 
was not possible. They all refused to co-operate further, however.
A comparison of the clinical diagnosis with the CIDI diagnosis was thus 
available for 96 (or 89%) of the 108 patients. The demographic characteris­
tics of the 12 patients with no CIDI diagnosis showed no significant diffe­
rences when compared to the sample of 96 patients, with the exception of 
educational level (x2(2,108) = 6.02, p  = .05) (see Table 4.2).
More of the patients who dropped out had only an elementary education 
when compared to those who did not drop out. Furthermore, the MDCL- 
based diagnoses (including mood disorder, anxiety disorder or comorbid 
mood and anxiety disorders) for the patients who dropped out were compa­
rable to those for the 96 patients who participated (x (2,108) = 2.05, p  > 
.05).
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Table 4.2 Demographic and clinical characteristics o f the analysed patient sample
(n=96) versus excluded cases (n=12) for the study o f diagnostic accuracy (Chapter 5)
Patient sample (n=96) Excluded cases (n=12)
M SD M SD
Agea 35.98 10.92 30.23 7.56
n % n %
Sexb
male 36 37.5 4 33.3
female 60 62.5 8 66.7
Marital statusc
married 40 41.7 6 50.0
never married 40 41.7 4 33.3
divorced 14 14.6 2 16.7
widowed 2 2.1
Educationd
elementary school 38 39.6 9 75.0
high school 41 42.7 3 25.0
higher 17 17.7
Treatment medicatione
fluvoxamine 50 52.1 5 41.7
imipramine 46 47.9 7 58.3
MDCL diagnosisf
Mood disorder (M) 25 26.0 1 8.3
Anxiety disorder (A) 47 49.0 8 66.7
comorbid M-A 24 25.0 3 25.0
Note. a t = -1.77, p  > .05; b x2(1,108) = .08, p  > .05; c x2(3,108) = .64, p  > .05; d x2(2,108) = 6.02, p  = 
.05; ex2(1,108) = .46, p  > .05; f x2(2,108) = 2.05, p  > .05
For the study o f the role ofprimary diagnosis in the efficacy o f antidepres­
sant treatment, we used the RIAGG Dordrecht sample exclusively (see 
Chapter 6). A total of 98 patients were included and randomised to one of 
the treatment conditions. However, before initiation of the treatment, five pa-
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tients refused to participate further and one patient turned out to meet one of 
the exclusion criteria, which produced a final RIAGG Dordrecht sample of 
92 patients.
For 81 of the 92 patients, the CIDI data were available to operationalise 
the diagnosis at first episode or the primary diagnosis. Three of the patients 
had no DSM diagnosis according to the CIDI (see above), which meant that 
the analyses of the role of primary diagnosis in the efficacy of antidepressant 
treatment involved a total of 78 patients. The 14 patients who were not in­
cluded in the efficacy analyses showed no significant differences with regard 
to demographic characteristics or clinical characteristics when compared to 
the 78 patients who were included, with the exception of completion of the 
6-week treatment (x2(1,92) = 46.92, p  < .001). The excluded sample consis­
ted of more noncompleters than the included sample (see Table 4.3).
A total of 15 patients did not complete the 6-week treatment. For the four pa­
tients who dropped out after 4 weeks of treatment, the CIDI-based diagnosis 
was available. Of the 78 patients included in the analyses, 74 patients com­
pleted the treatment and four patients thus did not complete the 6-week treat­
ment. Although the demographic characteristics were comparable for both 
groups, the exclusion of 14 patients from the analyses of treatment efficacy 
may nevertheless have introduced a selection bias because we cannot assume 
the two groups of patients to be equivalent with regard to diagnostic, clinical 
and personality characteristics.
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Table 4.3 Demographic and clinical characteristics o f  the analysed patient sample
versus excluded cases for study o f  the role o f  primary diagnosis in the efficacy o f
treatment (Chapter 6)
Patient sample (n=78) Excluded cases (n=14)
M SD M SD
Agea 35.05 10.03 31.45 9.15
Sexb
n % n %
male 27 34.6 6 42.9
female 51 65.4 8 57.1
Marital statusc
married 34 43.6 6 42.9
never married 33 42.3 5 35.7
divorced 10 12.8 3 21.4
widowed 1 1.3
Educationd
elementary school 27 34.6 9 64.3
high school 37 47.4 5 35.7
higher 14 18.0
Treatment medicatione
fluvoxamine 42 53.8 6 42.9
imipramine 36 46.2 8 57.1
Treatment completersf
completers 74 94.9 3 21.4
dropouts 4 5.1 11 78.6
MDCL diagnosisg
Mood disorder (M) 19 24.4 1 7.1
Anxiety disorder (A) 36 46.2 10 71.4
comorbid M-A 23 29.5 3 21.4
Note. a t = -1.25, p  > .05; b x2(1,92) = .35, p  > .05; c x2(3,92) = .93, p  > .05; d x2(2,92) = 5.54, p  > .05; e 
x2(1,92) = .57, p  > .05; f x2(1,92) = 46.92, p  < .001; g x2(2,92) = 3.41, p  > .05
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For the study o f the role o f temperament in the differentiation o f antidepres­
sant treatment response, a subsample (74 patients) of the RIAGG Dordrecht 
sample of 92 patients was used (see Chapter 7). At the start of the research 
project, we administered the TPQ at baseline. In light of the fact that our pa­
tient population reported considerable difficulty with the completion of the 
TPQ and the fact that the TPQ has been designed to assess dimensions of 
temperament which are relatively stable over time (Cloninger, 1987), we de­
cided to administer the TPQ at week 6 of treatment in stead of baseline to the 
remaining 74 patients. The TPQ was designed to assess a person’s habitual 
feelings and behaviour independent of the current period because tempera­
ment is assumed to not change over time. That is, temperament refers to 
automatic emotional responses which have been found to be moderately he­
ritable (Heath, Cloninger, & Martin, 1994) and stable throughout life (Clo­
ninger, 1987; Cloninger, Przybeck, Svrakic, & Wetzel, 1994). At the same 
time, however, considerable doubt has been raised about the stability of tem­
perament, and especially Harm Avoidance scores have been found to vary 
depending on the current mood state (Brown, Svrakic, Przybeck, & Clonin­
ger, 1992; Joffe et al., 1993). Additional evidence has also been raised more 
recently with regard to a lack of stability for the Harm Avoidance scale 
(Chien & Dunner, 1996) (see also Chapter 7, pp.90; Chapter 8, pp. 100-01). 
The 18 patients who were scheduled to complete the TPQ at baseline were 
not included in the final analyses to prevent possible bias due to different as­
sessment points. In other words, the analyses were restricted to a subsample 
of 74 patients who completed the TPQ after 6 weeks of treatment.
For the relevant subsample, no significant differences with regard to de­
mographic or clinical characteristics were found when compared to the other 
cases treated at the RIAGG Dordrecht (see Table 4.4).
Sixtyeight patients (or 92%) of the 74 patients completed the TPQ. The 63 
patients who completed the 6-week treatment all completed the TPQ. The 11 
patients who did not complete the 6-week treatment were asked by phone to 
still complete the TPQ, which was then mailed to them. Five of the 11 pa­
tients then completed the TPQ, all within four weeks after dropout. Five pa­
tients, however, refused to cooperate further and one patient never returned 
the questionnaire. To conclude, in six of the 74 patients the TPQ data were 
not available, which may have introduced a selection bias.
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Table 4.4 Demographic and clinical characteristics o f the subsample o f  the RIAGG 
Dordrecht sample (n=74) ) for study o f the role o f  temperament in the efficacy o f 
treatment versus the other cases o f  the RIAGG Dordrecht sample (n=18) (Chapter 7)
Patient sample (n=74) Other cases (n= 18)
M SD M SD
Agea 34.86 10.18 33.02 8.95
n % n %
bSexb
male 28 37.8 5 27.8
female 46 62.2 13 72.2
Marital statusc
married 32 43.2 8 44.4
never married 30 40.5 8 44.4
divorced 11 14.9 2 11.2
widowed 1 1.4
Educationd
elementary school 26 35.1 10 55.6
high school 35 47.3 7 38.9
higher 13 17.6 1 5.5
Treatment medicatione
fluvoxamine 36 48.6 12 66.7
imipramine 38 51.4 6 33.3
Treatment completersf
completers 63 85.1 14 77.8
dropouts 11 14.9 4 22.2
MDCL diagnosis8
Mood disorder (M) 17 23.0 3 16.7
Anxiety disorder (A) 36 48.6 10 55.6
Comorbid M-A 21 28.4 5 27.8
CIDI diagnosish
Mood disorder (M) 14 21.5 4 25.0
Anxiety disorder (A) 14 21.5 5 31.3
Comorbid M-A 34 52.3 7 43.8
No diagnosis 3 4.6
Note. a t = -.70, p > .05; b x2(1,92) = .64, p > .05; c x2(3,92) = .45, p > .05; d x2(2,92) = 3.14, p > .05; e
x2(1,92) = 1.88, p > .05; f x2(1,92) = .57, p >.05; g x2(2,92) = .41, p > .05; h x2(3,81) = 1.51, p > .05
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Based on the data control procedures (also see Chapter 7, pp. 86) we 
decided that outcome data collected more than two weeks difference from 
week 6 of treatment would be excluded from further analyses. Two patients 
were therefore excluded from the regression analysis for the role of tempera­
ment in treatment. The relevant regression analysis was thus based on 61 pa­
tients in the end. The patients in this subsample showed no significant diffe­
rences with regard to demographic characteristics when compared to the 
other patients, with the exception of educational level (x2(2,74) = 6.16, p  < 
.05) (see Table 4.5).
Furthermore, their clinical characteristics showed no significant diffe­
rences, with the exception of treatment completion x2(1,74) = 60.63, p  < 
.001). Inherent to the regression procedure, the analysed group consisted of 
patients who completed treatment. The noncompleters were therefore ana­
lysed separately because - as mentioned before - 5 of the 11 patients who did 
not complete treatment still completed the TPQ. The analysis of the non­
completers was therefore limited to 5 patients.
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Table 4.5 Demographic and clinical characteristics o f  sample included in TPQ
regression analyses (n=61) versus other cases (n=13) (Chapter 7)
Analysed sample (n=61) Other cases (n=13)
M SD M SD
Agea 35.69 10.45 33.92 8.05
Sexb
n % n %
male 24 39.3 4 30.8
female 37 60.7 9 69.2
Marital statusc
married 27 44.3 5 38.5
never married 24 39.3 6 46.2
divorced 9 14.8 2 15.4
widowed 1 1.6
Educationald
elementary school 18 29.5 8 61.5
high school 30 49.2 5 38.5
higher 13 21.3
Treatment medicatione
fluvoxamine 31 50.8 5 38.5
imipramine 30 49.2 8 61.5
Treatment completersf
completers 61 100 2 15.4
dropouts 11 84.6
MDCL diagnosisg
Mood disorder (M) 15 24.6 2 15.4
Anxiety disorder (A) 27 44.3 9 69.2
Comorbid M-A 19 31.1 2 15.4
CIDI diagnosish
Mood disorder (M) 14 23
Anxiety disorder (A) 12 19.7 2 50.0
Comorbid M-A 32 52.5 2 50.0
No diagnosis 3 4.9
Note. a t = -1.55, p  > .05; b x2(1,74) = .34, p  > .05; c x2(3,74) = .42, p  > .05; d x2(2,74) = 6.16, p  < .05; 
e x2(1,74) = .65, p  > .05; f x2(1,74) = 60.63, p  < .001; g x2(2,74) = 2.71, p  > .05; h x2(3,65) = 2.72, p  > .05
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5 A comparison of clinical diagnosis and diagnosis 
based on the Composite International Diagnostic In­
terview: comorbidity and agreement in diagnosing 
mood and anxiety disorders
Summary
In the present study diagnoses based on clinical judgement are compared to 
diagnoses based on a structured diagnostic interview for 96 patients with 
mood and anxiety disorders. The Munich Diagnostic Checklists (MDCL) 
were used by psychiatrists to arrive at DSM-III-R diagnoses. The psycholo­
gists undertook the Composite International Diagnostic Interview (CIDI) to 
also arrive at DSM-III-R diagnoses. The diagnostic agreement between the 
psychiatric diagnosis using the MDCL and the CIDI diagnosis was found to 
be moderate for major depression (k = .47). Fair agreement was found for 
social phobia (k = .40), panic disorder with and without agoraphobia (res­
pectively k = .36 and k = .29), bulimia nervosa (k = .32) and dysthymia (k = 
.26). Poor agreement was found for generalized anxiety disorder and agora­
phobia without panic attacks. According to the CIDI, comorbid mood and 
anxiety disorder existed in 49% o f the patients while the psychiatrists found 
comorbidity in only 25% o f the patients. The data suggest that psychiatrists 
choose between mood and anxiety disorder while the CIDI find both diagno­
ses. This suggests that comorbidity may not be the focus o f attention for ma­
ny clinicians. The only moderate agreement is not in line with other studies 
in which the agreement was found to be satisfactory. The present study casts 
doubt on the validity o f the diagnostic procedures used, while previous stu­
dies appear to confirm the reliability o f the diagnostic instruments. This po­
ses a problem for the interpretation and generalisation o f outcome studies 
on both the psychological and pharmacological treatments o f mood and an­
xiety disorders.
Introduction
One of the problems in diagnosing mood and anxiety disorders is the comor­
bidity of mood and anxiety disorders or, put differently, the overlap of symp­
toms related to depression and anxiety. This problem is apparent in the chan­
ges that have occurred in the criteria for mood and anxiety disorders in the 
succeeding editions of the Diagnostic and Statistical Manual of Mental Dis­
orders (DSM) (APA, 1980, 1990, 1994). The problem is also evident in the 
10th revision of the International Classification of Diseases (ICD-10) (WHO, 
1990a) where ‘mixed anxiety depression’ is recognised as a separate catego­
ry. In our research into the efficacy of antidepressants across different mood
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and anxiety disorders, the reliability and validity of the diagnosis is a major 
issue. In a recent study we therefore included two diagnostic procedures for 
comparison: Clinical diagnosis by the treating psychiatrists (as usual in most 
trials of antidepressants) and diagnosis based on a structured interview (as 
usual in many epidemiological studies). The results of our comparison are 
reported here.
In an attempt to stimulate a more systematic diagnostic process the Mu­
nich Diagnostic Checklists (MDCL) have been developed. The MDCL con­
tain checklists for each of the most important and frequently occurring psy­
chiatric diagnoses based on the systems DSM-III-R and/or ICD-10 classifi­
cation systems (Hiller, Zaudig, & Mombour, 1990a, 1990b). Thirty separate 
lists are involved, and each checklist represents a single diagnostic catego­
ry. Each checklist contains all of the criteria needed for a complete evalua­
tion of the corresponding disorder and a diagnostic decision, although the 
manner in which a particular item is assessed is left completely up to the cli­
nician. The reliability of diagnoses based on the checklists has been found to 
be satisfactory (Hiller, Von Bose, Dichtl, & Agerer, 1990c). High agreement 
between raters has been obtained for major depression (k = .73) and bipolar 
disorder (k = .85). Furthermore, a high level of agreement has been obtained 
in an overall analysis for anxiety disorders (k = .76). Less agreement has 
been found for agoraphobia, social phobia and dysthymia which may be due 
to flaws in their definition and/or operationalisation. However, Hiller et al. 
have suggested that diagnostic disagreement may also indirectly arise from 
the DSM-III-R concept of comorbidity.
The Composite International Diagnostic Interview (CIDI) (WHO, 1990b) 
is a completely structured interview which combines questions from the Dia­
gnostic Interview Schedule (DIS) with questions designed to elicit Present 
State Examination (PSE) items (Robins et al., 1988). The CIDI assesses 
mental disorders using the criteria from the tenth revised version of the In­
ternational Classification of Diseases (ICD-10, Diagnostic Criteria for Re­
search) and the third revised version of the American Psychiatric Associa­
tion’s Diagnostic and Statistical Manual (DSM-III-R) (Essau & Wittchen, 
1993). The CIDI was designed for use in epidemiological studies with nor­
mal populations, is available in a variety of languages and cultures, and is 
currently being used for clinical and other research purposes as well (Witt­
chen, 1994). In a review of the reliability and validity of the CIDI, Wittchen 
(1994) reports good to excellent test-retest and interrater reliability for most 
diagnoses. Use of the CIDI is thus judged to be acceptable for different sub­
jects in different settings and different countries. Only a few aspects of the 
validity of the CIDI have been examined to date and mostly in smaller, se­
lect clinical samples.
In a study on a comparison of the CIDI with clinical DSM-III-R criteria 
checklist diagnoses, the overall diagnostic concordance was found to be 
good (k = .78) (Janca, Robins, Bucholz, Early, & Shayka, 1992). To our
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knowledge, this is the only comparison study using the CIDI. The sample 
consisted of 32 primary care, psychiatric outpatient or volunteer subjects. In 
16 cases, the psychiatrist was an observer during the CIDI interview and co­
ded his or her clinical impressions using the DSM-III-R checklists. Clearly, 
further studies on the validity of the CIDI with clinical instruments are nee­
ded (Wittchen, 1994).
Methods
Participants
A total of 108 patients newly attending three ambulatory mental health servi­
ces in The Netherlands who were screened at intake by a psychiatrist, 
fulfilled DSM-III-R criteria of a mood or anxiety disorder and showed at 
least ‘moderate’ severity of their illness on the Clinical Global Impression 
(Guy, 1976). The patients were between 18 and 65 years of age. After inclu­
sion, a comprehensive structured interview to assess DSM-III-R diagnoses 
again was conducted in 96 of the selected patients: 60 females and 36 males 
with a mean age of 36 years (ranging from 18 to 64, SD = 10.92).
Diagnostic assessments
The Munich Diagnostic Checklists (MDCL) were used by the psychiatrist to 
make a diagnosis in accordance with the DSM-III-R (Hiller et al., 1990a, 
1990b). To encourage adoption of a more systematic diagnostic procedure, 
the use of the MDCL was semistructured by selecting a subset of the 30 
checklists which had to be completed all. For the present study, a subset of 
14 checklists was used: adjustment disorder, agoraphobia, alcohol depen­
dence and abuse, bulimia nervosa, cyclothymia, dysthymia, generalized an­
xiety disorder, major depressive disorder, obsessive compulsive disorder, pa­
nic disorder with and without agoraphobia, schizoaffective disorder, simple 
phobia, social phobia and somatization disorder. The checklists were admini­
stered by the treating psychiatrist as part of the routine screening prior to the 
initiation of treatment. A total of four psychiatrists participated in the study.
The CIDI (WHO, 1990b) was administered by an independent psycho­
logist trained at the Dutch WHO-CIDI Centre. A total of four psychologists 
participated in our study. The CIDI was administered four weeks after the 
start of treatment and took about 90 minutes to complete.
Statistical analysis
The kappa statistic (Cohen, 1960) was calculated as a measure of the asso­
ciation between the psychiatrist’s diagnosis based on the MDCL and the psy­
chologist’s diagnosis based on the CIDI. The interpretation of the k coeffi­
cient was based on the rules laid down by Landis and Koch (1977): <.00 
‘poor’; .00-.20 ‘slight’; .21-.40 ‘fair’; .41-.60 ‘moderate’; .61-.80 ‘substan-
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tial’; and .81-.1.00 ‘almost perfect’. Although the kappa statistic is known to 
decrease dramatically under low base rate conditions (Spitznagel & Helzer, 
1985), it is currently the standard method used to assess diagnostic concor­
dance in the field of psychiatry. Careful interpretation of the kappa statistic 
in connection with low frequency is thus called for. We also assessed the de­
gree of concordance at a broader level by comparing diagnoses involving 
mood, anxiety and comorbid mood-anxiety disorders. These composite dia­
gnostic categories consisted of 1) major depressive disorder and dysthymia 
(mood disorder), 2) panic disorder with and without agoraphobia, generali­
zed anxiety disorder, obsessive compulsive disorder, social phobia, simple 
phobia and agoraphobia without history of panic disorder (anxiety disorder) 
and 3) the comorbid mood-anxiety group with diagnoses of both mood and 
anxiety disorder.
The MDCL diagnoses were scored positively when coded with ‘met’ 
but not when coded with ‘probably met’.
Results
In 96 patients MDCL-based diagnoses and CIDI-based diagnoses were avail­
able. The MDCL-based diagnoses were made by the psychiatrist at scree­
ning, whereas the CIDI-based diagnosed were assessed after inclusion only 
for the selected patients. Then agreement between the clinical diagnosis and 
CIDI-based diagnosis was studied for the selected group of patients with 
mood or anxiety disorders.
The psychiatrists produced a total of 177 MDCL-based diagnoses for 
the 96 patients, which is a mean of 1.84 diagnoses per patient. The psycholo­
gists produced a total of 248 CIDI-based diagnoses, which is a mean of 2.58 
diagnoses. Three patients did not meet the full criteria for any current DSM- 
III-R diagnosis using the CIDI. The total number of diagnoses per patient 
was also found to differ for the CIDI and the MDCL. According to the 
MDCL, 48 patients (50%) had a single diagnosis and an additional 26 pa­
tients (27%) had two diagnoses. According to the CIDI, only 27 patients 
(28%) had a single diagnosis, 21 patients (22%) had two diagnoses, and an­
other 21 patients (22%) had three diagnoses. Some 24 patients (25%) had 
four to six diagnoses according to the CIDI while the psychiatrist produced 
four or more diagnoses using the MDCL in only 7 patients (7%).
Using both the CIDI and the MDCL, major depression was most com­
monly diagnosed followed by panic disorder with agoraphobia, as can be 
seen in Table 5.1.
Furthermore, dysthymia, social phobia, simple phobia and generalized an­
xiety disorder were diagnosed frequently. Low frequencies were found for 
bulimia nervosa, obsessive compulsive disorder and agoraphobia without pa­
nic disorder, which indicates that careful interpretation of the kappa statistic
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is needed for these categories. In addition to the mood and anxiety disorders, 
additional diagnoses were made using the CIDI for 15 patients: four patients 
were diagnosed with alcohol dependence, three patients with alcohol abuse, 
seven patients with somatoform pain and one patient with a schizophrenic 
disorder.
Relative to the diagnoses based on the MDCL, simple phobia and social pho­
bia were diagnosed more frequently using the CIDI. Conversely, generalized 
anxiety disorder was diagnosed more often using the MDCL (23 times) than 
the CIDI (seven times).
Table 5.1 DSM-III-R diagnoses based on MDCL and CIDI (n=96)
DSM-III-R diagnosis MDCL CIDI
n n
Major depression 45 63
Dysthymia 14 22
Panic disorder 3a
with agoraphobia 30 41
without agoraphobia 14 8
Simple phobia 18 32
Social phobia 16 36
Generalized anxiety disorder 23 7
Agoraphobia without panic disorder 6 10
Obsessive compulsive disorder 7 9
Bulimia nervosa 1 5
Alcohol dependence 4
Alcohol abuse 3
Somatoform pain 7
Schizophrenic disorder 1
Total 177 248
Note. a Specification with/without agoraphobia unknown.
Examination of Table 5.2 shows that concordance between the CIDI 
and MDCL is moderate for the diagnoses of major depression (k  = .47) and 
obsessive compulsive disorder (k  = .46). Fair agreement was found for: so­
cial phobia (k  = .40), panic disorder with and without agoraphobia (k = .36 
and k  = .29, respectively), bulimia nervosa (k  = .32) and dysthymia (k  = .26). 
The diagnoses for generalized anxiety disorder and agoraphobia showed 
kappa’s around zero. The kappa’s for obsessive compulsive disorder, buli-
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mia nervosa and agoraphobia should nevertheless be interpreted with caution 
due to their low frequency. Disagreement was strongest for the diagnosis of 
generalized anxiety disorder. This diagnosis was made for 7 patients using 
the CIDI and 23 patients using the MDCL, with only one of the patients dia­
gnosed similarly by the two instruments.
Table 5.2 Diagnostic agreement between MDCL and CIDI diagnoses (n=96)
DSM-III-R diagnosis CIDI +
MDCL
+
a
c
a
b
d k
M ajor Depression 41 22 .47*
4 29
Obsessive 4 5 .46*
Compulsive disorder 3 84
Social Phobia 14 22 .40*
2 58
Panic disorder with 21 20 .36*
agoraphobia 9 46
Bulimia nervosa 1 4 .32*
91
Panic disorder without 4 4 .29*
agoraphobia 10 78
Dysthymia 7 15 .26*
7 67
Simple Phobia 8 24 .11
10 54
Generalized Anxiety 1 6 -.05
disorder 22 67
Agoraphobia without 10 -.09
panic disorder 6 80
Note. a + = diagnosis present, - = diagnosis absent. * k  value significant at 1% level.
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Comorbidity o f mood and anxiety disorders
According to the CIDI, mood and anxiety disorders existed comorbidly in 
49% of the patients, as shown in Table 5.3. Some 26% of the patients had a 
pure anxiety disorder, 22% had a pure mood disorder and 3% had no DSM 
diagnosis according to the CIDI. The MDCL showed a different pattern: 
51% of the patients were diagnosed as having an anxiety disorder without 
comorbid mood, 24% were diagnosed as having solely a mood disorder and 
25% were diagnosed with comorbid mood and anxiety disorders.
Table 5.3 Agreement between MDCL and CIDI for anxiety disorders, mood disor­
ders, and comorbid mood-anxiety disorders
CIDI
Anxiety
MDCL
Mood Comorbid MAa total
n n n n
Anxiety 23 - 2 25 (26%)
Mood 3 15 3 21 (22%)
Comorbid MAa 18 10 19 47 (49%)
No diagnosis 3 - - 3 (3%)
Total 47 (49%) 25 (26%) 24 (25%) 96 (100%)
Note. a Comorbid mood and anxiety disorder. 
k  value = .43, p  < .001 (n=93).
For the three composite diagnostic categories, the agreement between 
the CIDI and the MDCL was found to be moderate. Disagreement was main­
ly due to the fact that 28 patients were diagnosed with a comorbid mood and 
anxiety disorder using the CIDI, whereas a pure anxiety disorder or a pure 
mood disorder was diagnosed using the MDCL. Conversely, 5 patients were 
diagnosed with a comorbid mood and anxiety disorder according to the 
MDCL but not according to the CIDI. Total disagreement was found for 
three patients who were diagnosed with a mood disorder according to the 
CIDI and an anxiety disorder according to the MDCL. No diagnosis could be 
made for 3 patients using the CIDI. This was not restricted to DSM diagno­
ses of mood or anxiety disorders. Based on the 93 patients with a diagnosis, 
the overall concordance between the CIDI- and MDCL-based diagnoses of 
the anxiety disorders, mood disorders or comorbid mood-anxiety group was 
found to be moderate (k = .43).
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Discussion
The present study shows only moderate agreement between the clinical dia­
gnoses of mood disorders, anxiety disorders, and comorbid mood-anxiety 
disorders by psychiatrists (using the MDCL) and the diagnoses using the 
CIDI. Disagreement was mainly due to the diagnosis of comorbid mood and 
anxiety disorders using the CIDI and either anxiety disorder alone or mood 
disorder alone using the MDCL. Of the DSM-III-R categories, the diagnosis 
of major depression showed the greatest degree of agreement although no 
more than moderate agreement. Social phobia and panic disorder both with 
and without agoraphobia showed only fair agreement, and poor agreement 
was found for generalized anxiety disorder. All patients were screened on 
either a mood or anxiety disorder and after this preselection agreement on 
diagnosis between two diagnostic procedures were examined. Taken into 
consideration that agreement was assessed within this selected patientgroup, 
no more than moderate agreement is of concern.
This overall lack of agreement is in contrast with other comparison stu­
dies in which the concordance between differently derived diagnoses has 
been found to be satisfactory (Janca et al., 1992; Kovess Sylla, Fournier, & 
Flavigny, 1992). However, the other studies were focused on the validation 
of diagnostic instruments by comparison to actual clinical diagnosis. In the 
study by Janca et al. (1992), for example, the clinical diagnosis was made by 
the psychiatrist during observation of the CIDI interview. Such a procedure 
is quite uncommon clinical practice and may remove most of the variance 
due to differences in interview style and information, with a higher level of 
agreement between the diagnoses as a result. In the present study, the focus 
was on the agreement between the psychiatrists’ diagnoses using the MDCL 
and the diagnoses using the standardised CIDI interview, independent of 
each other. We showed agreement to be low when two independent proce­
dures are used, which has important implications for the validity of psychia­
tric diagnoses.
An example of the validity problem is as follows. In most treatment out­
come studies with antidepressants, the DSM categories are used for inclusion 
but then according to the psychiatrists and without the use of such a structu­
red list as the MDCL or only with a list of the diagnoses relevant to the 
study. In other words, the population included in the study may differ depen­
ding on the procedures used by the psychiatrists and the focus of the re­
search. Which of the two procedures, the MDCL or the CIDI, is suited best 
for measurement of the DSM categories remains unclear due to the lack of a 
‘golden standard’ for psychiatric diagnosis (Faraone & Tsuang, 1994). Cli­
nical diagnosis is often used as the standard, but this is neither careful nor 
valid. And due to the lack of a golden standard, the differentiation between 
anxiety and mood remains a problem along with the validity of diagnosis of 
mood and anxiety disorders.
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The comorbidity of mood and anxiety disorders was found to be high 
according to the CIDI. The psychiatrists using the MDCL diagnosed both 
disorders simultaneously less frequently compared to the CIDI diagnoses. In 
daily practice, clinicians may actually tend to choose between mood and an­
xiety disorder as this is implicit in the DSM decision trees (APA, DSM-IV: 
pp. 696-699; DSM-III-R: pp. 380-385; DSM-III: pp. 342-344). There is also 
a diagnostic tradition of making single diagnoses rather than more diagnoses. 
In clinical trials for the treatment of anxiety disorders, patients with concur­
rent major depression are often excluded, for example. And our results show 
that a nonexclusive (i.e., comorbid) diagnosis may not even occur if the cli­
nical diagnosis of the psychiatrist is used. We must emphasise that the pau­
city of comorbid diagnoses was produced by the psychiatrists even though 
they completed the MDCL for all of the mood and anxiety disorders. Thus, 
the psychiatrists did not miss comorbid diagnoses only because they did not 
consider them.
The inclusion of the patients in a clinical trial solely on the basis of a 
psychiatric diagnosis can certainly complicate the interpretation of the re­
sults. The unclear validity of the psychiatric diagnosis may also explain cer­
tain contradictory results, as discussed by Ansseau (1992), who showed 
trials from Europe and the United States to often be contradictory due to dif­
ferences in clinical material, methodologies, health service systems, psychia­
tric traditions and the types of patients used on the two continents. The value 
of treatment outcome studies for clinical practice is, of course, based on the 
accuracy of the diagnosis. The use of such diagnostic checklists as the 
MDCL may help diminish this lack of consensus but continue to be rarely 
used in clinical research, unfortunately.
The current study also has some limitations to consider. The diagnostic 
instruments selected for comparison were assumed to measure the same con­
struct, namely diagnoses according to the DSM-III-R criteria. Some degree 
of disagreement could be expected as a result of the fundamental differen­
ces in the procedures and differences in the amount of time devoted to assess 
diagnosis. The CIDI, for example, is a fully structured instrument and strict­
ly measures all available diagnoses in terms of the criteria formulated within 
the DSM. No interpretations on the part of the interviewer is needed or al­
lowed. The MDCL, in contrast, is just a helping hand for the clinician, who 
relies on his or her own questions, observations and other information to de­
cide which checklists to complete (Wittchen & Essau, 1993). To encourage 
adoption of a more systematic diagnostic procedure in the present study, we 
semistructured the use of the MDCL by selecting fourteen of the thirty 
checklists which had to be completed all. Nevertheless, comorbid patterns of 
symptoms were still interpreted as part of one or the other disorder and not 
as a comorbid disorder, depending on the clinicians observation and interpre­
tation.
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The concordance between the psychiatric diagnosis using the MDCL 
and the diagnosis using the CIDI may also have been reduced by assessment 
at different points in time. The psychiatrist made the diagnosis during the 
screening phase, while the CIDI was conducted four weeks after the start of 
treatment. As the CIDI is designed to examine symptoms of the last episode 
retrospectively, however, comparison of the CIDI with the MDCL seems to 
be justified.
In conclusion, the present study shows important differences in the dia­
gnosis of mood and anxiety disorders when different diagnostic procedures 
are followed. Such inconsistency poses not only a problem for the interpre­
tation of research results but also for the generalisation of outcome studies 
with regard to both psychological and pharmacological treatments.
Note. Submitted for publication 
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6 Diagnosis at first episode to differentiate antidepres- 
sanf treatment response in patients with mooa and 
anxiety disorders
Summary
Comorbidity o f mood and anxiety disorders is often ignored in pharmaco­
treatment outcome studies, which complicates the interpretation o f treatment 
response. The clinical trials are usually based on single DSM categories. 
The present study is a first attempt to differentiate response to antidepres­
sants with a design which differs from that used in previous clinical trials. 
To avoid bias due to comorbidity, we included patients with any DSM-III-R 
diagnosis o f mood or anxiety disorder for which antidepressant treatment 
was indicated. We also explored the role o f the diagnosis at first episode in 
the efficacy o f the different antidepressants. A total o f 92 outpatients with a 
mood and/or anxiety disorder were randomly assigned to treatment with imi­
pramine or fluvoxamine in a 6-week study. The diagnosis at first episode, or 
primary diagnosis, was available for 78 patients, 40 with a primary depres­
sion and 38 with a primary anxiety disorder. Analyses using the MIXED pro­
cedure for repeated measures showed no general differences between treat­
ment with imipramine versus fluvoxamine. When the primary diagnoses were 
taken into consideration, differentiation occurred. Patients with primary de­
pression showed better response to imipramine than to fluvoxamine at 2 
weeks, but not at 6 weeks o f treatment. The assumption that patients with 
primary anxiety disorder would respond better to fluvoxamine than to imi­
pramine was observed for only the CGI, and not the CPRS-MA. Given the 
exploratory nature o f the study, however, replication o f our finding is nee­
ded. Further study o f the role o f primary diagnosis is also needed, along 
with further validation o f the outcome measures.
Introduction
Tricyclic Antidepressants (TCAs) as well as Selective Serotonin Reuptake 
Inhibitors (SSRIs) are effective for the treatment of depression (Song et al.,
1993) and such anxiety disorders as panic disorder, obsessive compulsive 
disorder, social phobia and generalized anxiety disorder (Black, Wesner, 
Bowers, & Gabel, 1993; Burke, Preskorn, Bloom, & Kupfer, 1995; Kent, 
Coplan, Gorman, 1998; McTavish & Benfield, 1990; Murphy & Pigott, 1990; 
Rickels, Downing, Schweizer, & Hassman, 1993; Rocca, Fonzo, Scotta, Za- 
nalda, & Ravizza, 1997; Tancer & Uhde, 1995; Van Balkom, 1994; Van 
Balkom et al., 1997; Wilkinson, Balestrieri, Ruggeri, & Bellantuono, 1991). 
Some studies suggest that TCAs may be more effective for certain types of
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depression (Klein & Ross 1993; Kraghsorensen, 1990; Potter, Rudorfer, & 
Manji, 1991) and SSRIs may be more effective for certain anxiety disorders 
(DenBoer & Westenberg, 1988; Van Balkom, 1997). It has also been sug­
gested that SSRIs may be particularly effective for atypical depression (Pan­
de et al., 1996). Most studies do not find such differences, however, which 
has resulted in the opinion that TCAs and SSRIs are equally effective for de­
pression (Andrews & Nemeroff, 1994). Although SSRIs are allegedly pre­
ferred for the treatment of anxiety disorders because of the contention that 
they act more specifically on the disturbed serotonergic system, their relati­
vely benign side effects are actually the reason for such a preference in clini­
cal practice(Kent et al., 1998).
Clinical trials always include patients meeting the DSM criteria for a 
single specific disorder, which obviously ignores comorbidity, even though 
this tends to be the rule with such disorders. It is also therefore not clear 
whether the paucity of results differentiating TCAs and SSRIs, is related to 
this artificial separation of categories of illnesses.
The preceding lack of differentiation between response to TCAs and 
SSRIs may also be related to the DSM categories being based on mainly the 
current symptomatology and not the development of the syndrome. It has 
been suggested, for example, that depression may be ‘primary’ (Cloninger et 
al., 1990) or ‘pure’ (Winokur, 1997), on the one hand, or secondary to anxie­
ty disorders or an emotionally unstable personality, on the other hand.
The present study is a first attempt to differentiate response to antide­
pressants using a different design than in from previous clinical trials. First, 
we included patients with any DSM-III-R diagnosis of mood or anxiety dis­
order for which antidepressants were indicated and sufficient severity occur­
red to warrant treatment. Our aim was to avoid the bias associated with the 
selection of specific DSM categories and to explore the possibility of treat­
ment differences when syndrome or symptomatic extremes for these disor­
ders are included in a single study. We also explored the role of the first epi­
sode and the assumption that patients with a first depressive episode (‘pri­
mary depression’) would respond better to treatment with a TCA and pa­
tients with a first anxiety episode (‘primary anxiety disorder’) would respond 
better to treatment with an SSRI.
Methods
Design
Patients with either a mood or anxiety disorder according to the DSM-III-R 
were randomly treated with either imipramine or fluvoxamine for six weeks. 
To include a representative outpatient sample and avoid selection bias, the 
treatment was not blind to the treating psychiatrists, but the crucial ratings 
were performed by a blind rater.
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Subjects
All newly attending patients at a community mental health centre in The 
Netherlands between 18 and 65 years of age were screened for anxiety or 
mood disorders using the DSM-III-R criteria. Those patients with at least a 
moderate (4) illness severity on the Clinical Global Impression (CGI: Guy, 
1976) were included. The following exclusion criteria were applied: a) con­
tra indications for antidepressant drugs, b) unsuccessful treatment with flu­
voxamine or imipramine during the present episode, c) treatment with an­
other antidepressant less than one week prior to randomisation and fluoxe­
tine less than five weeks prior to entering the study, d) concurrent use of 
CNS medication other than for night time sedation and/or to control anxiety, 
and e) use of psychedelics or daily use of alcohol (consisting of more than 3 
drinks a day for the latter).
During most of the study period, we collected intake data on the entire 
population at the clinical site to gain greater insight into the selection proce­
dures. In this period, 1235 patients were seen for intake and 564 (45.7%) 
were diagnosed with a mood or anxiety disorder based on the DSM classifi­
cation; 31.4% with an anxiety disorder, 23.2% with a major depressive dis­
order, 21.1% with an adaptation disorder, 12.8% with dysthymia, 7.6% with 
post traumatic stress disorder, 2.5% with obsessive compulsive disorder and 
1.4% with a bipolar disorder. Eighty-four (14.9%) of these 564 patients were 
included in the current study. The main reason for not including patients was 
insufficient severity (CGI below 4, 249/564 patients, 44.1%). This resulted 
in the exclusion of all patients with an adaptation disorder and most of the 
patients with dysthymia, obsessive compulsive disorder, post traumatic 
stress disorder and social and simple phobia. Additional reasons for exclu­
sion were: current use of other antidepressants (5.4%), crisis intervention 
(2.5%), hospitalisation (1.6%), severe alcohol or drug abuse (1.6%), lack of 
Dutch language capabilities (2.3%), refusal of medical treatment (3.4%), re­
fusal to cooperate in the treatment study (1.0%) and other (1.7%). The rea­
son for exclusion remained unknown for 19.7% of the patients. A total of 98 
patients thus entered the study, and 92 patients actually started treatment. Af­
ter randomisation and before initiation of treatment, five patients refused to 
participate further and one patient turned out to meet one of the exclusion 
criteria.
Treatment conditions
The patients were randomly treated with either imipramine or fluvoxamine. 
The dosage of fluvoxamine was 50 mg on the first day and increased to 150 
mg/d at the end of the first week. A temporary decrease of the dosage due to 
side effects was allowed, but the dosage of 150 mg/d had to be reached with­
in 14 days of the first treatment day. During week 2 through 6, a minimum 
dosage of 150 mg/d was maintained. During week 4 through 6, the dosage 
could be increased to a maximum of 200 mg/d in cases of non-response. The
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imipramine was started at 75 mg/d. After one week, blood was collected for 
blood level determination and assessed within five days. The dosage of imi­
pramine was then adjusted to obtain blood levels of 200-300^,g/1 of the sum 
of imipramine and desmethylimipramine, which was checked at week 4.
Diagnostic Assessments
The Munich Diagnostic Checklists (MDCL) were used by the treating psy­
chiatrists to screen for the DSM-III-R criteria (Hiller et al., 1990a, 1990b). A 
subset of the MDCL checklists was used: those checklists pertaining to ad­
justment disorder, agoraphobia, alcohol dependence and abuse, bulimia ner­
vosa, dysthymia, generalized anxiety disorder, major depressive disorder, 
obsessive compulsive disorder, panic disorder, schizo affective disorder, 
simple phobia, social phobia and somatization disorder. The full subset was 
completed for all patients and issues of hierarchy were disregarded.
The Clinical Global Impression severity measure (CGI) (Guy, 1976) 
was completed by the psychiatrist and had to be at least 4 (i.e., moderate) for 
the patient to enter the study.
The Dutch version 1.1 (Smeets & Van den Ham, 1994) of the Compo­
site International Diagnostic Interview (CIDI) (WHO, 1990) was admini­
stered four weeks after initiation of treatment by a trained research psycholo­
gist blind to all aspects of the treatment. The CIDI was used to obtain the 
diagnosis of the first episode, needed to distinguish between primary and se­
condary diagnosis based on sequential relationship of diagnoses. All patients 
with a major depression or dysthymia according to the DSM-III-R as their 
first illness episode were classified as having a primary depression, whether 
with or without a comorbid anxiety disorder. It is assumed that patients dia­
gnosed with a comorbid mood and anxiety disorder at the first episode, expe­
rienced mixed mood and anxiety symptoms that would be part of one under­
lying mood disorder. All patients with an anxiety disorder without a comor- 
bid mood disorder according to the DSM-III-R as their first episode were 
classified as having a primary anxiety disorder.
Outcome Measures
To assess response to treatment, an instrument suitable for the quantification 
of anxiety as well as depressive symptoms was needed. For this purpose, a 
composite of the subscales from the Comprehensive Psychopathological 
Rating Scale (CPRS) (Àsberg et al., 1978) for depression (Ma DRS) (Mont­
gomery & Âsberg 1979), anxiety (BSA) (Tyrer et al., 1984) and the OCD 
(Montgomery & Montgomery, 1980; Thorén et al., 1980) was used. This 
composite scale, the ‘mood and anxiety subscale’ of the CPRS (CPRS-MA) 
consists of 21 items (18 symptoms and 3 observed items). The CPRS-MA is 
similar to the recently developed self-rating scale for depression and anxiety 
states (CPRS-S-A) from the original CPRS (Svanvorg & Âsberg, 1994) 
which consists of 19 items. Seventeen items are the same as in the CPRS-
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MA with the item ‘inner tension’ from the CPRS-MA split into ‘inner ten­
sion’ and ‘panic attacks’ in the CPRS-S-A. Obviously, the 3 observed items 
were not included in the self rating scale. The CPRS-MA was completed by 
the research psychologist. The CGI-severity measure was completed by the 
research psychologist being a general outcome measure showing good sen­
sitivity to change in clinical trials (Leon et al., 1993).
Procedure
The patients visited the psychiatrist weekly for the first two weeks and then 
every two weeks. The visits took an average of about 20 minutes. On each 
visit, the patients were asked whether they had experienced any physical or 
other health problems; no side effects were suggested. No additional psycho­
therapy was provided. The research psychologist administered the CPRS and 
CGI the day the patient started with the medication (baseline), at two weeks 
of treatment (week 2) and at six weeks of treatment (week 6).
No concomitant medication was allowed, with the exception of oxaze­
pam or lormetazepam during the first 4 weeks. During weeks 4 through 6, 
these benzodiazepines were not allowed. In fact 45 patients (49%) (24 imi­
pramine, 21 fluvoxamine) were prescribed oxazepam (mean dose 21.8 mg/d; 
range 5 to 50); 11 patients (5 imipramine, 6 fluvoxamine) were prescribed 
lormetazepam (9 received the maximum dose of 2 mg/d); and 10 patients (4 
imipramine, 6 fluvoxamine) were prescribed both medications. Two patients 
were prescribed other concomitant medications (alprazolam, diazepam) and 
7 patients were prescribed concomitant medication during weeks 4 through 6 
(2 oxazepam, 3 lormetazepam, 2 combination).
Statistical analysis
The data were entered into a relational database, processed using DMSS 
(Broekman, 1994) and transferred to SAS\STAT software release 6.12 (SAS, 
1997). The data were analysed using the MIXED procedure for repeated 
measures. Five measurements were excluded, three at week 2 and two at 
week 6, because they deviated more than seven days from week 2 or more 
than 14 days from week 6 .
To test the efficacy of the different treatments a univariate mixed procedure 
for repeated measures was used (SAS, 1997) with the CPRS-MA as the main 
outcome measure. The CGI data were also analysed in a similar manner. The 
model consisted of the between-subjects factor Treatment group (imiprami- 
ne/fluvoxamine) and the within-subjects factor Assessment (baseline/ week 
2/week 6) and their two-way interaction. To test for diagnostic differences 
related to treatment response, the same procedure was used with the diagno­
sis at first episode (Primary depression/Primary anxiety) also entered into the 
model. The two- and three-way interactions of Treatment group, Assessment 
and Primary diagnosis were included.
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To specify at what point in time differentiation may have occurred, we 
entered two contrast statements into the model, namely the contrast between 
baseline and week 2, and the contrast between baseline and week 6 . Finally, 
we tested the contrast statements for the groups of patients with primary 
depression and primary anxiety disorder separately as well.
An advantage of the mixed procedure for repeated measures above ana­
lyses of variance procedures is that missing values, basically due to drop­
outs, do not lead to data reduction (Everitt, 1998). All intent-to-treat (ITT) 
cases were included in the analyses, independent of missing data at week 2 
or week 6, which makes the mixed procedure preferable over such alterna­
tives as LOCF analyses (L(ast) O(bservation) C(arried) F(orward)) or Obser­
ved Cases analyses.
Results
Of the 92 patients who started treatment, 59 were female with a mean age of
34.5 (range 18-65, SD = 9.93). Forty-four patients received imipramine and 
48 patients received fluvoxamine. Based on the diagnosis of the psychiatrist, 
20 patients were included with a DSM-III-R major depressive disorder or 
dysthymia (22%), 46 patients with an anxiety disorder (50%) and 26 patients 
with both a mood and an anxiety disorder (28%). Forty patients were mar­
ried, 38 patients were never married, 13 patients were divorced and one pa­
tient was a widow; 25 patients lived alone, 29 patients lived with a partner 
and 38 patients lived with their family. With regard to educational level: 9% 
had finished elementary school, 76% had finished high school and 15% had 
finished some form of higher education.
The six weeks of treatment were completed by 77 patients (81%), 35 on 
imipramine and 42 on fluvoxamine. Nine of the imipramine patients dropped 
out and 6 of the fluvoxamine patients; 11 of the 15 dropouts were within the 
first two weeks of treatment. For 5 of these patients the psychiatrist decided 
to stop treatment due to unacceptable side effects of the study medication. 
The other 10 dropouts (71%) decided themselves to stop treatment for the 
following reasons: unacceptable side effects (1 : on fluvoxamine), non-com­
pliance with treatment (4: 3 on imipramine and 1 on fluvoxamine), non-com­
pliance with the study procedures (4: 2 on imipramine and 2 on fluvox- 
amine) and lack of effect (1 : on fluvoxamine).
For the total sample of patients with mood and/or anxiety disorders (n = 
92), no significant differences between treatment with imipramine versus 
fluvoxamine were found. That is, no main effect of Treatment group (F(2, 
90) = 2.34, p  = .12) and no interaction effect between Treatment group and 
Assessment (F(2, 90) = 2.21, p  = .11).
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D iagnosis  a t f i r s t  episode a n d  trea tm ent e fficacy
The CID I in terview  to  assess lifetim e d iagnosis w as conducted  w ith  81 o f  
the 92 patients. Tw o patien ts d id  no t m eet the c rite ria  fo r any  D SM -III-R  
diagnosis, and  one pa tien t m et only  the crite ria  fo r a  sim ple phob ia  according 
to  the CIDI. O f  the rem aining 78 patien ts, 40 w ere identified  as having  a  p ri­
m ary depression  (20 on im ipram ine and 20 on fluvoxam ine) and 38 as h a ­
ving a  prim ary  anxiety  d iso rder (16 on im ipram ine and  22 on fluvoxam ine).
The m ean  C PR S-M A  score a t baseline w as observed  to  be h igher fo r 
the group o f  patien ts w ith  p rim ary  depression  w hen com pared  to  those w ith  
prim ary  anx ie ty  d iso rder although  no t sta tistically  sign ifican t (t =  1.34, p  = 
.18) (Table 6.1).
Table 6.1 CPRS-MA and CGI Scores for Primary Diagnosis, Mean and Standard 
Deviation (n=78)
baseline week2 week6
n M SD n M SD n M SD
Primary depression 40 39 39
CPRS-MA
imipramine 20 47.4 7.3 19 33.2 11.7 19 23.3 11.8
fluvoxamine 20 46.3 13.9 20 42.5 13.7 20 27.6 20.3
CGI-severity
imipramine 20 4.70 0.47 19 4.21 0.63 19 3.37 0.90
fluvoxamine 20 4.85 0.49 20 4.70 0.57 20 3.55 1.23
Primary anxiety 38 36 35
CPRS-MA
imipramine 16 42.3 12.1 15 36.6 9.6 15 23.5 10.1
fluvoxamine 22 43.2 13.0 21 37.2 12.4 20 24.1 13.2
CGI-severity
imipramine 16 4.88 0.62 15 4.80 0.41 15 4.00 0.65
fluvoxamine 22 4.86 0.56 20 4.50 0.76 19 3.32 0.89
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The MIXED procedure analyses including primary diagnosis showed no 
main or interaction effects (Table 6.2).
Table 6.2 MIXED Procedure for Repeated Measures with CPRS-MA (n=78)
Tests of fixed effects
Source NDF DDF TypellI F Pr > F
Assessment (A) 2 74 77.77 .001 *
Treatmentgroup (T) 1 74 0.80 .373
Assessment*T reatment 2 74 1.87 .161
Primary diagnosis (P) 1 74 1.34 .250
Assess*Prim 2 74 0.43 .653
Treatment*Prim 2 74 0.33 .570
Assess*Prim*Treatment 2 74 2.01 .142
Contrast statements
total interaction
Baseline-week2 1 74 4.01 .049 *
Baseline-week6 1 74 0.48 .491
primary depression
Baseline-week2 1 74 8.13 .006 *
primary anxiety
Baseline-week2 1 74 0.00 .960
Note. p  < .05
A significant difference was nevertheless observed for the effects of imipra­
mine versus fluvoxamine between baseline and week 2 for primary depres­
sion as opposed to primary anxiety disorder (total interaction of Treatment 
group, Assessment and Primary diagnosis (F(2, 74) = 4.01, p  = .049) but not 
between baseline and week 6 (F(2, 74) = 0.48, p  = .49). We tested these in­
teraction terms between baseline and week 2 for the primary diagnoses sepa­
rately and found a significant Treatment group by Assessment interaction ef­
fect for primary depression (F(2, 74) = 8.13, p  = .0056) but not for primary 
anxiety disorder (F(2, 74) = 0.00, p  = .96). Based on the CPRS-mA, thus, 
imipramine showed a larger effect than fluvoxamine at 2 weeks of treatment 
in patients with primary depression but not at 6 weeks and not in patients 
with primary anxiety disorder (see Figure 6.1).
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Figure 6.1 CPRS-MA response o f  imipramine and fluvoxamine in primary depres­
sion and primary anxiety disorder
The CGI results show a comparable pattern to those of the CPRS-MA 
for patients with primary depression (see Figure 6.2). In patients with pri­
mary anxiety disorders, moreover, treatment with fluvoxamine resulted in lo­
wer CGI scores at week 2 and week 6 than treatment with imipramine (inter­
action between Treatment group and Primary diagnosis: F  (2, 74) = 5.19, p  = 
.026; interaction between Treatment group, Primary diagnosis and Assess­
ment F  (2, 74) = 2.37, p  = .10). The CGI scores thus show a better response 
to imipramine for primary depression and a better response to fluvoxamine 
for primary anxiety disorder.
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week0 week2 week6
□  imipramine depression n=20
□  imipramine anxiety n=16
O  fluvoxamine depression n=20
O  fluvoxamine anxiety n=22
Figure 6.2 CGI response o f imipramine and fluvoxamine in primary depression and 
primary anxiety disorder
It should be noted that 40 patients with a first depressive episode were 
allocated to the primary depression group, although 18 of these patients had 
a comorbid anxiety disorder, (i.e. the first episode met the criteria for a mood 
as well as anxiety disorder in 45% of the primary depression patients). We 
also compared the CPRS-MA results for the 22 patients with a first depres­
sive episode without a comorbid anxiety disorder with the results for patients 
with a primary anxiety disorder (see Figure 6.3). The results were similar to 
those obtained for the primary depression group including comorbid anxiety 
disorders (significant interaction of Treatment group, Assessment and Pri­
mary diagnosis: F  (2, 56) = 3.20, p  = .048). However, the number of pa­
tients in these subgroups is restricted.
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Figure 6.3 CPRS-MA response o f  imipramine and fluvoxamine in primary depres­
sion without comorbid anxiety disorder and primary anxiety disorder
In sum, patients with primary depression responded better to imiprami­
ne than to fluvoxamine at week 2 but not at week 6 . The same was found for 
the subgroup of patients with primary depression without a comorbid anxiety 
disorder at first episode. Patients with primary anxiety disorder responded 
better to fluvoxamine than to imipramine at both week 2 and week 6 when 
assessed with the CGI, but not the CPRS-MA.
Discussion
The present clinical trial was a first attempt to differentiate response to anti­
depressants using a design different from that used in previous clinical trials. 
Patients with any DSM-III-R diagnosis of mood or anxiety disorder were in­
cluded in the study. In such a manner, the artificial separation into DSM ca­
tegories which are not in fact mutually exclusive is circumvented. As might 
be expected on the basis of the literature (Kessler et al., 1996), 28% of the 
patients indeed had a comorbid mood or anxiety disorder. Response to treat­
ment with fluvoxamine versus imipramine was initially evaluated in this
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group as an entity, i.e. across depressive and anxiety symptoms. For this pur­
pose, we used a composite scale of the depression, anxiety and OCD items 
from the CPRS (CPRS-MA). Although similar to the CPRS-S-A (Svanvorg 
& Âsberg, 1994) the CPRS-MA has yet to be validated and we therefore 
used the CGI to also gain a general impression of the patient’s improvement 
not explicitly relating to specific symptoms. For the patient group as a 
whole, no differences in the efficacy of treatment with fluvoxamine or imi­
pramine were observed.
We further analysed differences in treatment response to fluvoxamine 
and imipramine by breaking down the patients according to the nature of 
their first illness episode. The CIDI was used to assess whether the first epi­
sode was a depression (primary depression) or an anxiety disorder (primary 
anxiety disorder). Support for the hypothesis that imipramine would be more 
effective for primary depression and fluvoxamine more effective for primary 
anxiety disorder was found. Patients with primary depression showed a bet­
ter response to imipramine at week 2 (but not at week 6) according to both 
the CPRS-MA and the CGI. Patients with primary anxiety disorder, in con­
trast, showed a better response to fluvoxamine, according to CGI but not the 
CPRS-MA.
The origin of the differences in the results using the CPRS-MA and the 
CGI can only be guessed at. This may be related to psychometric qualities of 
the scales, including sensitivity and specificity, particularly in relation to the 
subgroups of patients studied here. The fact that the patients with primary 
depression have higher CPRS-MA scores at baseline than the patients with 
primary anxiety disorder hints at such an imbalance of items. Depressive 
symptoms appear to be emphasised more than anxiety symptoms within the 
CPRS-MA. The experience of panic attacks is subsumed under the item 
‘inner tension’, which may make the instrument insufficiently sensitive to 
patients with primary anxiety disorder. The present results should therefore 
be interpreted as preliminary, and more research with the CPRS-MA should 
be undertaken in the future.
The CIDI was used to assess the diagnosis of the first illness episode in 
retrospect. Retrospective assessment always depends on the quality of a per­
son’s recall which cannot be assumed to be particularly high or of equal qua­
lity across the different patient categories (Andrews & Nemeroff, 1994). At 
this moment there seems to be no clear solution to this problem except for 
prospective studies. We are not aware of instruments superior to the CIDI at 
this moment.
It should be pointed out that, in contrast to most other trials, we used 
therapeutic drug monitoring (TDM) to determine the imipramine dosage. 
This circumvents the dosing problem in most other trials which may have 
led to overly aggressive dosages (resulting in high dropout rates) or to sub­
optimal dosages of imipramine (Burke et al., 1995). We have shown before
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differences between imipramine and mirtazapine in depressed inpatients in a 
trial using TDM for imipramine (Bruijn et al., 1996).
In conclusion, despite the methodological problems yet to be solved the 
new paradigms used here to differentiate response to fluvoxamine, a SSRI, 
from response to imipramine, a TCA, appears to be promising. The results 
suggest that the nature of the first illness episode may be more valuable than 
the DSM categories of current mood or anxiety disorders, which may lend 
support to the concept of primary versus secondary depression (Cloninger et 
al., 1990) for purposes of differentiating treatment response.
Note. Submitted for publication
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7 The role of temperament to differentiate antidepres­
sant treatment response in patients with mood and 
anxiety disorders
Summary
Research on mood and anxiety disorders has not provided many clues with 
regard to differential response to pharmacological treatment. Temperament, 
according to the psychobiological personality model o f Cloninger, appears 
to be promising for the differentiation o f response to antidepressants. More 
specifically, the temperament dimension called Harm Avoidance is found to 
be consistently elevated in patients with mood and anxiety disorders. Res­
ponders and non-responders to antidepressant treatment have been distin­
guished according to their temperament scores, and non-responders found 
to score higher on Harm Avoidance than responders. In the present study, 
the role o f temperament was explored to detect any differences in response 
to antidepressant treatment (with a TCA or SSRI) in 74 patients with mood 
or anxiety disorders.
The Tridimensional Personality Questionnaire (TPQ) was completed by 
66 outpatients with a mood and/or anxiety disorder randomly assigned to 
treatment with either imipramine or fluvoxamine for six weeks. As expected, 
patients showed high scores on Harm Avoidance (61 completers, mean= 
18.98; 5 dropouts, mean=20.00). Treatment response was evaluated using a 
subscale o f the Comprehensive Psychopathological Rating Scale (CPRS- 
MA). Regression analysis based on the CPRS-MA for the 61 completers 
showed Harm Avoidance to be related to treatment response to antidepres­
sants but not to treatment with imipramine versus fluvoxamine. There were 
no interaction effects between the temperament dimensions Harm Avoidance 
and Reward Dependence on treatment outcome. Furthermore, persistence 
was found to be related to treatment response in the fluvoxamine group. The 
influence o f state mood effects on Harm Avoidance is discussed. Further re­
search is needed to confirm the present findings and clarify the role o f tem­
perament in antidepressant treatment response, particularly in light o f the 
new methods utilised in this study.
Introduction
The past decades have witnessed considerable progress in the treatment of 
mood and anxiety disorders with antidepressants. Tricyclic Antidepressants 
(TCAs) as well as Selective Serotonin Reuptake Inhibitors (SSRIs) have 
proved effective for the treatment of major depression (Anderson, 1998, 
2000) and such anxiety disorders as panic disorder, obsessive- compulsive
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disorder, social phobia and generalized anxiety disorder (Allgulander, 1999; 
Black, Wesner, Bowers, & Gabel, 1993; Burke, Preskorn, Bloom, & Kupfer, 
1995; McTavish & Benfield, 1990; Murphy & Pigott, 1990; Rickels, Down­
ing, Schweizer, & Hassman, 1993; Rocca, Fonzo, Scotta, Zanalda, & Raviz- 
za, 1997; Stein, Fyer, Davidson, Pollack & Wiita, 1999; Tancer & Uhde, 
1995, Van Balkom, 1994). Some studies suggest that TCAs may be more ef­
fective for certain types of depression (Klein & Ross, 1993; Potter, Rudolfer, 
& Manji, 1991) including depressed inpatients (Anderson, 2000; Kraghso- 
rensen, 1990) and SSRIs may be more effective for certain anxiety disorders 
(Den Boer & Westenberg, 1988; Van Balkom, 1994). While the effective­
ness of the latter is assumed to be connected to disturbed serotonergic neuro­
transmission in anxiety disorders (Kent, Coplan, & Gorman, 1998), it is still 
not possible to predict antidepressant treatment response for patients with 
mood and anxiety disorders or to meaningfully differentiate between the 
effects of TCAs and SSRIs.
The psychobiological personality model of Cloninger (Cloninger, 1987) 
is reputed to differentiate between responders and nonresponders to antide­
pressant treatment (Cloninger, Przybeck, Svrakic, & Wetzel, 1994). Tempe­
rament dimensions refer to automatic emotional responses which are mode­
rately heritable and stable throughout life. Large-scale twin studies have con­
firmed that the different dimensions of temperament are genetically homoge­
neous and independent of one another (Heath, Cloninger, & Martin, 1994; 
Stallings, Hewitt, Cloninger, Heath, & Eaves, 1996). The three dimensions 
of temperament considered in the model are Novelty Seeking, Harm Avoid­
ance and Reward Dependence. The Tridimensional Personality Question­
naire (TPQ) (Cloninger, 1987) consists of 100 items rated using a self-rating 
scale. Novelty Seeking is a tendency towards intense excitement in response 
to novel stimuli, which leads to frequent exploratory activity or active avoid­
ance of monotony and of potential punishment. Harm Avoidance is a tenden­
cy to respond intensely to signals of aversive stimuli and thereby a tendency 
to inhibit behaviour in order to avoid punishment, novelty and frustrative 
non-reward. Reward Dependence is a tendency to respond intensely to sig­
nals of reward and a related tendency to maintain behaviour and resist ex­
tinction of what has been previously associated with reward and/or relief 
from punishment (Cloninger, 1987). A subscale of Reward Dependence, 
called Persistence, has proved to be an independent dimension and repre­
sents the tendency to be hardworking, stable and industrious (Cloninger et 
al., 1994).
The temperament dimensions are postulated to reflect the underlying 
biogenetic structure of variations of the dopaminergic, serotonergic and no­
radrenergic brain system, which is moderately heritable and stable through­
out life. Scores on Harm Avoidance have been found to be positively corre­
lated with mesolimbic serotonergic activity (Cloninger et al., 1994). In addi­
tion, the temperament dimensions appear to be closely related to
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susceptibility to different neurotic syndromes (Cloninger, Svrakic, & Przy­
beck, 1993). Cloninger concluded that depressives are clinically and etiolo­
gically heterogeneous and that temperament may be a more powerful man­
ner of characterising their heterogeneity than their variation in depressive 
symptoms and any comorbid psychopathology.
Several studies have explored the role of temperament as a possible pre­
dictor of antidepressant response. Temperament has been found to be related 
to treatment response, although the results show limited consistency with re­
gard to the role of the various dimensions or types (i.e., combinations) of 
temperament. Joffe et al. (1993) showed outpatients who were non-respon­
ders to standard antidepressant treatment for major depression to score 
higher on Harm Avoidance at both baseline and after three months of treat­
ment when compared to outpatients who were responders. In addition, the 
Harm Avoidance scores of the non-responders remained relatively stable 
(mean scores of 26.8 and 26.7) while the Harm Avoidance scores of the res­
ponders changed over the course of treatment (mean scores of 21.9 and 
18.2). In another study, specific combinations (or types) of temperament 
have been related to response to antidepressants (Joyce, Mulder, & Clonin­
ger, 1994). In fact, type of temperament turned out to be the only predictor 
of treatment outcome when compared to personality disorder, severity of 
symptoms, age and gender. More recently, Nelson and Cloninger (1997) 
have shown patients with major depression and high scores on Reward De­
pendence to have the lowest antidepressant response. Harm Avoidance, 
Reward Dependence and their interaction clearly predicted treatment respon­
se. More specifically, patients with high scores on Harm Avoidance or Re­
ward Dependence showed lower treatment response when compared to other 
patients. It should be noted that although the model appears to have signifi­
cant predictive value due to the large number of patients included in the 
study, it actually accounts for only 1 .1% of the variance in treatment respon­
se. Nelson and Cloninger therefore conclude that although the clinical utility 
of these findings is uncertain, the line of investigation linking temperament 
to pharmacological treatment response is nevertheless promising. In a study 
of patients with a panic disorder or a generalized anxiety disorder (Winger- 
son et al., 1993), those dropping out were found to score significantly higher 
than those not dropping out on Novelty Seeking but not on other demogra­
phic or clinical variables. In conclusion, Harm Avoidance scores appear to 
be consistently elevated in non-responders to antidepressant treatment while 
paricular combinations of dimensions of temperament (e.g., Harm Avoid­
ance and Reward Dependence) are not consistently related to treatment res­
ponse. Clinical trials including measures of temperament, moreover, have 
primarily studied depressed patients and paid little or no attention to the 
differential effects of antidepressants (e.g., TCAs versus SSRIs).
The aim of the present study was therefore to examine the relation be­
tween temperament and response to an SSRI, fluvoxamine, and a TCA,
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imipramine. Given that the different dimensions of temperament cut across 
the DSM categories of disorders, we included all patients who could be ex­
pected to respond to treatment with antidepressants and thus patients with 
either a mood or an anxiety disorder or a comorbid combination of such. 
Rather than focus on the DSM categorisations in terms of current sympto­
matology, we also explored temperament as a means of detecting subtypes 
of patients who may respond particularly well or particularly poorly to 
treatment. We hypothesised that patients with high Harm Avoidance would 
respond better to fluvoxamine than to imipramine. This assumption is based 
on the fact that Harm Avoidance is assumed to be more directly related to 
susceptibility to anxiety and/or serotonergic neurotransmission. In addition, 
the role of Reward Dependence and the interaction of this with Harm Avoid­
ance will be explored. Those dropping out of treatment will also be consi­
dered in keeping with the assumption that noncompleters may produce 
higher scores on Novelty Seeking than completers.
Methods
Design
Patients with either a mood or an anxiety disorder according to the DSM-III- 
R were randomly treated with imipramine or fluvoxamine in a 6-week treat­
ment study. To obtain a representative outpatient sample and avoid a selec­
tion bias, the treatment was not blind but the ratings of treatment outcome 
were. Patients visited the psychiatrist weekly for the first two weeks and 
every two weeks thereafter. The visits took an average of 20 minutes. No ad­
ditional psychotherapy was given. The research psychologist administered 
the CPRS (Comprehensive Psychopathological Rating Scale; Âsberg, Mont­
gomery, Perris, Schalling, & Sedvall, 1978) on the day which the patient 
started with the medication (baseline) and during the sixth week of treatment 
(week 6; outcome measurement).
Subjects
All newly attending patients between 18 and 65 years of age were screened 
for the DSM-III-R criteria for a mood or anxiety disorder. Patients with at 
least a moderate severity (4) of their illness according to the Clinical Global 
Impression (CGI: Guy, 1976) were included. The following exclusion crite­
ria were next applied: a) contra indications for antidepressant drugs; b) un­
successful treatment with fluvoxamine or imipramine during the present epi­
sode; c) treatment with another antidepressant within one week of randomi­
sation and fluoxetine within five weeks of entering the study; d) concurrent 
use of CNS medication, other than for night-time sedation and to control an­
xiety; and/or e) use of psychedelics or alcohol on a daily basis (more than 3 
drinks a day).
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Treatment conditions
The patients were randomly selected to receive imipramine or fluvoxamine. 
The dosage for the fluvoxamine was 50 mg. the first day, to be increased to 
150 mg/d at the end of the first week. A temporary decrease of the dosage 
due to side effects was allowed, but the dosage of 150 mg/d had to be 
reached within 14 days of the first treatment day. During weeks 2 through 6, 
a minimum dosage of 150 mg/d was maintained. During weeks 4 through 6, 
the dosage could be increased to a maximum of 200 mg/d in cases of nonres­
ponse. The imipramine dosage started at 75 mg/d. After one week, blood 
was collected for blood level determination and assessed within five days. 
The dosages were adjusted to obtain blood levels of 200Fg/1 of the sum of 
imipramine and desmethylimipramine, which was checked at week 4. No 
concomitant medication was allowed, with the exception of oxazepam or lor­
metazepam during the first 4 weeks. During weeks 4 through 6, these ben­
zodiazepines were not allowed.
Assessments
The Munich Diagnostic Checklists (MDCL) were used by the treating psy­
chiatrists to screen for the DSM-III-R diagnoses (Hiller, Zaudig, & Mom- 
bour, 1990a, 1990b). The reliability of diagnoses based on the checklists has 
been found to be satisfactory (Hiller, Von Bose, Dichtl, & Agerer, 1990c). 
High agreement between raters has been obtained for major depression (k = 
.73) and for anxiety disorders as a whole (k = .76). Less agreement has been 
found for agoraphobia, social phobia and dysthymia. The MDCL enables 
clinicians to examine mental disorders in a systematic manner. For the 
present study, a subset of the checklists was used: adjustment disorder, ago­
raphobia, alcohol dependence and abuse, bulimia nervosa, dysthymia, gene­
ralized anxiety disorder, major depressive disorder, obsessive compulsive 
disorder, panic disorder, schizo affective disorder, simple phobia, social pho­
bia and somatization disorder. The psychiatrist had to complete the full sub­
set for all patients.
The Tridimensional Personality Questionnaire (TPQ) (Cloninger, 1987) 
was used to measure the different dimensions of temperament. Based on the 
assumption that temperament is relatively stable over time and for practical 
reasons, the TPQ was administered during the sixth week of treatment. In 
case of early dropout, we asked the patient to further co-operate and com­
plete the TPQ.
To assess response to treatment, an instrument suitable for quantifica­
tion of anxiety as well as depressive symptoms was needed. To this end, a 
composite of the subscales from the Comprehensive Psychopathological Ra­
ting Scale (CPRS) (Âsberg et al., 1978) was used for depression (MADRS) 
(Montgomery & Âsberg, 1979), for anxiety (BSA) (Tyrer, Owen, & Cicchet­
ti, 1984) and for obsessive compulsive disorder (Thorén, Âsberg, Cronholm, 
Jörnestedt, & Träskman, 1980; Montgomery & Montgomery, 1980). These
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composite scales have been specifically designed for treatment evaluation, 
and the MADRS in particular has been used extensively in pharmacotreat- 
ment studies. This composite scale (the ‘mood-anxiety subscale’ of the 
CPRS (CPRS-MA) consists of 21 items (18 symptoms and 3 observation 
items). The CPRS-MA is similar to the recently developed self-rating scale 
for depression and anxiety states (CPRS-S-A), which is based on the original 
CPRS (Svanvorg & Âsberg, 1994). The CpRS-S-A consists of 19 items. Se­
venteen items are the same as in the CPRS-MA with the item ‘inner tension’ 
from the CPRS-MA split into ‘inner tension’ and ‘panic attacks.’ Obviously, 
the 3 observational items are not included in the self-rating scale.
Statistical analysis
To examine the relationship between the treatment outcome measure (CPRS- 
MA) and temperament as measured by the TPQ, Pearson correlations were 
calculated. To explore the potential differences between the two treatment 
groups, regression analyses were performed with the CPRS-MA score at 
week 6 as the dependent variable. The general linear model included the 
CPRS-MA score at week 0 and Harm Avoidance, Reward Dependence and 
Persistence as independent factors. Assessments made more than 14 days 
difference from week 6 were excluded from any further analyses; a total of 
two measurements were excluded for this reason, which meant that the re­
gression analyses were based on 61 of the 63 patients who completed the six 
weeks of treatment. The data were analysed with the aid of SPSS for Win­
dows, release 7.5.2. The GLM General Factorial procedure was used for the 
regression analysis.
Results
A total of 74 patients started treatment. Sixty-three patients completed treat­
ment and 11 (14.8%) dropped out. Of the 63 completers, the TPQ data for 61 
patients was analysed in the end (see above). For 5 of the 11 dropouts, we 
were still able to administer the TPQ during week 6 . The clinical 
characteristics of the completers and noncompleters are presented in Table 
7.1.
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Table 7.1 Clinical characteristics o f  completers and noncompleters
Completers Noncompleters
n M SD n M SD
Age 61a 35.70 10.45 11 31.20 8.77
Male/female 24/37 4/7
Imipramine 30 7
Fluvoxamine 31 4
DSM-III-R diagnosis:
Mood disorder 15 1
Anxiety disorder 27 8
Mood and Anxiety 19 2
disorder
TPQ:
Harm Avoidance 61 18.98 7.55 5 20.00 4.64
Novelty Seeking 61 15.65 4.14 5 19.00 4.12
Reward Dependence 61 13.15 3.36 5 13.80 4.76
Persistence 61 5.01 2.02 5 3.20 2.86
Note. a n = 61, completers included for analyses
The mean TPQ scale scores are presented in Table 7.1. As expected, the 
mean Harm Avoidance score (18.98) is elevated when compared to a normal 
population. Recently, Dutch norm scores for the Temperament and Character 
Inventory (TCI) have been reported (Duysens, Goekoop, Spinhoven, & Eu- 
relings-Bontekoe, 1997) with a mean of 15.15 for Harm Avoidance, which is 
higher than the mean of 12.6 for an American norm group (Cloninger et al.,
1994).
Harm Avoidance was significantly correlated with the CPRS-MA sco­
res at week 0 (r = .27, p  < .05) as well as at week 6 (r = .40, p  < .01). In ad­
dition, the Persistence score was correlated with the CPRS-MA score at 
week 6 (r = .25, p  = .05). No significant correlations were found for Reward 
Dependence or Novelty Seeking. The correlation coefficients for the dimen­
sions of temperament were next considered per treatment group as shown in 
Table 7.2. Harm Avoidance correlated with the outcome score for both treat­
ment groups while Persistence correlated with the outcome score for the flu­
voxamine group only (r = .42, p  < .05).
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Table 7.2 Pearson correlation coefficients (r) for TPQ scale scores with CPRS-MA 
outcome scores o f  all patients who completed treatment and per treatment group
total patients (n=61) fluvoxamine (n=31) imipramine (n=30)
TPQ scale week0 week6 week0 week6 week0 week6
Harm Avoidance .27* .40** .27 .36* .28 .49**
Novelty Seeking .04 .04 .05 .01 .04 .15
Reward Dependence -.02 -.03 -.15 -.14 .15 .13
Persistence .06 .25 .11 .42* -.02 -.11
Note. *p  < 0.05, **p < 0.01
The regression analyses including treatment group, the CPRS-MA week 
0 score, Harm Avoidance, Reward Dependence and Persistence as indepen­
dent factors proved significant (df = 5, F  = 8.70, p  < .001) (see Table 7.3). 
Harm Avoidance (F = 8.19, p  < .01) and Persistence (F = 6.46, p  < .05) 
showed significant main effects on treatment outcome. No differences be­
tween the treatment groups were found.
To further explore the differences between treatment with fluvoxamine 
and imipramine, the interaction of Harm Avoidance with treatment group 
and Persistence with treatment group was included. The general linear model 
was significant (df = 7, F  = 6.92, p  < .001) and explained 47% of the varian­
ce. The main effect of Harm Avoidance remained significant (F = 7.03 , p  < 
.05), but the interaction with treatment group was not significant. Persistence 
showed no significant main effect, but the interaction with treatment group 
approached significance (F = 3.64, p  = .062).
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Table 7.3 Regression analyses on TPQ scales and treatment outcome
Model Independent variables F p  value F  model p  model
1a 8.70 .000***
CPRS-MA baseline 16.96 0.000***
Harm Avoidance 8.19 0.006**
Persistence 6.46 0.014*
Reward Dependence 0.01 0.910
Treatment group 1.87 0.177
2b 6.92 .000***
CPRS-MA baseline 16.98 0.000***
Harm Avoidance 7.03 0.011*
Reward Dependence 0.14 0.711
Persistence 2.49 0.120
Treatment group 1.04 0.312
Harm Avoidance x
Treatment group 0.01 0.915
Persistence x
Treatment group 3.64 0.062
Note. * p  < 0.05, ** p  < 0.01, ***p  < 0.001.
a n = 61; R Square = .442; d f  = 5. 
b n = 61; R Square = .478; d f  = 7.
The TPQ scale scores for completers versus noncompleters are presen­
ted in Table 7.1. Comparison of the completers with the noncompleters 
showed the dropouts to score higher on Novelty Seeking and lower on Per­
sistence although not significantly (t-test; resp. t =-1.74, p  = .08 and t =1.87, 
p  = .06, resp.). No differences were found with regard to Harm Avoidance or 
Reward Dependence.
Discussion
The Harm Avoidance scores for our patient sample were found to be higher 
than for normals, which is in line with prior reports on patients with mood 
and anxiety disorders (Cloninger et al., 1994). Harm Avoidance negatively 
correlated with treatment response. While Joffe et al. (1993) observed a si­
milar relation between Harm Avoidance and antidepressant treatment res­
ponse in depressed patients, Joyce et al. (1994) obtained results to the con­
trary. The present sample of patients with mood and anxiety disorders was
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analysed in terms of temperament because it was assumed that temperament 
factors would be more related than DSM classification to treatment response. 
Temperament was indeed found to play a role in treatment response although 
the assumption that high Harm Avoidance would be more specifically rela­
ted to response to fluvoxamine was not confirmed.
Neither Reward Dependence nor Novelty Seeking related to treatment 
outcome. Non-completion of treatment appeared to be related to high scores 
on Novelty Seeking, which is similar to a previous report on patients with 
panic or generalized anxiety disorder (Wingerson et al., 1993). This also 
suggests a selection bias with regard to temperament characteristics when it 
comes to samples of patients completing experimental trials such as the pre­
sent one.
A new finding is the relation of scores on the TPQ Persistence scale to 
treatment outcome. The Persistence scale was separated from the Reward 
Dependence scale only after introduction of the TpQ, which means that the 
Persistence items were originally included in the Reward Dependence scale 
(e.g., Joffe, et al., 1993; Joyce et al., 1994). In addition, the Persistence scale 
has not been included in analyses of response to antidepressant treatment in 
recent studies (Nelson & Cloninger, 1997). In the present study, high scores 
on the Persistence scale were correlated with low response to fluvoxamine 
but not to imipramine. The interaction between Persistence and treatment 
group approached statistical significance in the regression analysis. Low sco­
rers on Persistence tend to be inactive, modest and give up easily. And such 
patients may respond preferentially to an SSRI than to a TCA regardless of 
their disorder being a mood or anxiety disorder according to the DSM crite­
ria.
The present study was the first to compare the therapeutic effects of an 
SSRI versus a TCA in a group of patients with mood and anxiety disorders 
warranting antidepressant treatment. Further studies are certainly needed to 
confirm the present results, and a number of methodological issues should be 
addressed while doing this. We assumed the TPQ to be largely state-inde­
pendent and therefore administered it during week 6 of treatment. It has ne­
vertheless been reported that Harm Avoidance in particular may be state de­
pendent (Cloninger et al. 1994; Chien & Dunner, 1996; Strakowski et al.,
1995). In addition, we used an outcome scale which closely resembles the 
self-rating scale developed by Svanvorg and Âsberg (1994) but has yet to be 
validated: the CPRS-MA. The number of patients included in the analyses in 
the present study tended to be rather small although this does not alter the 
heuristic value of the present findings. Assignment to treatment condition 
was random but not blind in the present study, which could result in an 
assessment bias, although the outcome scale was scored by a judge blind to 
treatment condition. Patients who would otherwise have refused to partici­
pate in a double blind study were presumably included in the present study, 
which could be at the basis of the present results. Finally, treatment with imi-
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pramine was blood level controlled. This avoided the usual problem of un­
dertreatment or high dropout rates due to side-effects. Given that the detec­
tion of a relation of treatment effects to other variables may critically de­
pend on optimal dosing, the blood level control may also be significant with 
regard to the results obtained (Bruijn et al., 1999).
In conclusion, the present study showed an inverse relation of Persisten­
ce with treatment response to fluvoxamine but not to imipramine. It also 
confirmed an inverse relation between Harm Avoidance and treatment 
response to both antidepressants. Previous findings on the role of particular 
combinations of the different temperament dimensions (i.e., types of tempe­
rament) in response to treatment with antidepressants have not been suppor­
ted. Further studies are nevertheless needed to confirm these findings, parti­
cularly in light of the new methods utilised in this study.
Note. Submitted for publication
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8 General discussion
The present thesis was an exploration of how to detect differences in antide­
pressant treatment response in patients with mood and anxiety disorders. The 
efficacy of TCAs and SSRIs for the treatment of mood as well as anxiety 
disorders is generally accepted. Nevertheless, it is still not possible to predict 
antidepressant treatment response with accuracy and to differentiate mea­
ningfully between TCAs and SSRIs. The current empirical evidence is limi­
ted to showing a favourable response to TCAs in severely depressed pa­
tients. The presupposed favourable response to SSRIs in patients with anxie­
ty disorders has not been confirmed by empirical research. In other words, 
meaningful differences between treatment with SSRIs versus TCAs have not 
been found in less severe patients, classified with either a mood disorder or 
an anxiety disorder. Such patients are characterised by a high level of co­
morbidity, and the currently accepted DSM classification system does not 
suitably distinguish mood and anxiety disorder patients. As a consequence, 
the DSM criteria are also not suitable for the selection of subtypes of patients 
who may show a favourable treatment response to either TCAs or SSRIs.
In the present study the value of alternative classification models was 
therefore explored to detect any differences in the efficacy of SSRIs and 
TCAs which may have gone undetected using the current DSM classification 
system. First, classification of patients according to primary diagnosis was 
explored. Patients with a primary anxiety disorder (i.e., anxiety disorder as 
the first disorder in their lifetime) were assumed to respond favourably to an 
SSRI, while patients with a primary depression were assumed to respond fa­
vourably to a TCA. Patients can also be classified according to personality 
factors or temperament, which have been shown to be related to the predic­
tion of antidepressant treatment response. The personality model of tempera­
ment put forth by Cloninger is also therefore included in the present study. 
Finally, it should be noted that the patients included in research are usually 
selected on the basis of a single DSM diagnosis. In light of the frequent co­
morbidity of mood and anxiety disorders, however, a clear bias towards the 
patient selection may exist. Conversely, possible differences between treat­
ments may go undetected as a result of the confounding of mood and anxiety 
disorders within a single diagnosis. To avoid such a selection bias, all pa­
tients who might benefit from antidepressant treatment were included in the 
present study; this thus included patients with mood disorders, anxiety dis­
orders, or both.
To summarise, the basic aim of the present study was to reduce selec­
tion bias and include all patients who might benefit from antidepressant 
treatment based on current symptomatology, patients thus meeting the DSM 
criteria for mood disorder and/or anxiety disorder. The patients were then 
classified according to primary diagnosis and temperament in order to tho-
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roughly explore any differences in treatment response to TCAs and SSRIs. 
The main issues of the present study will be discussed in the current chapter.
8.1 The impact of comorbidity on patient selection
The DSM classification of mood and anxiety disorders as separate disorders 
is often artificial in clinical practice. Nevertheless, the DSM criteria are wi­
dely accepted for the selection of patient samples in treatment outcome re­
search. Due to the high co-occurrence of mood and anxiety symptoms, pa­
tients often may fulfil criteria of both disorders. Patient selection procedures, 
therefore, contribute to the empirical evidence of the outcome results. The 
following questions are poorly described in re-search reports and especially 
clinical trials: How were patients recruited? What diagnostic procedure was 
used (clinical judgement or structured clinical interview)? Who selected the 
patients (the treating clinician, an independent assessor)? And, how many 
and which of the suitable patients finally entered the study? In an attempt to 
cope with the comorbidity of mood and anxiety disorders, exclusion rules for 
the omission of patients with comorbid disorders are common. Nevertheless, 
only those patients with clearly comorbid disorders are typically excluded 
which means that cases with less severe comorbid symptoms are still inclu­
ded.
The current study therefore included all patients with mood as well as 
anxiety disorders in order to limit the effects of a possible selection bias due 
to comorbidity. The diagnostic procedure for the selection and inclusion of 
patients was semi-structured with the use of the Munich Diagnostic check­
lists (MDCL) which allowed the psychiatrists to make a more accurate dia­
gnosis. Furthermore, a fully standardised instrument (the Composite Inter­
national Diagnostic Interview: CIDI) was administered by a psychologist 
who was not involved in the regular treatment of the patients. The compari­
son of psychiatric diagnosis and CIDI diagnosis confirmed the confounding 
role of comorbidity. Clinicians tend to choose either a mood disorder or an 
anxiety disorder, even though the DSM criteria for both are met when 
assessed with the CIDI. Of the DSM-III-R categories, agreement was found 
to be best although no more than moderate for major depression, and lowest 
for generalized anxiety disorder. These findings are in line with the assump­
tion that a subgroup of major depressed patients can be clearly detected and 
probably constitute the most severe cases. A lot of patients nevertheless pre­
sent with a mixture of mood and anxiety symptoms, such as in generalized 
anxiety disorder. In line with other comorbidity research, half of the patients 
in the present study showed a comorbidity of mood and anxiety disorders as 
assessed by the CIDI standardised instrument. In these patients, problems 
thus arise when a differential diagnosis has to be made and a distinct dia­
gnostic category must be assigned.
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The present findings illustrate the selection bias which can occur in stu­
dies with a focus on only patients with a mood disorder or an anxiety dis­
order. By including both patient groups, selection bias due to the tendency of 
clinicians to opt for either a mood or an anxiety disorder was avoided. They 
nevertheless entered the study.
8.2 The consequences of diagnostic procedures for the outcomes of clinical 
trials
The current finding of low agreement when two independent diagnostic pro­
cedures are used has important implications for the validity of psychiatric 
diagnosis. In addition, most treatment outcome studies with antidepressants 
make use of the DSM criteria for patient selection even though the differen­
tiation of mood and anxiety disorders remains a problem within the DSM 
classification system. As a consequence, patient selection is dependent on 
the diagnostic procedures used by the clinicians.
In the present study, the selection of the patients started with screening 
by a psychiatrist for the presence or absence of an affective disorder (either a 
mood or anxiety disorder based on the DSM criteria). For the group of pa­
tients meeting the DSM criteria for an affective disorder, the agreement be­
tween the psychiatric diagnosis and the CIDI diagnosis turned out to be low. 
Clinicians tend to assign a diagnosis of either a mood disorder or an anxiety 
disorder in line with the clinical tradition of making a single diagnosis. This 
occurred despite a lack of consistent rules for how to differentiate between 
mood and anxiety disorders and suggests that inclusion based on a diagnostic 
procedure other than the psychiatric diagnosis as assessed with the Munich 
Diagnostic Check Lists, which we used, may have produced a very different 
patient group. Depending on the diagnostic category assigned to a patient, 
the patients will be either included or not included and the treatment results 
thereby influenced. DSM categorisation fosters artificial differentiation of 
mood and anxiety disorders and the value of outcome studies using separate 
diagnostic categories is limited due to the use of different inclusion proce­
dures and thus little comparability. Therefore it is of main importance to 
raise consensus on how to differentiate between categories of mood and an­
xiety disorders and how to use inclusion and exclusion rules. The inclusion 
of patients solely on the basis of a psychiatric diagnosis further complicates 
the interpretation of treatment results as the accuracy of the diagnosis is of 
critical importance for the study of treatment outcome. The use of standard 
procedures for clinical diagnosis is therefore recommended in outcome re­
search (also not restricted to pharmacotreatment).
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The problem of differentiating response to TCAs and SSRIs is also related to 
the existence of comorbidity. We assumed diagnosis at first episode in a pa­
tient’s lifetime to be of greater value for the differentiation of mood and an­
xiety disorders in line with the work of Cloninger (1990) and Winokur 
(1997). The primary/secondary distinction is based on the development of 
the syndrome rather than on current symptomatology. Research on the se­
quential relationship of mood and anxiety disorders has shown primary de­
pression to rarely change into an anxiety disorder while the occurrence of se­
condary depression in patients with an initial anxiety disorder (also named 
demoralisation depression), is rather common. These findings suggest the 
existence of different disease processes and potentially different etiological 
bases for different subtypes of mood and anxiety disorders.
In the present study, the role of primary diagnosis in treatment response 
to TCAs and SSRIs was explored. The assumption that patients with a pri­
mary depression respond better to a TCA (imipramine) while patients with a 
primary anxiety disorder respond better to an SSRI (fluvoxamine) was sup­
ported to some extent. Patients with a primary depression showed a better 
response to imipramine than to fluvoxamine at week2 but not at week6 for 
both of the outcome measures, the CPRS-MA and CGI, respectively. In 
other words, the initial response to imipramine is better than the initial res­
ponse to fluvoxamine in patients with a primary depression. The findings 
were stronger for the subgroup of patients with a primary depression and no 
comorbid anxiety disorder. Comparison of the group means for the CPRS- 
MA items specific to mood disorders or anxiety disorders showed patient 
improvement to not be restricted to certain symptoms. These results show 
clear improvement within the first two weeks of treatment with imipramine 
for primary depression. This temporary difference from the response to treat­
ment with fluvoxamine may be a result of the increased symptoms of arousal 
which is often interpreted as being a side-effect of fluvoxamine (Den Boer & 
Westenberg, 1988).
Patients with a primary anxiety disorder, in contrast, showed a better 
response to fluvoxamine for only the CGI outcome measure. The origin of 
the differences in the results for the CPRS-MA and CGI measures can only 
be guessed at, however. The differences may stem from the psychometric 
properties of the scales, such as variation in the sensitivity and specificity of 
the scales to the different subgroups of patients. Given our focus on patients 
with any DSM-III-R diagnosis of mood or anxiety disorder, we needed an 
outcome measure sensitive to a wide range of symptoms, including both 
mood and anxiety symptoms. The existing outcome measures, such as the 
Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960) or the Cli­
nical Anxiety Scale (CAS) (Snaith, Baugh, Clayden, Husain & Sipple, 
1982), did not meet this need. We therefore adopted a composite scale
8.3 The role of primary diagnosis in antidepressant treatment response
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composed of the depression, anxiety and OCD items from the CPRS (CPRS- 
MA) as the best possible outcome measure available at this point. Although 
comparable to the CPRS-S-A (Svanborg & Âsberg, 1994), this scale has not 
been validated and we therefore also decided to use the CGI, a general mea­
sure of improvement not related to specific symptoms. The fact that the pa­
tients with a primary depression were found to have higher baseline scores 
on the CPRS-MA when compared to the patients with primary anxiety sug­
gests a lack of balance in the items constituting this measure. Indeed, mood 
symptoms appeared to be measured more extensively than anxiety 
symptoms; for example, experience of panic attacks is included under the 
item 'inner tension'. For the CPRS-S-A (Svanborg & Âsberg, 1994), in fact, 
the experience of panic attacks has been added as a separate item for this 
very same reason. This lack of balance in the items may also suggest that the 
CPRS-MA is not sufficiently sensitive to detect treatment differences in pa­
tients with primary anxiety disorder. Indeed, only the results based on the 
CGI showed favourable response to fluvoxamine in patients with primary 
anxiety disorder. In conclusion, the CPRS-MA appears to be a more sensi­
tive measure to assess treatment response in patients with primary depres­
sion than in patients with primary anxiety disorder. Nevertheless, it is also 
possible that indeed a difference in the severity of the primary depression 
versus primary anxiety disorder exists. The present results should therefore 
be considered preliminary and more research with the CPRS-MA is manda­
tory to be applied for the same purpose in future studies.
The operationalisation of the primary-secondary distinction to discern 
subtypes of mood and anxiety disorders also raised some difficulties. We 
used the CIDI to measure lifetime diagnosis but this has the problem of re­
trospective assessment. The extend to which primary depression and primary 
anxiety disorder may have been classified incorrectly in retrospect remains 
to be investigated. At this moment, there seems to be no clear solution to this 
problem except for prospective study. Some support for the validity of the 
CIDI to assign primary diagnosis is provided in the present study in that res­
ponse differences to imipramine and fluvoxamine became most apparent in 
patients with a primary depression without comorbid anxiety disorder. These 
patients may be the 'pure' melancholic depressions and are compared to pri­
mary anxiety disorder patients who may develop a secondary depression at a 
later stage. The existence of a first episode consisting of a mood disorder and 
an anxiety disorder at the same time needs further investigation. In addition 
to this, the CIDI may not be adequate for distinguishing the onset of DSM 
disorders particularly when the disorders appear relatively close to each 
other over time. The value of retrospective assessment clearly depends on 
the recall of the patients and recalling the time of onset of symptoms may be 
particularly difficult when numerous symptoms appear within a certain pe­
riod of time.
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Three additional methodological issues should be noted at this point. 
The validity of our inclusion criterion, namely a CGI score of at least mode­
rate severity (score 4) needs to be considered. With interrater sessions under 
the supervision of a psychiatrist who did not participate in treatment, we 
aimed to raise the degree of agreement on this measure. Furthermore, al­
though the study was not double-blind, the raters were blind to which of the 
treatments the patients were assigned to. Finally, in contrast to most other 
trials, we used therapeutic drug monitoring (TDM) to determine the appro­
priate dosage of imipramine. This strategy circumvents the problem of over­
ly aggressive dosages which can lead to high dropout rates, or suboptimal 
dosages of imipramine. The use of TDM may also, thus, be related to the ef­
ficacy of imipramine.
In conclusion, and despite the methodological problems yet to be sol­
ved, the paradigms used in the present study to differentiate treatment res­
ponse to a SSRI from response to a TCA appears to be promising. The fin­
dings are fairly consistent with the initial assumptions we made, namely that 
patients with a primary depression will respond better to imipramine while 
patients with primary anxiety disorder will respond better to fluvoxamine. 
The results suggest that the information on the nature of the first illness epi­
sode may be more valuable than the categorisation as a current DSM mood 
or anxiety disorders. Support is also thus provided for the relevance of dis­
tinguishing between a primary versus secondary depression (Cloninger et al., 
1990; Winokur, 1997) to predict antidepressant treatment response. In the 
words of Klerman: "The growing acceptance of operational criteria has led 
to widespread dissatisfaction with the existing system, because of the exclu­
sive reliance on clinical symptomatic and behavioural features. The search 
for pathological processes remains a fervent hope of many investigators. 
They accept the high level of comorbidity as a starting point and look to ge­
netics, physiology, stress and personality dynamics for underlying mecha­
nisms that would explain and unite the diverse comorbid states" (in: Maser 
& Cloninger, 1990, p. 37).
8.4 The role of temperament in antidepressant treatment response
The psychobiological personality model of Cloninger has been reputed to 
differentiate responders from nonresponders to antidepressant treatment 
(Cloninger et al., 1994). The four temperament dimensions of Harm Avoid­
ance, Novelty Seeking, Reward Dependence and Persistence are postulated 
to reflect underlying biogenetic variations in dopaminergic, serotonergic and 
noradrenergic brain systems. And the aforementioned dimensions of tempe­
rament appear to be related to susceptibility to different neurotic syndromes 
(Cloninger et al., 1993). Harm Avoidance is postulated to reflect variations 
in serotonergic activity and empirical findings show Harm Avoidance scores
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to be consistently elevated in patients with m ood and anxiety disorders when 
compared to the normal population (Brown et al., 1992; C loninger et al., 
1994; Cowley et al., 1993; Joffe et al., 1993). W hereas high Novelty Seeking 
in combination with high Harm Avoidance is assumed to be related to dys­
thym ia as a result o f  the continual approach-avoidance conflicts within the 
person, high Novelty Seeking in combination with low Harm Avoidance is 
associated with impulsive-aggressive behaviour. Finally, high Reward D e­
pendence has been related to the developm ent o f  atypical depression (Clo­
ninger et al., 1994). Cloninger concluded that depressives are clinically and 
etiologically heterogeneous and that tem peram ent is a more powerful way o f 
characterising these people than depressive symptoms and co-morbid psy­
chopathology. In line with this, the present study focused on patients with a 
mood and/or anxiety disorder and explored the role o f  tem peram ent in their 
response to treatm ent with a TCA or SSRI. Tem peram ent was used to iden­
tify  subgroups o f  patients and the scores determined with the aid o f  the Tri­
dimensional Personality Questionnaire (TPQ) were found to be consistent 
with those in prior reports (Cloninger et al., 1994). Harm Avoidance scores 
were elevated when com pared to normals. Furthermore, patients with high 
Harm  Avoidance showed poorer treatm ent response although their scores did 
not differentiate between imipramine and fluvoxamine. Earlier findings re­
garding the role o f  Reward Dependence and the effects o f  an interaction be­
tween Harm Avoidance and Reward Dependence on treatm ent outcome were 
not confirmed.
It should be noted that the results regarding Harm Avoidance may be an 
artefact o f  state dependency. Harm Avoidance scores m ay be tem porarily 
elevated as a result o f  depressive or anxious feelings as part o f  the disorder 
rather than a more perm anent personality trait, and Harm Avoidance has in­
deed been found to be related to current mood state (Chien & Dunner, 1996; 
Joffe et al., 1993). In the present study the Harm  Avoidance scores, m ea­
sured at week6 o f  treatment, were found to signifycantly decrease in respon­
ders but not in nonresponders while the Novelty Seeking and Reward D e­
pendence scores did not change. Difficulties with the measurem ent o f  trait 
characteristics due to interference o f current psychopathology are frequently 
acknowledged but no conclusive solution is available. Based on the theore­
tical assumption that tem peram ent dimensions remain stable, we examined 
the TPQ at week 6 but still may have m easured the state effects o f  depres­
sive symptomatology. In future studies, the assumed influence o f state mood 
effects on tem peram ent scores m ust be ruled out. As long as the scores are 
state dependent, prediction o f treatm ent outcome based on dimensions o f 
tem peram ent has limited value. In any case, tem peram ent should preferably 
be m easured at baseline. Best, o f  course, is to assess tem peram ent twice, be­
fore and after treatment, in order to explore any changes in tem peram ent 
scores during treatment.
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The role o f  Persistence also needs further explanation. Persistence was 
originally a subscale o f  Reward Dependence but turned out to be a separate 
fourth dimension o f  temperament. In line with this, the Persistence items 
have been excluded from Reward Dependence in more recent studies (e.g., 
N elson & Cloninger, 1997). W e found, as postulated a-priori, a differential 
role for Persistence in response to treatm ent with fluvoxamine versus im ipra­
mine (i.e., patients with lower scores on Persistence responded better to flu­
voxamine than patients with higher scores) while no such differences were 
found for the imipramine group. According to the model o f  personality used 
in the present study, Persistence is viewed as a tendency to be hard working, 
stable and industrious (Cloninger et al., 1994). Low scorers on Persistence 
are viewed as inactive, m odest and tending to give up easily. The question, 
then, is what m ay link low Persistence to a better response to treatm ent with 
an SSRI? A t first sight, it would be expected that high Persistence improves 
treatm ent outcome for both groups due to a tendency to active participation 
and compliance with the treatment. An alternative psychological explanation 
is that a low score on Persistence indicates a need for help or dependence on 
help. The dependent personality characteristics may then help explore which 
types o f  m ood and anxiety disorders respond best to SSRIs. These prelim i­
nary findings on the role o f  Persistence in treatm ent outcome need to be 
further investigated in future research, however.
In conclusion, the present study showed, consistent with prior reports, a 
negative relation o f  Harm Avoidance to antidepressant treatm ent response. 
However and contrary to our initial assumption, no differentiation between 
fluvoxamine and imipramine was found. Furthermore, Persistence turned out 
to be related to fluvoxamine response. The present data provide support for 
the role o f  tem peram ent based on the personality model o f  Cloninger in anti­
depressant treatm ent response although the ability o f  tem peram ent to diffe­
rentiate between response to TCAs and SSRIs needs further exploration.
8.5 Limitations of the present study
The present study constitutes an initial attem pt to differentiate response to 
antidepressants using a different design than in m ost outcome studies. The 
inclusion o f  patients with any DSM -III-R diagnosis o f  m ood or anxiety dis­
order and use o f the alternative concepts o f prim ary diagnosis and tem pera­
m ent nevertheless raises the following m ethodological problems.
1. Use o f  the C PRS-M A as an outcom e m easure. As already pointed out, in­
clusion o f patients with m ood as well as anxiety disorders m eant that the 
regular outcome measures did not suffice. No fully validated outcome 
m easures were available to assess both mood as well as anxiety symp­
toms, so it was decided to compose a composite subscale o f  the CPRS,
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the CPRS-M A, which includes the items form the depression, anxiety and 
OCD subscales. The CPRS-M A was thus used as the main outcome m ea­
sure along with the CGI, a global clinical measure. As already discussed, 
the CPRS-M A turned out to be higher at baseline for patients with a 
prim ary depression when com pared to patients with a primary anxiety 
disorder. This suggests that the CPRS-M A is also not sufficiently sensi­
tive to detect differences in patients with primary anxiety disorder. V ali­
dation o f  the CPRS-M A is therefore needed before further use in similar 
studies.
2. A ssessm en t o f  p r im a ry  d iagnosis. As discussed in section 7.2, the opera­
tionalisation o f  primary diagnosis raised some problems. The chronology 
o f  lifetime diagnoses is assessed retrospectively, which limits the reliabi­
lity and validity o f this measure. Information regarding the tem porally 
onset o f  mood and anxiety symptoms at first episode appears to be parti­
cularly im portant for distinguishing prim ary depression from primary an­
xiety disorder patients. In the present study, 18 o f  the 40 patients in the 
prim ary depression group had a co-occurring anxiety disorder at first epi­
sode. The decision to include patients with both a mood and anxiety dis­
order at first episode in the primary depression group m ay thus be arbi­
trary, although we assumed that the anxiety symptoms were an epipheno- 
m ena o f the m ood disorder. The CIDI provides lifetime diagnosis but 
gives no information on the onset o f  the separate mood and anxiety 
symptoms within the first episode, which would be helpful to further dis­
tinguish primary depression versus primary anxiety disorder. Given that 
the treatm ent response differences were m ost clear for the subgroup o f 
patients with prim ary depression w ithout a comorbid anxiety disorder, the 
comorbid group m ay indeed be more heterogeneous. The assessm ent o f 
the onset o f  the first episode o f  a m ood or anxiety disorder in a person’s 
lifetime should therefore be specified in future research as well.
3. A ssessm en t o f  tem peram ent. A t the time at which the present project was 
initiated in 1994, we considered tem peram ent a personality trait and in 
line with this theoretical concept, relatively stable throughout life. From 
this perspective the time at which the TPQ was adm inistered seemed ire- 
levant. Because the study was conducted in a community mental health 
centre (RIAGG) and our research protocol had to be followed with res­
pect to the usual clinical practice, concessions were made. It was decided 
to adm inister the TPQ after six weeks o f  treatm ent due to the limited time 
available for assessment at baseline. For the same reasons, the CIDI was 
administered after four weeks o f treatment. It is now known that at least 
in the case o f  m ood disorders Harm Avoidance scores do not remain 
stable during treatm ent and that the sta te  o f  the individual at the time o f 
assessment may influence such scores, which clearly limits the utility o f 
Harm  Avoidance scores for the prediction o f  treatm ent response. In fur­
ther outcome research it is also therefore recommended that the TPQ be
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adm inistered at baseline as well. In such a manner, the stability o f  tem pe­
rament during treatm ent can be assessed and explored for different sub­
groups o f  patients w ith m ood and/or anxiety disorders. If  patients with 
(primary) m ood disorders indeed show indeed less stable patterns during 
treatm ent than patients with (primary) anxiety disorders, this m ay indeed 
be an indication o f  differences in antidepressant treatm ent response. From 
this perspective, it is im portant to determine whether tem peram ent scores 
changes solely as a result o f  treatm ent (e.g., the reduction o f  symptoms) 
or not, and whether this is different for mood versus anxiety disorders. 
Otherwise, for example, high Harm Avoidance scores m ay still be viewed 
as no more than an epiphenom enon o f  severity, which is known to be re­
lated to antidepressant treatm ent outcome.
A nother issue is the difficulty patients were found to experience with 
the adm inistration o f  the TPQ. The TPQ consists o f  100 true/false items 
to be completed in about 20 minutes. Several patients reported difficulties 
concentrating and asked for help on several questions. The psychometric 
properties o f  the Am erican version o f  the questionnaire have been found 
to be adequate. The Dutch version o f  the TpQ, however, has not been va­
lidated. In this light, it is certainly possible that the difficulties we expe­
rienced are in line with some more general discrepancies between Am eri­
can and European clinical research. Clinical trials are often contradictory 
due to differences in the clinical material, methodologies, health service 
systems, psychiatric traditions and types o f  patients used (Ansseau, 1992). 
Our patient sample was recruited from a community mental health centre 
where research was rather uncommon and as little interference in the re­
gular clinical practice was made as possible. Psychometric research on 
the dimensions o f  tem peram ent within a Dutch population has been ini­
tiated with the latest version o f  the TPQ, the TCI (Duijsens, Goekoop, 
Spinhoven & Eurelings-Bontekoe, 1997). Validation within psychiatric 
populations, outpatients as well as inpatients, is o f  particular interest a l­
though not yet available.
4. Selection  bias. To include a wide range o f  patients in line with regular 
clinical practice and also prevent a selection bias due to the comorbidity 
o f  symptoms, the selection procedure was monitored. Extensive descrip­
tion o f  the inclusion procedure was available and regularly discussed in 
research meetings to prevent arbitrary selection. Nevertheless, our goal o f 
selecting a broad patient population was only realised in part. Because we 
studied a clinical population from a community mental health centre 
(RIAGG), the study was restricted to outpatients. A multi-centre study 
with the inclusion o f  also more severely depressed inpatients is preferable 
to examine the role o f  prim ary diagnosis to detect relevant subtypes o f 
depression and has recently been started. It is expected that the distinction 
between primary and secondary depression for inpatients will be more 
closely related to differential treatm ent response than for less severe ca-
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ses. It should be noted, however, that the inclusion o f  inpatients raises 
new selection problems. Depressed inpatients tend to have a history o f 
nonresponse to earlier treatments which can clearly influence the current 
treatm ent response (Bouvy, 1997) and complicate the com parison o f  the 
patient groups in multi-centre trial. It may therefore be preferable to in­
clude all patients from the same institution offering both am bulatory and 
inpatient care in an attempt to obtain a more or less un-biased patient 
group, although the diagnostic and treatm ent choices o f  the general prac­
titioner prior to admittance may still influence the treatm ent results. 
P a tien t sam ple size. During the screening period o f  two years, 564 pa­
tients were diagnosed with either a mood disorder or anxiety disorder. In 
the end, 98 o f  the patients (17%) entered the study and 92 o f  them  (16%) 
actually started treatment. M ost cases m et one o f  the exclusion rules. 
Nevertheless, in one out o f  five cases no reason for exclusion could be 
traced which supports the assumption that at least part o f  these patients in 
fact should have been included in the study. The relatively small sample 
finally entering treatm ent in the present study illustrates the common pro­
blem o f  reaching large sample sizes in clinical research. It also illustrates 
the difficulty o f  obtaining a patient group representative o f  clinical prac­
tice. W e also made choices within the selection procedure and our sample 
is only representative o f  patients fitting the inclusion and exclusion rules. 
Yet, another six patients were later excluded because they did not start 
the antidepressant treatment, which further reduced the com parability o f 
our sample with those in other clinical trials. As already discussed, con­
sensus m ust be reached on how to use the diagnostic categories and selec­
tion criteria in studying patients with affective disorders (mood or anxiety 
disorders). Furthermore, the patient samples we analysed did not include 
all treatm ent noncompleters because CIDI diagnosis and TPQ scores 
were not available for m ost dropouts, which may introduce a selection 
bias. W e can not assume the noncompleters to be an a-selective sample 
based on diagnoses, clinical and personality characteristics.
In our attem pt to detect meaningful underlying typologies within the 
spectrum o f  mood and anxiety disorders, a larger patient population 
would have been preferable. A t this point, the analyses o f  the primary de­
pression group w ithout comorbid anxiety are limited by our small sample 
size. W ith regard to the role o f  temperament, our findings on patients 
who did not complete treatment, or dropouts, were limited although con­
sistent with prior reports. The role o f  the combinations o f  dimensions o f 
temperament, or tem peram ent types in antidepressant treatm ent response 
certainly merits further study with larger patient samples.
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Because the present study constitutes an initial exploration o f  the role o f  p ri­
mary diagnosis and the role o f  tem peram ent in TCA and SSRI treatm ent res­
ponse, replication o f  our findings is needed before they m ay have im plica­
tions for treatm ent guidelines. Some suggestions for further research are as 
follows.
1. To overcome the comorbidity problem  in outcome research, an outcome 
measure suited to the wide spectrum o f m ood and anxiety disorder pa­
tients should be developed. Further study with the CPRS-M A seems pro­
mising. The m ood and anxiety items should be brought into better balan­
ce and the validity o f the scale should be examined.
2. In addition to the need to verify tem peram ent as a possible predictor o f 
response to antidepressants, further research into the influence o f current 
mood state on putatively stable tem peram ent scores should be under­
taken. For this purpose, exclusion o f  those items correlating highly with 
current mood state (indicated by the severity measures o f  mood and 
anxiety) to explore the stability o f  the remaining scores over time and 
their relation to treatm ent outcome is a possibility.
3. As discussed before, the assessm ent o f  prim ary diagnosis raises problems 
because the data m ust be collected retrospectively. Given that primary 
diagnosis appears to be a promising predictor o f  antidepressant treatm ent 
response it is im portant to search for objective measures that distinguish 
(primary) m ood disorders and (primary) anxiety disorders. For this pur­
pose, an experimental design taking current evidence showing memory 
bias in patients with m ajor depression but not an anxiety disorder m ay be 
welcome (Bootzin & M cKnight, 1998; Gotlib & Krasnoperova, 1998; 
M acLeod & M athews, 1991). If differences in cognitive information 
processing are confirmed, a valuable objective measure becomes avail­
able to distinguish m ood and anxiety disorders, apart from DSM  classifi­
cation. In addition, the detection o f  consistent differences in memory bias 
depending on primary diagnosis suggests that diagnosis at first episode in 
a patient’s lifetime m ay not no longer be omitted from any diagnostical 
procedures. Finally, greater information on treatm ent response to TCAs 
versus SSRIs is still needed to facilitate the choice o f  antidepressants and 
enhance treatm ent efficacy as a result.
8.6 Suggestions for further research
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Summary
M ood and anxiety disorders are the m ost prevalent psychiatric disorders. The 
symptoms o f mood and anxiety disorders also frequently co-occur. In the 
present thesis, the implications o f  comorbid m ood and anxiety disorders for 
the accuracy o f psychiatric diagnosis and the implications o f  such com orbi­
dity for treatm ent with antidepressants will be explored. The past three deca­
des have witnessed considerable progress in the pharmacological treatm ent 
o f  mood disorders. The efficacy o f  antidepressants has not been restricted to 
mood disorders, however. Patients with anxiety disorders also appear to be­
nefit from treatm ent with antidepressants. Even though there is a growing 
knowledge o f  the efficacy o f  different antidepressants and their range o f  uti­
lity, it is still not possible to predict with accuracy response to antidepres­
sants in m ood and anxiety disorders, or to find meaningful differences be­
tween antidepressants. A part from evidence that tricyclic antidepressants 
(TCA) are probably more effective for the treatm ent o f  severely depressed 
patients, no differences in the efficacy o f  TCAs versus SSRIs (selective sero­
tonin reuptake inhibitors) have been found for the treatm ent o f  m ood and an­
xiety disorders. The present research is therefore an attem pt to detect any 
differences in the efficacy o f  different antidepressants.
Chapters 1, 2 and 3 provide a theoretical introduction to the empirical re­
search presented in subsequent chapters. Chapter 1 provides a general intro­
duction and addresses the main research questions. The existence o f  com or­
bidity between m ood and anxiety disorders is an im portant issue for the in­
terpretation o f  treatm ent outcome although often ignored. Appropriate 
classification o f  m ood and anxiety disorders remains difficult due to w ide­
spread comorbidity. The criteria from the Diagnostic and Statistical M anual 
o f  M ental Disorders (DSM) as formulated by the Am erican Psychiatric A s­
sociation do not adequately distinguish these patient groups although the 
DSM  categorises m ood and anxiety disorders as separate disorders. In fact, 
the existing overlap in m ood and anxiety symptoms raises the question o f 
whether mood and anxiety disorders actually constitute different syndromes 
or are part o f  one and the same syndrome. In addition, when different anti­
depressants (e.g., TCA versus SSRI) are studied with presumably ‘pure’ 
groups o f  patients with a m ood or anxiety disorder, the question remains as 
to w hether the treatments really have the same effect when they do not p ro­
duce significantly different results. W hether the patient recovers from only a 
mood disorder, co-existing anxiety symptoms or vice versa is simply un­
known. In other words, possible differences in the effectiveness o f  antide­
pressants may go undetected because the patient selection was based on the 
DSM  criteria for mood and anxiety disorders. That is: The DSM  is widely 
accepted but classification according to the DSM  has not resulted in the
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identification o f  proper patient groups for treatm ent with specific antide­
pressants.
The aim o f  the present research is also, therefore, to examine response 
to treatm ent with TCAs versus SSRIs within a broad range o f  patients suffe­
ring from either a m ood disorder, an anxiety disorder, or both. In doing this, 
the selection bias associated with the use o f  single diagnostic categories is 
presumably reduced. A lternative models for the identification o f  subgroups 
o f  patients responding differentially to antidepressant treatm ent were ex­
plored. O f particular interest were the role o f  primary diagnosis and the role 
o f  temperament. The use o f  systematic diagnostic procedures for the selec­
tion o f  the patient sample was also o f  particular interest. The present re­
search thus had two m ain areas o f  interest: 1) diagnostic accuracy for mood 
and anxiety disorders (see Chapter 5) and 2) antidepressant treatm ent res­
ponse (see Chapters 6 and 7).
In Chapter 2, the issues regarding the comorbidity o f m ood and anxiety 
disorders are considered in greater detail along with the implications o f 
certain issues for research. In the present thesis, the term  comorbidity refers 
to the situation in which more than one psychiatric disorder can be diagno­
sed in the same person. The rates o f observed comorbidity have been found 
to differ enormously across studies from 15% to 91%. Such differences may 
be due to variability in the definition o f the concept, sample selection, study 
time span and the assessment instrument. Along these lines, an anxiety disor­
der is more likely to precede a mood disorder than the reverse, and anxiety 
disorders are associated with an elevated risk o f  a mood disorder later in life. 
Finally, when mood and anxiety disorders co-occur, they tend to be associa­
ted with more severe symptoms, greater impairment, more chronic illness, 
poorer treatm ent outcome and a higher incidence o f  suicide.
The focus o f  Chapter 3 is on the personality model o f  C loninger and the 
model o f  tem peram ent in particular. Tem peram ent refers to the individual 
differences in the automatic emotional reactions and habits o f people. The 
model includes four dimensions o f  temperament: Novelty Seeking, Harm A ­
voidance, Reward Dependence and Persistence. The theoretical model and 
corresponding inventory, the Tridimensional Personality Questionnaire 
(TPQ), are considered in greater detail in Chapter 3. The personality model 
o f  C loninger has been reputed to differentiate between responders and non­
responders to antidepressant treatment. For example, high scores on Harm 
Avoidance have been found to be related to nonresponse to antidepressant 
treatment. In the present research, the model o f  tem peram ent is therefore in­
cluded to explore the responses o f  patients with m ood and/or anxiety disor­
ders to treatm ent with a TCA versus a SSRI. Rather than a focus on the 
DSM  categories based on current symptomatology, moreover, the persona­
lity model o f  C loninger provides an alternative typology o f  patients based on 
temperament.
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Chapter 4 provides an outline o f  the empirical research project on which 
the results presented in the subsequent chapters are based. Special attention 
is paid to the patient selection procedures, clear consideration o f  the exclu­
ded cases and the sample sizes analysed to answer the different research 
questions.
In Chapter 5, the results regarding diagnostic accuracy for m ood and 
anxiety disorders are presented. More specifically, diagnoses based on 
clinical judgem ent were compared to diagnosis based on a structured 
diagnostic interview in patients with m ood and/or anxiety disorders. The 
M unich Diagnostic checklists (MDCL) were used by the psychiatrists to 
establish the DSM -III-R diagnoses. The psychologists adm inistered the 
Composite International Diagnostic Interview (CIDI) to establish the DSM - 
III-R diagnoses. The results showed only moderate agreem ent between the 
clinical diagnoses o f m ood and anxiety disorders and the CIDI-based 
diagnoses. M ajor depression showed the greatest degree o f  agreement 
although no more than moderate. Poor agreem ent was found for generalized 
anxiety disorder. Furthermore, comorbidity between m ood and anxiety 
disorders was found to be common when assessed using the CIDI while the 
psychiatrists tended to diagnose either a m ood disorder or an anxiety 
disorder. This finding suggests that comorbidity m ay not be the focus o f  
attention for m any clinicians and shows that im portant differences in the 
diagnosis o f  m ood and anxiety disorders occur when different diagnostic 
procedures are followed. Such inconsistency poses not only a problem  for 
the interpretation o f  research results but also for the generalisation o f 
outcome results for both psychological and pharmacological treatm ent 
purposes.
In Chapter 6, the role o f  prim ary diagnosis (i.e., diagnosis at first epi­
sode) in antidepressant treatm ent response is considered using a design 
which was different than for m ost clinical trials. To avoid bias due to com or­
bidity, patients w ith any DSM -III-R diagnosis o f  a m ood or anxiety disorder 
for which antidepressant treatm ent was indicated were included. Response to 
treatm ent with a TCA (imipramine) or an SSRI (fluvoxamine) was initially 
evaluated for this group as a whole (i.e., across mood and anxiety symp­
toms). For this purpose, a composite scale with the depression, anxiety and 
OCD items from the CPRS (CPRS-M A) was used. The CPRS-M A has yet to 
be validated, and we therefore used the Clinical Global Impression (CGI) to 
gain an overall impression o f  patient im provem ent independent o f  specific 
symptoms. For the patient group as a whole, no differences in the efficacies 
o f  the treatments with fluvoxamine or imipramine were observed. For sub­
sequent analyses, the patients were grouped according to their first illness 
episode. The CIDI was used to assess whether the first episode was a mood 
disorder (primary depression) or an anxiety disorder (primary anxiety disor­
der). Support for the hypothesis that imipramine is more effective for the 
treatm ent o f  primary depression and fluvoxamine is more effective for the
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treatm ent o f  primary anxiety disorder was found. Patients with prim ary de­
pression responded better to imipramine at week 2 (but not at week 6), ac­
cording to both the CPRS-M A and the CGI. Patients with primary anxiety 
disorder, in contrast, responded better to fluvoxamine, according to the CGI 
but not the CPRS-MA. Given the exploratory nature o f  the present study, re­
plication o f  our findings is still needed. The differences in the results using 
the CPRS-M A and the CGI are discussed along with some limitations on the 
present study. The results suggest that information on the nature o f  the first 
illness episode m ay provide more valuable information than the current 
DSM  classification as a mood or anxiety disorder, which underlines the im ­
portance o f  differentiating between a primary versus secondary depression 
for the prediction and analysis o f  treatm ent response.
In Chapter 7, the role o f  tem peram ent in the response o f  patients to anti­
depressant treatm ent is considered. Based on the assumption that tem pera­
m ent is more related to antidepressant treatm ent response than DSM  dia­
gnoses, the present sample consisted o f  patients w ith a m ood disorder, an an­
xiety disorder, or both. The hypothesis was that patients with high Harm A ­
voidance scores would respond better to fluvoxamine than to imipramine. 
This is because Harm Avoidance is assumed to be associated with a height­
ened susceptibility to anxiety and/or serotonergic neurotransmission. The 
main finding was that Harm Avoidance was indeed related to antidepressant 
treatm ent response but did not distinguish between imipramine and fluvoxa- 
mine. A num ber o f  im portant m ethodological issues are raised, including the 
assessm ent o f  tem peram ent at 6 weeks rather than at baseline. W hile Harm 
Avoidance was assumed to be a relatively stable personality trait, it appeared 
to be related to current mood, which has clear implications for the interpreta­
tion o f  treatm ent results.
Finally, in Chapter 8, the m ajor results o f  the present research are dis­
cussed along with some m ethodological limitations arising from the use o f 
new paradigms to differentiate response to antidepressant treatment. The use 
o f  the CPRS-M A as an outcome measure, the assessm ent o f primary diagno­
sis, the assessm ent o f tem perament, and selection bias are discussed. The 
chapter ends with some suggestions for further research. The present re­
search was a first attem pt to differentiate antidepressant treatm ent response 
with a design different from that used in previous clinical trials. Replication 
is therefore necessary before recommendations for clinical practice can be 
made.
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Samenvatting
Stemmingsstoornissen en angststoornissen zijn de m eest voorkomende psy­
chiatrische stoornissen en de symptomen van stemmings- en angststoornis­
sen komen ook vaak samen voor. Deze com orbiditeit tussen stemmings- en 
angststoornissen heeft implicaties voor de diagnostiek en voor de behande­
ling met antidepressiva, en vorm t het onderwerp van dit proefschrift. De 
laatste drie decennia is er aanzienlijke vooruitgang geboekt rondom de far­
m acologische behandeling van stemmingstoornissen. H et effect van antide­
pressiva is niet beperkt gebleven to t de behandeling van stem m ingsstoor­
nissen. Patiënten m et angststoornissen hebben ook baat bij behandeling met 
antidepressiva. Ondanks de toegenom en kennis over antidepressiva en het 
brede indicatiegebied is het nog altijd niet m ogelijk een goede voorspelling 
te m aken van de respons op een bepaald antidepressivum, dan wel om rele­
vante respons verschillen tussen antidepressiva op te sporen. Behalve dat tri- 
cyclische antidepressiva (TCA) waarschijnlijk effectiever zijn bij de behan­
deling van ernstig depressieve patiënten, zijn er geen eenduidige verschillen 
gevonden tussen TCAs en selectieve serotonine heropname remmers (SSRIs) 
voor de behandeling van stemmings- en angststoornissen.
Hoofdstuk 1, 2 en 3 vormen een theoretische inleiding op het empirisch 
onderzoek dat gepresenteerd w ordt in de daaropvolgende hoofdstukken. 
Hoofdstuk 1 is een algemene inleiding met uiteenzetting van de onderzoeks­
vragen. Het optreden van com orbiditeit van stemmings- en angststoornissen 
speelt een rol bij de interpretatie van behandelresultaten al w ordt dit vaak ge­
negeerd. Juiste classificatie van stemmings- en angststoornissen wordt be­
m oeilijkt door het bestaan van comorbiditeit. De diagnostische criteria van 
de DSM  (Diagnostic and Statistical M anual o f  M ental Disorders) zoals ge­
formuleerd door de Am erican Psychiatric Association m aken geen duidelijk 
onderscheid tussen deze patiëntengroepen ook al categoriseert de DSM  
stemmings- en angststoornissen als aparte groepen. De bestaande overlap 
van depressie- en angstsymptomen brengt ons bij de vraag o f stemmings- en 
angststoornissen werkelijk verschillende syndromen zijn o f een onderdeel 
vormen van een en hetzelfde syndroom. Als nu verschillende antidepressiva 
(bijv. TCAs en SSRIs) worden onderzocht bij zogenaamde ‘pure’ patiënten­
groepen m et een depressieve stoornis ofwel een angststoornis, blijft het de 
vraag o f de behandelingen werkelijk even effectief zijn, zoals blijkt uit on­
derzoeksresultaten. In hoeverre de patiënt herstelt van slechts een stem ­
mingsstoornis, van de bijbehorende angstsymptomen o f vice versa blijft on­
bekend. M et andere woorden, mogelijke respons verschillen tussen antide­
pressiva kunnen verborgen blijven om dat patiënten selectie is gebaseerd op 
de DSM  criteria van stemmings- en angststoornissen. De DSM  is wereldwijd 
geaccepteerd m aar classificatie op basis van de DSM  heeft niet geresulteerd
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in de identificatie van de juiste patiënten groepen voor behandeling met spe­
cifieke antidepressiva.
Het doel van dit onderzoek was dan ook om respons op TCAs versus 
SSRIs te bestuderen bij een brede groep patiënten m et een stem m ingsstoor­
nis, een angststoornis o f  beiden. H ierdoor werd de selectie bias die optreedt 
bij het includeren van aparte diagnostische categorieën waarschijnlijk gere­
duceerd. Vervolgens zijn twee alternatieve modellen geëxploreerd voor de 
identificatie van subgroepen van patiënten die m ogelijk verschillend reage­
ren op antidepressiva, te weten de rol van primaire diagnose en de rol van 
temperament. V erder was er speciale aandacht voor het gebruik van een sys­
tem atische diagnostische procedure voor de selectie van de patiënten. Dit on­
derzoek was dan ook gericht op twee aspecten: 1) diagnostische nauw keu­
righeid van stemmings- en angststoornissen (zie Hoofdstuk 5) en 2) respons 
op antidepressiva (zie Hoofdstuk 6 en 7).
Hoofdstuk 2 is gericht op com orbiditeit van stemmings- en angststoor­
nissen en de implicaties van com orbiditeit voor onderzoek. In dit proefschrift 
verw ijst de term  com orbiditeit naar de situatie waarbij m eer dan een psychia­
trische stoornis gediagnosticeerd wordt bij dezelfde persoon. De comorbidi- 
te it percentages verschillen enorm tussen studies van 15% to t 91%. Deze 
spreiding is te w ijten aan de verschillen in de definitie van comorbiditeit, 
steekproef selectie, tijdsduur van de studie en gekozen m eet instrumenten. 
V erder gaat een angststoornis vaker vooraf aan een stemmingsstoornis dan 
omgekeerd, en angststoornissen hangen samen m et een verhoogd risico op 
een stemmingsstoornis later in de tijd. Tot slot, als stemmings- en angst­
stoornissen samen voorkomen, hangt dit vaak samen met hogere ernst van de 
klachten, een chronisch verloop, slechter behandelresultaat en een hogere in­
cidentie van suïcide.
Hoofdstuk 3 beschrijft het persoonlijkheidsm odel van Cloninger en het 
model van Tem peram ent in het bijzonder. Tem peram ent verw ijst naar de in­
dividuele verschillen in automatische reacties en gewoonten van mensen. 
H et model bevat vier dimensies van temperament: Novelty Seeking (sensatie 
zoekend), Harm Avoidance (gevaar vermijdend), Reward Dependence 
(belonings afhankelijk) en Persistence (volhardend). H et theoretisch model 
en de bijbehorende vragenlijst, de Tridimensional Personality Questionnaire 
(TPQ), worden nader toegelicht in Hoofdstuk 3. H et persoonlijkheidsm odel 
van Cloninger w ordt in verband gebracht m et differentiatie tussen respon­
ders en nonresponders op behandeling met antidepressiva. Ter illustratie, ho­
ge scores op Harm  Avoidance zijn gerelateerd aan een slechte response op 
antidepressiva. In het huidige onderzoek is het model van tem peram ent dan 
ook gebruikt om respons op behandeling met een TCA dan wel een SSRI bij 
patiënten m et stemmings- en angststoornissen te exploreren. In plaats van 
ons te richten op de DSM  categorieën gebaseerd op huidige symptomatolo­
gie, biedt het persoonlijkheidsm odel van Cloninger een alternatieve typolo­
gie van patiënten gebaseerd op temperament.
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Hoofdstuk 4 geeft een overzicht van het onderzoeksproject waarvan de 
resultaten in de daaropvolgende hoofdstukken zijn beschreven. Speciale aan­
dacht is besteed aan de selectie procedures en de geanalyseerde steekproef 
aantallen bij de beantwoording van de verschillende onderzoeksvragen.
In Hoofdstuk 5 zijn de bevindingen rondom de diagnostische overeen­
stemming van stemmings- en angststoornissen beschreven. In concreto, de 
diagnose volgens het klinisch oordeel van de psychiater werd vergeleken 
m et de diagnose volgens een gestructureerd diagnostisch interview bij pa­
tiënten m et stemmings- en /of angststoornissen. De M unich Diagnostic 
Checklists (M DCL) werden gebruikt door de psychiaters om de DSM -III-R 
diagnose te bepalen. De psychologen namen de Composite International 
Diagnostic Interview (CIDI) waarmee ook de DSM-III-R diagnose werd 
vastgesteld. De resultaten toonden slechts matige overeenstemming tussen 
de klinische diagnose van stemmings- en angststoornissen en de CIDI dia­
gnose. De overeenstemming was het grootst voor de depressieve stoornis, al 
betro f het slechts een matige overeenstemming. De laagste overeenstemming 
werd gevonden voor de gegeneraliseerde angststoornis. V erder werd gevon­
den dat com orbiditeit tussen stemmings- en angststoornissen vaak voorkomt 
volgens de CIDI terw ijl de psychiaters m eer geneigd zijn te kiezen voor een 
stemmingsstoornis dan wel een angststoornis. Deze bevinding suggereert dat 
clinici w ellicht weinig aandacht hebben voor de bestaande com orbiditeit en 
laat verder zien dat er belangrijke verschillen tussen diagnosen van stem- 
mings- en angststoornissen optreden als verschillende diagnostische proce­
dures worden gebruikt. Dit bem oeilijkt de interpretatie van onderzoeksre­
sultaten en de generalisatie ervan voor zowel psychologische als farm acolo­
gische behandelingen.
In Hoofdstuk 6 zijn de bevindingen beschreven over de rol van de p ri­
maire diagnose (de diagnose van de eerste ziekte episode) op de behandel- 
respons op antidepressiva. Er is voor een andere studieopzet gekozen dan ge­
bruikelijk in klinisch onderzoek. Om vertekening (bias) te voorkomen door 
het bestaan van com orbiditeit zijn alle patiënten m et een DSM -III-R stem- 
mings- o f angststoornis voor wie behandeling m et antidepressiva is geïndi­
ceerd geincludeerd. Response op een TCA (imipramine) o f  een SSRI (flu- 
voxamine) werd in eerste instantie onderzocht over de gehele groep (dus in­
clusief depressie en angst symptomen). Als uitkomstm aat is een compositie 
schaal gebruikt bestaande uit de depressie, angst en OCS items van de CPRS 
(CPRS-MA). De CPRS-M A is nog niet gevalideerd en daarom hebben we 
ook de Klinische Globale Impressie (CGI) gebruikt voor een algemene im­
pressie van de verbetering onafhankelijk van specifieke symptomen. V oor de 
totale groep werden geen verschillen gevonden tussen behandelrespons van 
fluvoxamine en imipramine. Vervolgens werden de patiënten gegroepeerd 
op basis van hun primaire diagnose. De CIDI werd gebruikt om te bepalen o f 
de diagnose van de eerste ziekte episode een stemmingsstoornis was (pri­
maire depressie) o f  een angststoornis (primaire angst stoornis). De hypothese
119
dat imipramine effectiever is voor de behandeling van primaire depressie en 
fluvoxamine effectiever voor de behandeling van een primaire angststoornis 
werd ondersteund. Patiënten m et primaire depressie reageerden beter op im i­
pramine na 2 weken behandeling (maar niet na 6 weken), volgens zowel de 
CPRS-M A als de CGI. Patiënten m et een primaire angststoornis daarente­
gen, reageerden beter op fluvoxamine volgens de CGI, m aar niet volgens de 
CPRS-MA. De verschillen in resultaten tussen de CPRS-M A en de CGI w er­
den bediscussieerd samen m et beperkingen van deze studie. De resultaten 
veronderstellen dat informatie over de eerste ziekte episode van grotere bete­
kenis is dan de huidige DSM  classificatie van stemmings- en angststoornis­
sen. D it onderschrijft het belang van differentiatie tussen primaire en secun­
daire depressie voor de predictie van behandelrespons.
In Hoofdstuk 7 zijn de bevindingen over de rol van tem peram ent op res­
pons op antidepressiva beschreven. Gebaseerd op de assumptie dat tem pera­
m ent m eer gerelateerd is aan respons op antidepressiva dan de DSM  diagno­
se, bestond de onderzochte steekproef uit patiënten m et een stem m ingsstoor­
nis, een angststoornis o f  beiden. De hypothese was dat patiënten met hoge 
Harm  Avoidance scores beter reageren op fluvoxamine dan op imipramine 
om dat verondersteld w ordt dat Harm Avoidance geassocieerd is m et ver­
hoogde kwetsbaarheid voor angst en /of serotonerge neurotransmissie. De be­
langrijkste bevinding was dat Harm Avoidance inderdaad was gerelateerd 
aan respons op antidepressiva, m aar er werd geen onderscheid gevonden tus­
sen fluvoxamine en imipramine. Een aantal methodologische kwesties w er­
den bediscussieerd, waaronder het m eten van tem peram ent na 6 weken be­
handeling in plaats van voor aanvang van de behandeling. Terwijl Harm A ­
voidance werd verondersteld een relatief stabiele persoonlijkheidskenm erk 
(trait) te zijn, bleek het samen te hangen m et huidige stemming (state), wat 
duidelijke implicaties heeft voor de interpretatie van de resultaten.
Tot slot worden in Hoofdstuk 8 de belangrijkste resultaten bediscus­
sieerd als ook m ethodologische beperkingen die samenhangen met het ge­
bruik van een nieuw paradigm a om verschillen in behandelrespons op anti­
depressiva op te sporen. Het gebruik van de CPRS-M A als uitkom st maat, 
bepalen van de primaire diagnose, het m eten van temperament, en selectie 
bias worden bediscussieerd. H et hoofdstuk eindigt met suggesties voor ver­
der onderzoek. D it exploratieve onderzoek betro f een eerste aanzet om res­
pons verschillen van verschillende antidepressiva op te sporen waarbij een 
andere studieopzet werd gekozen dan to t dusver gebruikelijk in klinisch on­
derzoek. Valideren van de uitkomstm aat en replicatie van de bevindingen is 
dan ook nodig voordat aanbevelingen voor de klinische praktijk gedaan kun­
nen worden.
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recht. Je was altijd behulpzaam en hield het overzicht. Ik vond het heel p le­
zierig om met je  samen te werken.
Ik dank ook M arja Kool voor haar ondersteuning vanuit het IPPO. Je hebt 
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Bedankt.
Ik dank Theo Broekman. Je was er voor de statistische ondersteuning. Het 
was een luxe om m et je  samen te werken. Je was vaak kritisch m aar altijd 
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overheerlijk kopje espresso maakte veel goed. Bedankt.
Tijdens de afwerking van dit proefschrift heb ik veel te danken gehad aan 
Lee Ann W eeks (engelse correcties) en Edith de Kemp (ontwerp omslag). 
Jullie hebben je  enorm ingezet ondanks de tijdsdruk en namen m ijn gestress 
voor lief. Bedankt voor de geweldige hulp.
Dan komen we nu bij ‘Otto Venius B leens’. H et begon m et een grapje tij­
dens onze studie in M aastricht. W e zijn nu v ijf vriendinnen voor het leven. 
N icole, Petra, Jolianne en Tanya, jullie zijn m ijn paranimfen. Jullie waren er 
voor de ontspanning w aar ik zo vaak behoefte aan had. Bedankt voor alle 
hulp bij de voorbereidingen voor deze promotie, w ant dit staat vast: ‘to ­
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Graag wil ik m ijn ouders bedanken. Pap en Mam, bedankt voor ju llie gren­
zeloze vertrouwen in mij. Jullie hebben mij altijd gestim uleerd om m ijn 
eigen pad te kiezen. Lieve Mamaria, bedankt voor die vele uren dat je  er was 
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baar.
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erop, je  geduld is behoorlijk op de proef gesteld. M aar we hebben dit klusje 
toch m aar mooi samen geklaard. Bedankt voor alles.
En Jannes, m ijn lieverd, voor jou  heb ik doorgezet.
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